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Hepatitis E virus is an important target for experimental virology 
Hepatitis E virus is an emerging health issue world-wide and its morbidity is on the rise. 
HEV was isolated and discovered in faecal extracts from infected soldiers during the Soviet 
occupation of Afghanistan in the 1980s. For a long time, HEV was considered to be a 
significant public health problem but confined to developing countries with poor sanitary 
conditions. Now, however, it is recognized to be prevalent in industrialized countries as well 
1-5. As one of the most common causes of acute viral hepatitis, it provokes approximately 
twenty million HEV infections and three million HEV cases per year. There are also around 
70 thousand deaths associated with HEV infection annually 6. Although only a single HEV 
serotype exists, four genotypes of human HEV have been identified, genotype 1 and 2 are 
restricted to human beings, primarily found in developing countries and are transmitted via 
the fecal-oral route (involving e.g. contaminated water sources), and exhibits a mortality 
rate from 0.5% to 3% in young adults 7. In contrast, the potentially zoonotically-derived 
genotypes 3 and 4 are prevalent in industrialized countries, with sporadic occurrence and 
spread mainly through eating undercooked pork or game products 8. HEV is originally 
considered to be a self-limited, acute disease associated with low mortality, however, the 
main clinical challenge is posed by HEV genotype 3 infection in patients receiving orthotopic 
organ transplantation. More than 60% of organ recipients infected with HEV will develop 
chronic hepatitis with rapid progression to cirrhosis 8-10. The mortality in pregnant women 
with acutely infection by genotype1 HEV was described to reach on average a rate of 25% 11-
13. Hence HEV represents an important target for investigation in current experimental 
virology. 
The molecular virology of HEV is still only partially understood 
HEV was originally classified as a non-A, non-B hepatitis. With the evidence emerging 
that disease associated with the detection of a highly conserved RNA-dependent-RNA-
polymerase (RdRp) in a cDNA library constructed from infectious bile, the existence of a RNA 
virus was inferred that would constitute the pathogen for this non-A, non-B hepatitis and 
thus HEV was defined 14. Subsequent investigations on this virus belonging to the family 
Hepeviridae showed that HEV is a non-enveloped single positive-stand RNA virus with a size 
of 27-34nm 15. The genome is approximately 7.2-kb in size. It starts with a short 5′
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noncoding region (NCR), followed by three open reading frames (Figure 1). ORF1 of HEV is 
the largest ORF in nucleotide length 16,17, encoding the nonstructural proteins of the virus 
and contains several functional domains, including a methyltransferase, a protease, a RNA 
helicase, and a RNA-dependent RNA polymerase, all involved in viral replication and protein 
processing 18, 19. This ORF starts at the 5’ end of the genome after the 25 bp NCR and can be 
translated directly from the HEV genome following infection. A hypervariable region (HVR) 
that distinguishes different HEV strains and genotypes with respect to the characteristics of 
viral replication and their differences in in vitro infection efficiency is also present in ORF1 20. 
The question whether the ORF1 product functions as a signal polyprotein or needs to be 
cleaved to smaller molecules by viral or cellular proteases is still controversial 21-24. The 
majority of studies, however, support the later notion and suggest that HEV ORF1 is typically 
processed into small units, each exerting specific functions. The products of ORF2 are 
responsible for the immunogenicity of HEV and encode the capsid proteins necessary for 
virion assembly exploiting the host cell cytoplasmic machinery. Several host proteins are 
implicated in supporting the HEV life cycle, especially HSP90, Grp78 and HSPGs, which play a 
role in facilitating HEV entry into the host cells and its subsequent intracellular transport 25. 
Obviously, in the HEV life cycle the capsid protein needs to combine with HEV genomic RNA 
for infectious viral particle formation 26. Intriguingly, however, the capsid protein was also 
found to interact with cellular proteins involved in cellular signaling, potentially provoking 
inhibition of apoptosis and inhibition of NF- κB activation, which may aid HEV replication 
and infection by counteracting programmed cell death of infected cells and by constraining 
cell-autonomous immunity 27. ORF3 encodes multifunctional proteins that are responsible 
for virion morphogenesis and release, but not replication 28, 29. ORF2 overlaps with ORF3 and 
there is a junction region (JR) between ORF1 and the subgenomic coding region 30.  
Additionally, two cis-reactive elements (CREs) overlap with ORF2 and the JR, respectively 31. 
Both of the CREs are essential for HEV replication 31. The 5′end of the HEV genome 
contains a 7-methylguanosine cap structure, which is essential for HEV infection. Although 
ORF3 is not fully characterized, many studies demonstrated that ORF3 plays multiple roles 
during HEV infection by activating or inhibiting specific cellular signaling pathways. For 
example, ORF3 can modulate host gene expression by binding and activating mitogen-
activated protein kinase (MAPK), a cardinal regulator of cellular gene expression 32. ORF3 
can also downregulate STAT3-mediated gene expression, but concomitantly enhance host 
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interferon induction through increasing RIG-1 expression 33, 34. Interestingly, OPR3 has also 
been identified as a protective factor with respect to from mitochondrial depolarization and 
demise by stimulating mitochondrial voltage-dependent anion channel genes, indicating 
that ORF3 plays an important role in inhibiting mitochondrial apoptosis pathways 35. 
 
Figure 1. Overview of HEV RNA genome. The genome is 7.2-kb in length. It starts with a short 5′noncoding 
region (NCR), followed by three open reading frames (ORF). ORF1 encodes a polyprotein that gives rise to viral 
nonstructural proteins and is created as a 1693 amino acid (aa) precursor. From it a methyltransferase (MT)  
derived, a putative papain-like cysteine protease (PPR), RNA helicase (Heli), RNA-dependent RNA polymerase 
(RdRp) and a hypervariable region (HVR) are derived. ORF2 encodes a capsid protein of 660 aa. ORF3 encodes 
a small multifunctional protein of 14 aa. 
The life cycle of HEV is relatively poorly understood. A putative HEV infection cycle has 
been proposed and is depicted in Figure 2. The entry of HEV into the cell is initiated by ORF2 
capsid protein binding to cellular surface receptors 36. However, the exact cellular receptor 
for HEV remains still unidentified despite several studies proposing putative receptor 
proteins on the cell or candidate binding sites located in HEV, and thus requires further 
elucidation 37-39. Subsequently, the RNA genome of virus becomes uncoated and is subject 
to intracellular transport as to allow translation of the three ORFs. The translation of non-
structural proteins in ORF1 yields RdRp, necessary for the production of negative-sense RNA, 
which serves as a template for positive-strand RNA formation and thus for viral progeny. 
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Then the ORF2 and ORF3 subgenomic RNA are translated into capsid proteins. The non-
structural proteins subsequently package genomic viral RNA to assemble new virion 40. ORF3 
plays a crucial role at last step of viral egress by contacting with cell membrane. Thus 
although significant progress has been made, HEV biology remains only partially elucidated, 
prompting further investigations. 
 
Figure 2. Life cycle of HEV. (1) Viral attachment to cell surface and entry through  receptors; (2) Virus genome 
is uncoated and positive-strand RNA is released into the cytosol; (3) Translation of viral RNA to ORF1 non-
structure protein; (4) Replication of viral genome RNA with negative-sense RNA being an intermediate, by the 
action of RdRp; (5) Translation of the subgenomic RNA located in ORF2 and ORF3; (6) Packaging of full-length 
genomic RNA into ORF2-derived capsid proteins and their assembly into presumptive virion; (7) Transport of 
the newly formed virion by ORF3 to the cell membrane and its release from the infected cells. 
The lack progress in understanding HEV biology could largely be attributed to absence 
of stable HEV cell culture models, which had hampered investigation of HEV for a long time. 
Recently, however, the situation has dramatically improved with the development of a 
genotype 3-based cell culture system that provides a bona-fide and efficient tool for HEV 
research 41, 42. I exploited this situation in the research described in this thesis. The data 
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obtained in my thesis are mostly on the basis of the genotype 3 infected HEV replication and 
infection cell cultures. A plasmid construct containing the full-length HEV genome (Kernow-
C1 p6 clone, GenBank Accession Number JQ679013) and a construct containing subgenomic 
HEV sequence coupled with a Gaussia luciferase reporter gene (p6-luc) were used to 
generate HEV genomic RNA by using the Ambion mMESSAGE mMACHINE in vitro RNA 
transcription Kit (Life Technologies Corporation, Carlsbad, CA). Huh7 cells were 
electroporated with p6 full-length HEV RNA or p6-Luc subgenomic RNA to generate 
infectious or replication models, respectively. The contemporary body of biomedical 
literature indicates that this constituted a valid strategy for investigating the biology of HEV 
and it allowed me to investigate the role of host factors as targets for anti-viral therapy. 
Acute and chronic infection of HEV – outstanding questions 
HEV is one of the most common causes of acute hepatitis. Although the most common 
transmission routes of HEV have been identified, and appear to include contaminated food, 
contaminated water, uncooked meat, in most cases source of infection remains uncertain. 
In majority of immunocompetent patients, the virus manifests itself as an acute HEV 
infection with self-limiting and low motility with respect to inter-individual transmission (2%) 
properties, and is characterized by full recovery within 4-6 weeks following virus exposure 43. 
An evident risk population for HEV acute infection accompanied by severe symptoms are 
pregnant women in India 13, 44, 45. The mortality in this population reaches up to 25% and is 
largely restricted to HEV genotype 1 and 2-mediated disease, even though a few case 
studies reported infection with genotype 3 and 4. Despite of the finding that HEV viral load 
was evidently higher in pregnant female as compared with non-pregnant patients, further 
studies are needed to clarify the underlying cause of the excessive mortality rate in 
pregnant female with HEV infection. In addition further understanding of the biology of HEV 
will aid the rational design of strategies aimed at reducing mortality in this group of patients. 
Chronic HEV infection is defined as persistent detection of HEV replication, lasting at 
least 3-6 months after acute infection became evident. Of note, and referring only to a 
limited number of reports, only genotype 3 appears capable to progress to chronic HEV 
infection, while genotype 1,2 and 4 of HEV have solely been described in the context of 
acute infection 46. Chronic HEV infection that strikingly and rapidly progresses to fibrosis and 
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cirrhosis becomes increasingly documented in immunocompromised patients, especially in 
recipients of solid organ transplantation receiving immunosuppressive therapy but also 
cases of HIV co-infected patients have been described 9, 10, 47, 48. The course of liver fibrosis 
course in chronic HEV-infected solid organ transplant recipients appears to be more severe 
than that observed in solid organ transplant patients with chronic HCV infection, as evident 
by progression full-blown cirrhosis 2-3 years following initial HEV infection 49. No correlation 
has been observed between HEV load and the progression of liver fibrosis 50. Studies show 
that the lower adaptive immune response in organ transplant patients with 
immunosuppressants therapy is likely the key factor explaining the sensitivity to and the 
clinical of chronic HEV infection in organ orthotopic transplantation recipients 9, 51-56. The 
patients with persisting HEV infection presented evidently reduced size of the CD2, CD3 and 
CD4 T-cell compartment as compared to those that cleared HEV spontaneously 9. Clinical 
analysis of the association between various of immunosuppressive medicines with the 
development of chronic HEV infection revealed that tacrolimus are associated with a worse 
disease course as compared to those patients using other immunosuppressants, especially 
cyclosporine 54 . Mechanistically the interaction of different immunosuppressants and HEV 
lifecycle remains obscure at best, however, prompting further investigations. 
Cases of chronic HEV infection have also been observed in hematological patients and 
patients with pre-existing liver disease 57-59. The prevalence or incidence of this chronic HEV 
infection manifestation has not been recorded systematically, because of the small amount 
of clinical cases involved. 
Current treatment for HEV – room for improvement 
In lieu of approved medication, only a few acute HEV infection patients have been 
given antiviral treatment, except in those instances when patients were considered to be 
severely ill and at high risk, such as those with pre-existing liver disease. This experience has 
suggested that monotherapy with ribavirin is sufficient for rapid clearance of HEV 60, 61.  
The development of HEV infection has been studied mainly in organ transplantation 
patients with chronic HEV infection because they are administered with 
immunosuppressants for preventing organ rejection, which has been proposed to be a key 
factor for developing chronic hepatitis after HEV infection. Thus, reduction of 
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immunosuppressive therapy is the first line of strategy for combatting chronic HEV infection, 
which is sufficient in approximately one third of patients for clearance of the virus 54. In case 
of non-response to the reduction immunosuppressants 62 or those cases that cannot 
tolerate a reduced dose of immunosuppressive drugs, pegylated interferon (peg-IFN), 
ribavirin monotherapy or a combination have been used as antiviral therapy, and have 
achieved HEV clearance in the majority of patients, despite that both of the medicines are 
not FDA-approved anti-HEV drugs. It is the opinion of the author of this thesis ribavirin 
monotherapy has now become the most prevalent treatment modality in this respect, 
probably because of its apparently validated efficiency towards chronic HEV infection in 
large case series reports 63. A very recent study showed that ribavirin treatment failure for 
chronic HEV was the consequence of a specific mutation in specific HEV polymerase, 
providing an intriguing insight into the factors that underlie ribavirin resistance, while 
simultaneously highlighting the need for novel therapeutic modalities to combat HEV 
infection 64.In this context it is important to note that peg-IFN monotherapy for kidney, 
heart, or long transplant recipients must be done with caution because of the associated 
high risk for acute rejection 65, 66. Nevertheless, also in view that all observations are based 
on the scattered case reports or small case series and thus that firm conclusions still require 
systematic analysis like large cohort evaluation or randomized trials 67, the conclusion is 
justified that clinical management of HEV still lacks appropriate medication. 
In this context, one should take into account that different from patients with chronic 
HEV infection, fulminant HEV-induced hepatitis is a major concern, especially genotype 1 
strains in pregnant women with their associated high mortality rates requiring improved 
treatment modalities. To date no evidence is available on the role of pharmaceutical 
intervention in the treatment in pregnant women with acute hepatitis E, non-pregnant 
patients with acute liver failure, or during neonatal HEV infection. The largest challenge in 
this respect is arguably hitting the temporal therapeutic window, when curative treatment 
might still be possible 67. 
Manipulation  of Immunosuppressant use in HEV infection  
Immunosuppressants are used life-long in organ transplant patients in order to 
prevent rejection, but by definition put patients at risk for becoming immunocompromised. 
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Thus it is not surprising that administration of immunosuppressants also affects host 
immunity against viral challenges, putting patients at risk for development of hepatitis 
infection. Nevertheless, different immunosuppressive regimen may have very different 
effects on viral susceptibility and this aspect deserves urgent investigation. 
In agreement with the above-mentioned notion, the majority of chronic HEV patients 
are derived from the organ transplantation recipient population, who receive 
immunosuppressants for preventing organ rejection, resulting in immunosuppression. 
Furthermore, good evidence exists that chronic HEV infection was diagnosed and 
progressed to cirrhosis usually in immunosuppressed individuals associated with weak 
adaptive immune response 49, 68. However, clinical evidence obtained hitherto suggests not 
all the immunosuppressants facilitate HEV infection, as might be expected, but that 
different immunosuppressive regimens can differentially affect the infection course of HEV. 
The calcineurin inhibitor tacrolimus, but not cyclosporin A (CsA), has been found to be more 
frequently associated with persistent HEV infection 54, and mycophenolate mofetil, the pre-
drug form of mycophenolic acid (MPA) can help to clear the virus 56. However, due to 
insufficient cohort clinical data and obscurity at to the mechanistic insight with respect to 
which key factors determine chronic HEV infection course and how such factors are 
influenced by different immunosuppressants, the association of various of 
immunosuppressive medications and outcomes of HEV infections is still uncertain.  
Fortunately, with the establishment of robust genotype 3 HEV cell culture models I 
was able to evaluate the distinct impacts of various of immunosuppressive agents on HEV 
replication and infection in vitro. In chapter 3 and  chapter 4, I describe how different 
immunosuppressants affect HEV infection in cell culture models and prove that different 
immunosuppressants interact radically different with the HEV life cycle. 
De novo nucleotide synthesis as an anti-viral target 
Understanding virus and host interaction is essential for development of anti-viral 
medicine. The purine and pyrimidine nucleotides play critical role in cell metabolism such as 
genome replication and replication through producing ATP, GTP, UTP and CTP. 
Ribonucleotides can be synthesized through de novo pathways, which involve their 
assembly starting from fairly simple small molecules and proceeded piece-by-piece to end 
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products, each step catalyzed by specific enzymes, culminating in the attachment of the 
product to ribose (Figure 3). Alternatively, nucleosides can also be supplied by salvage 
pathways, which convert residual purine and pyrimidine bases into nucleotides by 
reconnecting to ribose.  
 
Figure 3. Schematic overview of de novo biosynthesis of purine and pyrimidine nucleotides. The blue boxes 
are intermediates in the de novo biosynthesis of purine and pyrimidine nucleotides. The oval boxes are 
catalyzed enzymes.  
Viral replication is known to completely rely on the host to supply nucleosides 
essential for viral genesis. Inhibition of the de novo purine and pyridine biosynthesis 
pathway at any particular reaction provokes depletion of intermediates in the pathway, 
leading to an imbalance in nucleotide concentrations, in turn possibly affecting the life cycle 
of viral pathogens. The pathways of nucleotide biosynthesis thus become attractive targets 
for the clinical control of rapidly dividing cells such as cancers or infectious bacteria. Many 
antibiotics and anticancer drugs are inhibitors of purine or pyrimidine nucleotide 
biosynthesis. Thus, host enzymes participating in nucleoside biosynthesis are potential 
targets for antiviral therapeutic drug development. Many de novo nucleotides synthesis 
inhibitors have been reported to exert antiviral activity. Ribavirin and MPA, as IMPDH 
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inhibitors deplete the GTP pool and potently suppress dengue virus, yellow fever virus (YFV), 
hepatitis B, hepatitis C and hepatitis E virus 69-74. Likewise, Brequinar and Leflunomide, 
targeting Dihydroorotate dehydrogenase (DHODH), an enzyme essential for de novo 
biosynthesis of urine nucleotides, has been shown to inhibit human polyomavirus type BK 
(BKV), YFV, and dengue virus. However, it remains questionable, with the possible exception 
of IMPDH, as to how the other catalytic enzymes involved in the two de novo nucleotides 
biosynthesis pathways regulate HEV replication. In chapter 6, I profiled these activities and 
chart the modulation of HEV replication by targeting catalytic enzymes involved in purine 
and pyrimidine synthesis, in an effort aimed at identifying promising targets for anti-HEV 
medication. 
Interplay between mitochondria dynamics and virus infection 
Mitochondria constitute a central element in cellular metabolism and are principal 
constituents of the molecular events involved in immune defense, apoptosis, autophagy and 
other signaling pathways 75. Mitochondria are unique not only because they contain their 
genomic DNA, replicating independently from nuclei, but also because they are highly 
dynamic organelles that can be constantly undergo continuous cycles of homotypic fusion 
and fission, resulting in alteration of organelle shape, size, number, mitochondrial DNA 
stability and other signaling 76, 77 (Figure 4). These dynamic processes are sensitive to the 
alteration of cellular environmental or metabolic conditions, examples are oxygen stress, 
cancer, viral infection, a dynamism that appears essential to maintain cellular homeostasis 
78-83. Perturbations of the mitochondrial quality control machinery accordingly provoke 
substantial physiological consequences and are tightly related to pathogenesis of a number 
of genetic and neurological disorders, cardiac dysfunctions, cancer and metabolic diseases 
84-88.   
The two opposing events in mitochondrial dynamics, fusion and fission are ultimately 
coordinated by dynamin-related proteins. The main molecules governing  mitochondrial 
fusion are optic atrophy 1 protein (OPA1), and Mitofusins (Mfn1 and Mfn2), at least in 
mammals. Mitochondrial fusion takes place on either outer or inner mitochondrial 
membranes to merge two individual mitochondria and quickly exchange and equilibrate 
matrix metabolites, intact mtDNA copies and mitochondrial membranes components. Outer 
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and inner mitochondrial fusion  are orchestrated by Mitofusins and OPA1, respectively 89, 90. 
In contrast to fusion-related proteins located in mitochondria, the key regulator protein 
Drp1 in mitochondrial fission localizes to the cytosol 91. Other fission proteins, including 
mitochondrial fission factor (Mff), mid49 and Mid51, which mediates Drp1 recruitment to 
mitochondria are confined to the mitochondria.  
 
Figure 4. Overview of mitochondrial dynamics. Under normal physiological conditions, the mitochondria are 
usually tubular. Physiological or metabolic stress induces mitochondrial injury and causes mitochondrial 
impairment. The impaired part of the mitochondria is segregated by fission process. The impaired 
mitochondria are selectively flagged by the PINK1 that facilitates Parkin recruitment and mitophagy. All the 
repaired mitochondria are recruited to the functional mitochondrial network by fusion with other 
mitochondria (Adapted from Mohsin Khan, et al. Biochimica et Biophysica Acta, Review 2015.1 
83
).  
In the past, the dysfunction of mitochondrial dynamics was initially reported to 
correlate with a myriad of neurodegenerative disease, in particular Alzheimer's, 
Huntington's and Parkinson's disease 92. More recently, however, various infectious diseases, 
including HBV and HCV have been related to prominent mitochondrial injury as well 93-95. 
The role of mitochondrial dynamics in viral infection is still highly controversial but the idea 
that exploring the role of mitochondrial dynamics in viral-host interaction might be 
promising and might provide promising targets for anti-viral therapy is gaining. Indeed, the 
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role of mitochondrial dynamics as a hub of innate immune signaling, cell apoptosis and 
mitophagy implicate that mitochondria represents a key factor in viral pathogenesis. Its 
relation, however, to HEV infection remains unexplored.  
Virus infection modulates mitochondrial networks either through directly contact of 
the virus with mitochondria or by influencing mitochondrial morphology by altering 
physiological environment. Viruses may actively highjack such events to make host cells 
more permissive for their infection: activating mitophagy may e.g. impair cellular apoptosis 
and thus foster persistent viral infection while simultaneously suppress innate immune 
signaling. The common notion of the connection between mitochondrial dynamics and 
antiviral immunity is that mitochondrial fusion contributes to enhancement of MAVS 
signaling and IFN production, whereas mitochondrial fission dampens these innate immune 
response 96, 97.  Recent studies on HBV and HCV, reveal that both viruses can induce 
mitochondrial fission, leading to mitophagy and attenuating apoptosis of infected cells 95. 
Moreover, the fission event also contributes to interference of virus triggered innate 
immune response to subvert mitochondrial associated antiviral signaling. Human 
cytomegalovirus was identified to stimulate mitochondrial fission and displayed anti-
apoptosis properties 98. For the influenza virus, on one hand, virus induces mitophagy, 
protecting host cells against virally triggered immunopathology 99; on the other hand, 
influenza virus protein PB1-F2 downregulates innate immune response via directly targeting 
MAVS to affect IFN synthesis or via induce mitochondrial fragmentation 100. One exception 
in this aspect is the severe acute respiratory syndrome-coronavirus (SARS), which induces 
mitochondrial fusion, but impair MAVS signaling, indicating that other mechanisms may be 
operative 101. Thus in this thesis, I investigate the mitochondrial dynamics following HEV 
infection and explore their significance for viral propagation.  
Aim and outline of this thesis 
The factors that determine HEV infection and progression are still ambiguous. In this 
thesis, I aim to develop potential anti-HEV therapy in cell culture models based on 
discovering host factors involved in HEV infection.  
Immunosuppressive medication used in organ transplantation recipients is a risk 
factor for chronic HEV development. Despite sporadic clinical cases described HEV 
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progression in response to different common used immunosupprants, the lack of cohort 
and systemic analysis make it difficult to draw solid conclusion with respect to the 
association of different immunosuppressants and the outcome of HEV progression. Thus, in 
chapter 2 and chapter 3, I investigated how different immunosuppressants affect HEV 
infection in cell culture models. Combining with clinical case reports, chapter 4 ties together 
the recent steps forward in manipulation of immunosuppressants in organ transplantation 
and emphasize the current clinical and experimental evidence regarding the key 
implications of immunosuppressants in chronic hepatitis E. The most frequently used option 
for the chronic HEV, ribavirin, is also a IMPDH inhibitor, but not an immunosuppressive drug. 
The antiviral activities of both IFN-α and Ribavirin against HEV replication in vitro were 
characterized in chapter 5. Of note, I found that ribavirin and MPA, both of which are 
IMPDH inhibitors, potently inhibited HEV infection. Considering its property of inhibiting 
purine nucleotide synthesis, I propose the inhibition of nucleotide synthesis might be an 
attractive strategy for anti-HEV therapy. Therefore, in chapter 6, I investigated the role of 
different enzymatic cascades of nucleotide biosynthesis in hepatitis E virus (HEV) replication. 
Considering that protein kinases are principal components of the machineries that 
orchestrate immune response against diverse pathogenic entities, knowledge of such 
pathways could prove exceedingly useful for the rational design of therapeutic avenues 
against HEV infection.  In chapter 7, I comprehensively profile kinase-mediated cascades in 
cell–autonomous antiviral immunity on Huh7 based HEV replication cell model and we 
identified protein kinase C alpha (PKC) as an important anti-HEV mediator. The interest of 
mitochondria in virology is gaining popularity as viral infection involves modulation of the 
dynamics of this organelle. In chapter 8, I describe the role of mitochondria dynamics in HEV 
infection, providing a novel avenue to explore the viral-host interaction. Finally in chapter 9, 
I summarize and discuss the results and describe future perspectives. 
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Abstract 
BACKGROUND & AIMS: Many recipients of organ transplants develop chronic hepatitis, due 
to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally 
associated with immunosuppressive therapies, little is known about how different 
immunosuppressants affect HEV infection.  
METHODS: A subgenomic HEV replication model, in which expression of a luciferase 
reporter gene is measured, and a full-length infection model were used. We studied the 
effects of different immunosuppressants, including steroids, calcineurin inhibitors 
(tacrolimus [FK506] and cyclosporin A), and mycophenolic acid (MPA, an inhibitor of inosine 
monophosphate dehydrogenase) on HEV replication in human hepatoma cell line Huh7. 
Expression of cyclophilins A and B (the targets of cyclosporin A) were knocked down using 
small hairpin RNAs. 
RESULTS: Steroids had no significant effect on HEV replication. Cyclosporin A promoted 
replication of HEV in the subgenomic and infectious models. Knockdown of cyclophilin A and 
B increased levels of HEV genomic RNA by 4.0  0.6-fold and 7.2  1.9-fold, respectively (n = 
6; P < 0.05). A high dose of FK506 promoted infection of liver cells with HEV. In contrast, 
MPA inhibited HEV replication. Incubation of cells with guanosine blocked the antiviral 
activity of MPA, indicating that the antiviral effects of this drug involve nucleotide depletion. 
The combination of MPA and ribavirin had a greater ability to inhibit HEV replication than 
MPA or ribavirin alone.  
CONCLUSIONS: Cyclophilins A and B inhibit replication of HEV; this might explain the ability 
of cyclosporin A to promote HEV infection. On the other hand, the immunosuppressant 
MPA inhibits HEV replication. These findings should be considered when physicians select 
immunosuppressive therapies for recipients of organ transplants who are infected with HEV. 
 
Keywords: Cell Culture Model; Liver Disease; Immunity; Transplantation. 
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Introduction 
Hepatitis E virus (HEV) is one of the most common causes of acute hepatitis worldwide. 
It is a single stranded positive-sense RNA virus that mainly infects the liver hepatocytes. 
Although only a single HEV serotype is recognized, at least 4 different genotypes of human 
HEV exist 1. Genotypes 1 and 2 are found mainly in developing countries and are 
transmitted via contaminated water sources. In contrast, genotypes 3 and 4 are prevalent in 
industrialized countries and are zoonotic nature and spread mainly through eating 
undercooked pork or game products 2. In general, HEV infection is a self-limiting disease and 
is associated with low mortality, but fulminant hepatitis and high mortality have been 
described, reaching 25% in cases of pregnant women infected with genotype 1 in 
developing countries 3. In the Western world, the main clinical challenge is posed by HEV 
genotype 3 infection in patients receiving orthotopic organ transplantation 4. More than 60% 
of organ recipients infected with HEV will develop chronic hepatitis with rapid progression 
to cirrhosis 5,6. Which factors that determine outcomes in these patients remains obscure at 
best, hampering efforts to develop rational therapy and to address the increasing challenge 
of HEV infection in organ transplantation recipients. 
Organ transplant patients take immunosuppressants for life to prevent graft rejection. 
The resulting immunosuppression, however, also affects host immunity against viral 
challenges, and the use of immunosuppressive drugs has been proposed to be a key factor 
for developing chronic hepatitis after HEV infection. Consequently, dose reduction of 
immunosuppression is often used as the first intervention strategy to achieve viral clearance 
in HEV-infected organ recipients 7. Interestingly, however, clinical evidence suggests that 
different immunosuppressive regimens can differentially affect the infection course of HEV. 
The calcineurin inhibitor tacrolimus, but not cyclosporin A (CsA), has been found to be more 
frequently associated with persistent infection, and mycophenolate mofetil, the pre-drug 
form of mycophenolic acid (MPA) can help to clear the virus 8. However, the current clinical 
studies are not able to conclusively address the impact of different immunosuppressants 
because of limited patient numbers and lack of mechanistic insight as to how differences in 
immunosuppressive medication might be linked with an altered clinical course of HEV 
infection.  
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The observation that different immunosuppressive medication seems to have specific 
effects on the outcomes of HEV infection suggests that such medication can have direct 
effects on viral replication, apart from influencing antiviral immunity. This consideration 
prompted us to test whether different immunosuppressive medication affects HEV 
replication in hepatocytes directly. The recent development of a genotype 3-based cell 
culture system 9,10 makes it possible to study such questions in a highly detailed fashion. We 
show that different commonly used immunosuppressants have very specific effects on viral 
replication and that especially calcineurin inhibitors strongly facilitate HEV replication, and 
MPA suppresses viral replication. These results will serve as an important reference about 
the choice of particular immunosuppressive medication for HEV infected orthotopic organ 
transplant recipients. 
Materials and Methods 
Immunosuppressants 
CsA and tacrolimus (FK506) were purchased from Abcam (Cambridge, MA). 
Dexamethasone (Dex), prednisolone (Pred) and MPA were purchased from Sigma (St Louis, 
MO). All the reagents were dissolved in dimethyl sulfoxide, except MPA, which was 
dissolved in methanol. The effects of these immunosuppressants on host cell viability were 
determined by MTT assay (Supplementary Figure 1). 
Cell culture 
Human hepatoma cell line Huh7 and human embryonic kidney epithelial cell line 293T 
cells were cultured in Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 IU/mL 
streptomycin. 
Hepatitis E Virus Cell Culture Models 
A plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, 
GenBank Accession Number JQ679013) and a construct containing subgenomic HEV 
sequence coupled with a Gaussia luciferase reporter gene (p6-luc) were used to generate 
HEV genomic RNA by using the Ambion mMESSAGE mMACHINE in vitro RNA transcription 
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Kit (Life Technologies Corporation, Carlsbad, CA) 9,10. Huh7 cells were electroporated with p6 
full-length HEV RNA or p6-Luc subgenomic RNA to generate infectious or replication models, 
respectively 10. 
Quantification of Hepatitis E Virus Infection 
For the HEV replication model (p6-Luc), the activity of secreted gaussia luciferase in 
the cell culture medium was measured using BioLux Gaussia Luciferase Flex Assay Kit (New 
England Biolabs, Ipswich, MA), as quantification of viral replication. To further determine 
the specific effects on viral replication-related luciferase activity, Huh7 cells constitutively 
expressing the firefly luciferase reporter gene driven by the human PGK promoter were 
used as household luciferase activity for normalization 11. For firefly luciferase, luciferin 
potassium salt (100 mM; Sigma) was added to cells and incubated for 30 minutes at 37 ℃. 
Both gaussia and firefly luciferase activity were quantified with a LumiStar Optima 
luminescence counter (BMG LabTech, Offenburg, Germany). 
For the p6 infectious HEV model, SYBR Green–based quantitative real-time 
polymerase chain reaction (qRT-PCR) was used to quantify genomic RNA. The HEV primer 
sequences were 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’- 
CCGTGGCTATAATTGTGGTCT-3’ (antisense), and the primers of housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase were 5’-TGTCCCCACCCCCAATGTATC-30 (sense) 
and 50-CTCCGATGCCTGCTTCACTACCTT-3’ (antisense). 
Gene Knockdown by Lentiviral Vector Delivered Short-Hairpin RNA 
Lentiviral vectors, targeting cyclophilin A (CypA), cyclophilin B (CypB) or green 
fluorescent protein, were produced in 293T cells as described previously.12 After pilot study, 
the shRNA vectors exerting optimal gene knockdown were selected. The shRNA sequences 
were: CypA, 50-CCGGTGGTGACTTCACACGCCATAACTCGAGTTATGGCGTGTGAAGTCACCAT 
TTTTG-3’, and CypB, 5’-CCGGGCCTTAGCTACAGGAGAGAAACTCGAGTTTCTCTCCTGTAGCTAAG 
GCTTTTTG-3’. 
To generate stable gene knockdown cells, Huh7 cells were transduced with lentiviral 
vectors. Because the vectors also express a puromycin resistance gene, transduced cells 
were subsequently selected by adding 2.5 μg/mL puromycin (Sigma) in the cell culture 
Chapter 2 
 
- 36 - 
 
medium. For the infectious model, HEV particles were incubated with knockdown and 
control Huh7 cells. For the subgenomic model, p6-Luc cells were directly transduced with 
lentiviral shRNA vectors and selected by adding 2.5 μg/mL puromycin. 
Western Blot 
For Western blot, commercial antibodies against CypA and CypB (rabbit polyclonal; 
Abcam) were used. Proteins in cell lysates were heated 5 minutes at 95℃, followed by 
loading onto a 15% sodium dodecyl sulfate polyacrylamide gel and separating by 
electrophoresis. After 90 minutes running in 115-V voltage, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride membrane (Invitrogen) for 
1.5 hours with an electric current of 250 mA. Subsequently, the membrane was blocked 
with 2.5 mL blocking buffer and 2.5 mL phosphate-buffered saline containing 0.05% Tween 
20. It was followed by incubation with rabbit anti-CypA (1:5000) or anti-CypB (1:7500) 
antibody overnight at -4℃. Membrane was washed 3 times followed by incubation for 1.5 
hours with an anti-rabbit peroxidase–conjugated secondary antibody (1:5000). After 
washing 3 times, protein bands were detected with Odyssey 3.0 Infrared Imaging System. 
Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-
Whitney test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values 
<0.05 were considered statistically significant. 
Results 
Glucocorticosteroids Did Not Affect Hepatitis E Virus Replication 
Pred and its close analogue Dex remain important drugs in the clinical management of 
patients receiving orthotopic organ transplantation 13. To study the possible effects of these 
drugs on HEV replication, we used a model in which cells were transfected with a 
subgenomic construct of HEV coding sequence in which the 5’ portion of ORF2 was replaced 
with the in-frame secreted form of luciferase derived from the marine copepod Gaussia 
princeps. Accumulation of luciferase serves as reporter for HEV RNA synthesis (p6-luc), and 
the loss of the capsid protein precludes the formation of novel viral particles. In parallel, 
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Huh7 cells constitutively expressing a nonsecreted firefly luciferase were used for 
normalization of nonspecific effects on luciferase signals. However, as shown in Figure 1 
neither Pred nor Dex significantly affected HEV replication. We conclude that steroids have 
no direct effects on HEV replication. 
Figure 1. The effects of steroids on HEV replication in subgenomic cell culture model. Huh7 cell based 
subgenomic HEV replicon containing the luciferase reporter gene was treated for 24, 48, and 72 hours with a 
dose-range of Dex and Pred. (A) Dex and (B) Pred did not significantly affect luciferase activity. Data presented 
as mean  SD of 3 independent experiments. 
Cyclosporin A Dose-Dependently Enhanced Hepatitis E Virus Replication 
CsA, a calcineurin inhibitor, is an important drug for prevention of graft rejection. To 
examine the effects of CsA on HEV replication, we tested the effects of 0.1, 0.5, and 5 μg/mL 
CsA on viral replication using the subgenomic p6-Luc model as a read-out. It appeared that 
CsA dose dependently increased HEV replication-related luciferase activity (Figure 2A). 
Consistently, CsA also dose dependently increased HEV infection in the full-length (p6) 
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infectious model (Figure 2B). Forty-eight hours of treatment with CsA (5 μg/mL) resulted in a 
mean SD of 2.67  0.7-fold (n = 5; P < 0.01) increase of HEV genomic RNA level (determined 
by qRT-PCR), compared with the control (Figure 2B). CsA directly promotes viral replication 
in a hepatocyte-like cells and experimentation was initiated to establish the molecular basis 
of this effect. 
Figure 2. CsA promoted HEV infection. (A) The subgenomic HEV replicon containing the luciferase reporter 
gene was treated for 24 hours (n = 5), 48 hours (n = 7), and 72 hours (n = 7) with different doses of CsA. 
Treatment with CsA (0.5 or 5 μg/mL) significantly increased HEV luciferase activity. (B) The Huh7 cells-based 
infectious HEV model was treated with CsA for 48 hours. CsA significantly increased HEV RNA at 0.5 and 5 
μg/mL concentrations (n = 5). Data presented as mean  SD of multiple experiments. * P < 0.05; ** P <0 .01. 
Silencing the Cellular Targets of Cyclosporin A, Cyclophilin A and B, Enhanced Hepatitis E 
Virus Replication 
CsA acts through binding and inhibition of the CypA/B complex. The effects of CsA on 
HEV replication could be potentially mediated through cyclophilins. CypA 14 and CypB 15 
have been implicated in the anti–hepatitis C virus (HCV) mechanism of CsA. Therefore, 
lentiviral-mediated RNA interference was used for knockdown of these 2 genes, as to allow 
investigation of their potential function in the effects of CsA on HEV replication. To this end, 
Huh7 cells were transduced with integrating lentiviral vectors expressing both shRNA and 
puromycin. Cells stably transduced with the vector were selected and expanded by adding 
puromycin to the relevant cell cultures. The shRNA clones with most potent efficacy of CypA 
and CypB knockdown were selected for follow-up experimentation (Figure 3A). Cells stably 
integrated with shRNA targeting GFP (as control), CypA or CypB were inoculated with 
infectious HEV viruses (p6). The level of infection was quantified by qRT-PCR of genomic 
viral RNA in the cells 3 days post inoculation. As shown in Figure 3B, knockdown of CypA 
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resulted in a 4.0  0.6-fold (n = 6; P < 0.01) increase of HEV RNA; and knockdown of CypB 
has resulted in a 7.4  1.9-fold (n = 6; P < 0.05) increase of viral genomic RNA. Consistently, 
silencing of CypA and CypB in HEV subgenomic model significantly increased viral 
replication-related luciferase activity by a mean  SEM of 350.4%  11.7% (n = 12; P < 0.001) 
and 406%  14.5% (n = 12; P < 0.001), respectively (Figure 3C). The most straightforward 
explanation of these results is that CsA through cyclophilin binding and inhibition facilitates 
HEV infection (Figure 2). 
 
 
 
 
 
Figure 3. Gene silencing of CypA 
or CypB facilitated HEV infection. 
(A) Western blotting showed 
dramatic downregulation of 
CypA and CypB protein by 
lentiviral RNA interference– 
mediated gene knockdown. (B) 
Silencing of CypA or CypB 
resulted in a significant increase 
of cellular HEV RNA. Data 
presented as mean  SEM of 6 
independent experiments. * P < 
0.05; ** P < 0.01. (C) Silencing of 
CypA or CypB significantly 
increased viral replication-
related luciferase activity in the 
HEV subgenomic model (mean  
SEM, n = 12 replicates of 3 
experiments in total). *** P < 
0.001. 
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High Dose of FK506 Promoted Hepatitis E Virus Replication 
FK506 is another type of calcineurin inhibitor that binds to FK binding proteins. To 
determine the effects of FK506 on HEV replication, p6-Luc cells were treated with FK506 at 
concentrations of 0.1, 0.5, and 5 μg/mL. As shown in Figure 4A, only high does (5 μg/mL) of 
FK506 significantly increased HEV replication, seen at 24, 48, and 72 hours post-treatment. 
This was also further confirmed in the p6 infectious model that HEV genomic RNA was 
increased by a mean  SD of 35%  9.6% (n = 4; P < 0.01) by treatment with 5 μg/mL FK506 
for 48 hours (Figure 4B). 
Figure 4. High dose of FK506 enhanced HEV infection. (A) Treatment with 5 μg/mL (but not 0.5 and 1 μg/mL) 
resulted in significant increase of luciferase activity in the HEV subgenomic model (mean  SD; n = 5-8) and (B) 
significant increase of HEV RNA in the infectious model (mean  SD, n = 4). * P < 0.05; ** P < 0.01; *** P < 
0.001. 
Because the immunosuppressive mechanisms of calcineurin inhibitors are mediated 
via the Ca2+ -NFAT signal transduction, we tested the effects of N,N-dimethyl-Derythro- 
sphingosine, a compound that can efficiently increase cellular Ca2+ levels 16, on HEV infection. 
As shown in Supplementary Figure 2A, N,N-dimethyl-D-erythro-sphingosine (1- 4 μg/mL) 
triggered clear induction of Ca2+ levels in Huh7 cells visualized with a fluorescent dye, Fluo-
4/AM. However, no clear effects were observed on HEV infection in either the subgenomic 
(Supplementary Figure 2B) or the infectious (Supplementary Figure 2B) model. Therefore, 
the proviral effects of calcineurin inhibitors on HEV infection appear to be independent of 
Ca2+ levels. 
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Mycophenolic Acid Inhibited Hepatitis E Virus Replication by Depletion of Cellular 
Nucleotide Pool 
MPA, an inhibitor of inosine monophosphate dehydrogenase (IMPDH) (the 
biosynthesis of guanine), is an immunosuppressive drug often used in organ transplantation, 
but also has a broad antiviral activity against a spectrum of viruses 17. We investigated 
whether MPA could also be able to inhibit HEV infection. Treatment with MPA (0.1-10 
μg/mL) has resulted in a significant reduction of HEV replication-related luciferase activity in 
the subgenomic replicon. For example, with 10 μg/mL MPA treatment, the luciferase activity 
were 42.8%  2.3% (mean  SEM) (n = 9; P < 0.001), 32.8%  5.3% (n = 10; P < 0.001), and 
39.5%  4.6% (n = 12; P < 0.001) of the control group at days 1, 2, and 3, respectively (Figure 
5A). Consistently, MPA also dose-dependently inhibited cellular viral RNA in the infectious 
HEV model. Forty-eight hours of treatment with MPA (10 μg/mL) resulted in 65%   9% (n = 
5; P < 0.01) inhibition of HEV genomic RNA level (determined by qRT-PCR) compared with 
the control (Figure 5B) 
Figure 5. Potent anti-HEV activity of MPA. (A) Treatment of MPA for 24, 48, or 72 hours has resulted in 
significant reduction of HEV luciferase activity in the subgenomic model (mean  SEM, n = 9-12). (B) In the 
infectious model, treatment with 0.1, 1, and 10 μg/mL of MPA for 48 hours has significantly inhibited HEV RNA 
by 32%, 57%, and 65%, respectively (mean  SEM, n = 5). * P < 0.05; ** P < 0.01; *** P < 0.001. 
To further investigate whether the effects of MPA are via depletion of cellular 
nucleotides, additional guanosine was added to the MPA treatment. As shown in Figure 6, 
supplement of exogenous guanosine completely abrogated the antiviral activity of MPA in 
both subgenomic and infectious HEV models, suggesting that the action of MPA is 
exclusively via nucleotide depletion. Immunosuppressive drugs have highly diverse effects 
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on HEV replication, calcineurin inhibitors stimulating viral replication, but MPA exerting 
direct inhibition of HEV replication. 
Figure 6. Supplement of exogenous guanosine completely abrogated the anti-HEV effects of MPA. (A) In the 
subgenomic HEV replicon, the antiviral effects by treatment of MPA at concentration of 10 μg/mL for 24 hours, 
48 hours, and 72 hours were abrogated by adding exogenous guanosine (100 μg/mL) (mean  SEM, n = 7-10). 
(B) Similarly, the antiviral effects by treatment of MPA at concentration of 10 μg/mL for 48 hours was also 
abrogated by adding 100 μg/mL exogenous guanosine in the infectious model (mean  SEM, n = 8). ** P < 0.01; 
*** P < 0.001. 
Combination of Mycophenolic Acid With Ribavirin Extended Their Antiviral Activity 
Because the use of ribavirin monotherapy as off-label drug is gaining favor for treating 
hepatitis E 18, we also investigated the antiviral effects of combining MPA with Ribavirin. As 
shown in Figure 7, a serial of combination groups demonstrated a general beneficial effect 
and no negative drug–drug interference was observed. For instance, combining 1 μg/mL 
MPA with 25 μm ribavirin resulted in a mean  SEM of 76%  1% inhibition of HEV luciferase, 
and MPA alone resulted in 60%  2% and ribavirin alone resulted in 17%  3% inhibition (n = 
16; P < 0.001) after 72 hours treatment (Figure 7A). Therefore, a combination of ribavirin 
with MPA appears compatible against HEV infection and constitutes an attractive clinical 
option for preventing rejection in HEV-infected patients. 
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Figure 7. Combination of MPA with ribavirin extended their antiviral activity. Treatment with ribavirin alone 
has showed significant anti-HEV effects (mean  SEM, n = 16 replicates in total) and a combination of MPA 
with ribavirin demonstrated an additional antiviral potency in particular combination groups; MPA doses: 1 
μg/mL; 10 μg/mL; ribavirin doses: 25 μm; 100 μm. (A) 1 μg/ml MPA combined with 25 μm ribavirin. (B) 10 
μg/ml MPA combined with 25 μm ribavirin. (C) 1 μg/mL MPA combined with 100 μm ribavirin. (D) 10 μg/mL 
MPA combined with 100 μm ribavirin. * P < 0.05; ** P< 0.01; *** P < 0.001. 
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Discussion 
Immunosuppressive medication has been proposed to be a key factor for developing 
chronic hepatitis E in organ transplantation recipients 4 and is often solely attributed to 
diminished antiviral immunity. Clinical evidence, however, suggests that different 
immunosuppressive regimens can differentially affect the infection course of HEV 6,8. By 
testing different immunosuppressants in 2 HEV replication models, we have consistently 
demonstrated that steroids (Pred and Dex) did not affect viral replication, calcineurin 
inhibitors (CsA and FK506) promoted HEV infection, and MPA suppressed viral infection in 
vitro. The concentrations of these immunosuppressants used in this study are in general 
covering the achievable blood concentrations in patients 19-21. Of note, animal studies have 
indicated that certain immunosuppressants even accelerate in the liver and drug levels in 
hepatocytes will exceed those observed in serum 22. Therefore, we propose that the results 
of this in vitro study will be a valuable reference regarding the choice of the particular 
immunosuppressant for orthotopic organ transplantation patients who are infected with 
HEV. 
Steroids have been used since the early years of organ transplantation. Pred and its 
close analogue Dex are potent suppressors of the immune system, as they modulate cellular 
and inflammatory responses via stimulation or inhibition of gene transcription 23. In the 
setting of liver transplantation for HCV patients, evidence suggested that steroid boluses 
used to treat acute rejection are associated with an increase in viral load and the severity of 
HCV recurrence 24,25. Using subgenomic cell culture model of HCV replicon, a study 
demonstrated that both Pred and Dex have no stimulatory effect on viral RNA levels, but 
rather have minor inhibitory effects 13. As to infectious HCV model, however, Pred was 
reported to promote HCV infection by enhancing virus entry, including up-regulation of 2 
essential HCV entry factors: occluding and scavenger receptor class B type I 26. In both 
subgenomic and infectious models of HEV, we did not observe clear effect on HEV infection 
by either Pred or Dex. Although limited studies have reported the impact of steroids in HEV 
patients, one case report has documented a good clinical and biochemical response to 
steroid therapy in a patient with acute hepatitis E with autoimmune hepatitis, who 
maintained health with low dose of steroids 27. 
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The first in vitro evidence that CsA but not FK506 can inhibit HCV replication 28 sparked 
the clinical debate on the possible differential effects of these 2 drugs on HCV recurrence 
after liver transplantation 29. Several follow-up studies have demonstrated that the targets 
of CsA, CypA, and CypB are host factors supporting HCV infection 14,15 .CsA exerts anti-HCV 
effects by inhibition of these cellular factors 30. Interestingly, we observed a proviral effect 
of CsA in HEV cell culture models. Using RNA interference gene silencing approach, we 
further demonstrated that knockdown of either CypA or CypB enhanced HEV infection, 
suggesting that both factors could restrict HEV infection. This convincingly explained why 
CsA could facilitate HEV infection. Although a number of reports have demonstrated a 
supportive role of CypA in infections of HIV,31 HCV,14 or HBV,32 recent studies also reported 
that CypA possesses a repressive effect on the replication of some viruses, including 
influenza A virus 33 and rotavirus 34, similar to what we have observed for HEV. Because the 
mechanistic insight is still largely missing for the antiviral action of cyclophilins, it deserves 
additional investigation. In addition, we also observed a proviral effects of FK506, but only 
at high dose. To our knowledge, there is no evidence of FK506 affecting HCV infection in cell 
culture 28,35. In fact, compared with CsA, dose reduction of FK506 was assumed to be 
associated more with clearance of HEV in cases of renal transplantation with acute infection 
36. In a large retrospective study (although only 85 patients were included), the use of FK506 
was the main predictive factor for chronic hepatitis E in organ recipients 6. Our in vitro 
results have indicated that both FK506 and CsA can promote HEV infection. However, these 
data do not necessarily contradict to the clinical observation, because the number of 
patients currently investigated in the clinic is rather too small to draw solid conclusion. In 
addition, besides the direct effects we observed in cell culture, drugs can also have indirect 
influence on the infection. 
The antiviral effects of MPA/mycophenolate mofetil have been demonstrated against 
a broad spectrum of viruses, including Dengue virus, West Nile, yellow fever virus, 
Chikungunya virus, HBV, and HCV 36–39. This is consistent with our finding that MPA also 
potently inhibited HEV replication. For several viruses, MPA exerts antiviral effects by 
targeting IMPDH to deplete cellular nucleotide pools 36. In the case of HCV, the IMPDH-
dependent pathway only partially contributed to its antiviral activity 11. In contrast, 
supplementation of exogenous guanosine completely abrogated the anti-HEV activity of 
Chapter 2 
 
- 46 - 
 
MPA, suggesting a crucial role of IMPDH inhibition leading to depletion of cellular 
nucleotides. Interestingly, clearance of HEV after heart transplantation was found to be 
more frequent in patients with immunosuppressive medication containing MMF 8, although 
this might be biased by a reduced dose of CsA or FK506 in these cases. 
Despite a clear benefit to manipulating immunosuppressive regimens, a substantial 
proportion of patients are still not able to clear the virus and rapidly progresses toward 
chronic hepatitis 6. Although no proven medication is available, the use of ribavirin 
monotherapy as off-label drug is gaining acceptance for treating hepatitis E 18. An intriguing 
question is whether immunosuppressants can interfere with or promote the anti-HEV 
efficacy of ribavirin. In this study, we have finally demonstrated a beneficial effect of 
combining ribavirin with MPA (Figure 7). This does provide a proof of concept that it is 
important to choose the right immunosuppressive medication while under antiviral therapy 
of HEV in organ transplant recipients. 
different immunosuppressants on HEV infection in cell culture. Steroids did not affect 
genotype 3 HEV replication in vitro, but a high dose of FK506 promoted HEV infection. CsA 
dose-dependently facilitated HEV infection by targeting cellular factors CypA and CypB. In 
contract, MPA potently suppressed HEV infection by depletion of cellular nucleotide pools. 
In addition, a clear beneficial effect was observed when MPA combined with another 
antiviral regimen ribavirin. Although experimental research alone will not be able to clarify 
these complicated but important clinical issues, the knowledge gained from this study is 
certainly a valuable reference for the management of immunosuppression in organ 
transplant recipients infected with HEV. Hopefully, it will also promote the initiation of 
randomized controlled clinical studies to address these issues in the near future. 
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Supplementary Materials  
Methods: 
MTT assay 
Huh7 cells were plated in 96-well plates and treated with immunosuppressants. At the indicated 
times, the number of metabolically active cells was quantified by the 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (MTT, 0.5 mg/mL) assay. 
Measurement of [Ca2+] concentration 
The intracellular [Ca2+] concentration was measured using the fluorescent dye, Fluo-4/AM 
(Dojindo Laboratories, Kumamoto, Japan). The Huh7 cells were treated with serial dilutions of 
DMS for 48 h, then resuspended in PBS containing 1% bovine serum and incubated for 30 min 
with 5 μM Fluo-4/AM in the dark. After being washed with PBS, the Fluo-4/AM-labeled cells were 
observed under an inverted fluorescence microscope. 
 
Figures and Legends: 
Supplementary Figure 1. The effects of immunosuppressants on viability of Huh-7 cells. Cells were treated 
with immunosupprants at different concentrations for 24, 48 and 72 h. Cell viability was assayed by the MTT 
test. Shown is Mean ± SD from at least 3 independent experiments. 
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Supplement Figure 2. Induction of cellular Ca2+ concentration by N,N-Dimethyl-D-erythro-sphingosine (DMS) 
did not affect HEV infection. (A) DMS (1-4 µg/ml) triggered clear induction of Ca2+ levels in Huh7 cells 
visualized with a fluorescent dye, Fluo-4/AM. (B) HEV replication in the subgenomic model was not affected by 
DMS treatment for 24, 48 and 72h, respectively. (C) HEV infection was also not affected by DMS treatment for 
48 hrs in the infectious model quantified by qRT-PCR. Shown is Mean ± SD from 3 independent experiments. 
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Abstract 
BACKGROUND & AIMS: Humans are frequently exposed to hepatitis E virus (HEV). 
Nevertheless, the disease mainly affects pregnant women and immunocompromised 
individuals. Organ recipients receiving immunosuppressants, such as rapalogs, to prevent 
rejection have a high risk for developing chronic hepatitis following HEV infection. Rapalogs 
constitute potent inhibitors of mTOR including rapamycin and everolimus. As a master 
kinase, the mechanism-of-action of mTOR is not only associated with the 
immunosuppressive capacity of rapalogs but is also tightly regulated during pregnancy 
because of increased nutritional demands. 
METHODS: We thus investigated the role of mTOR in HEV infection by using two state-of-the 
art cell culture models: a subgenomic HEV containing luciferase reporter and a full-length 
HEV infectious cell culture system. 
RESULTS: In both subgenomic and full-length HEV models, HEV infection was aggressively 
escalated by treatment of rapamycin or everolimus. Inhibition of mTOR was confirmed by 
Western blot showing the inhibition of its downstream target, S6 phosphorylation. 
Consistently, stable silencing of mTOR by lentiviral RNAi resulted in a significant increase in 
intracellular HEV RNA, suggesting an antiviral function of mTOR in HEV infection. By 
targeting a series of other up- and downstream elements of mTOR signaling, we further 
revealed an effective basal defense mechanism of the PI3K-PKB-mTOR pathway against HEV, 
which is through the phosphorylated eIF4E-binding protein 1 (4E-BP1), however 
independent of autophagy formation. 
CONCLUSIONS: The discovery that PI3K-PKB-mTOR pathway limits HEV infection through 4E-
BP1 and acts as a gate-keeper in human HEV target cells bears significant implications in 
managing immunosuppression in HEV-infected organ transplantation recipients. 
 
Keywords: Hepatitis E virus; Rapamycin; Everolimus; PI3K-PKB-mTOR pathway. 
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Introduction 
Although hepatitis E virus (HEV) infection is underdiagnosed, it is clear that the virus 
represents one of the most abundant infectious challenges to humans 1. In Western 
countries, HEV infection of healthy individuals almost exclusively remains subclinical and 
otherwise causes an acute and self-limiting infection in immunocompetent individuals with 
low mortality rates 2. In contrast, patients with HEV infection in immunocompromised 
individuals that include organ transplantation recipients 3, HIV patients 4 and cancer patients 
receiving chemotherapy 5 have a substantially high risk of developing chronic hepatitis. The 
use of immunosuppressants, such as rapalogs, in organ transplant recipients to prevent 
rejection is associated with substantial pathology and in particular an increased risk of 
developing chronic hepatitis with substantial graft loss and mortality rates 6. 
However, in undernourished populations in the developing world, fulminant hepatitis 
and high mortality are described, reaching 25% in the case of pregnant women 7. In the 
current (2012–2013) hepatitis E outbreak among refugees in South Sudan, a total of 5080 
acute jaundice syndrome cases had been reported from all four Maban County refugee 
camps, as of January 27, 2013. An acute jaundice syndrome case-fatality rate of 10.4% was 
observed among pregnant women across all camps 8. Humans appear to have powerful HEV 
combating mechanisms, but these apparently require a good nutritional and host defence 
status for optimal functionality 9. The nature of these mechanisms has not been 
characterised, due to the lack of robust HEV cell culture models. The advent of new 
technology that mimics the HEV infectious process in vivo, in particular the development of 
in vitro adapted infectious clones and subgenomic HEV reporters, has led to hopes that the 
mechanisms that control HEV infection in normal physiology can now be identified 10,11. 
Rapalogs comprise, amongst others rapamycin (RAPA, rapamune, sirolimus; originally 
isolated from Streptomyces hygroscopicus) and everolimus (the 40-O-[2-hydroxyethyl] 
derivative of rapamycin). This immunosuppressive medication is gaining increasing 
popularity in the transplantation context, mainly because of its low nephrotoxicity 12. Their 
molecular mode of action is well characterised and involves inhibition of the mammalian 
target of rapamycin (mTOR) pathway. mTOR is a central element within the 
phosphatidylinositol-3 kinase (PI3K)-protein kinase B (PKB)-mTOR signaling 13 and integrates 
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nutritional information and receptor tyrosine kinase signaling to control cellular growth via a 
variety of cellular effectors, including activation of p70 S6 kinase and subsequent protein 
synthesis as well as inhibition of autophagy. Activation of PI3K-PKB-mTOR signaling 
following viral infection of liver cells has been reported and linked to both viral supportive 
functions (e.g., prevention of apoptosis in hepatitis C-infected cells) 14, but also to the 
induction of the production of antiviral interferons 15. Thus, generally speaking the role of 
this signaling cascade in combating viral infection of the liver remains unclear, prompting 
further research. 
Given the important and increasing role of rapalog implications in clinical practice and 
the lack of insight into the mechanisms employed by the body to constrain HEV infection, 
we investigated the role of the PI3K-PKB-mTOR signaling cascade in HEV infection using 
state-of-the-art cell culture models. These results show that mTOR inhibition drastically 
promotes HEV replication in an autophagy-independent fashion but through 
phosphorylated 4E-BP1 in infected hepatocytes. 
Materials and Methods 
Reagents 
Stocks of rapamycin (Merck, Schiphol-Rijk, The Netherlands) and everolimus (Sigma-
Aldrich, St Louis, MO) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, 
MO) with a final concentration of 2 mM. Stocks of LY294022, an inhibitor of PI3K-PKB 
(Sigma-Aldrich), BEZ235, a dual inhibitor of PI3K-PKB and mTOR (Selleck Chemicals), FG-
4592, an inhibitor of HIF-1a (Selleck Chemicals) and PF-478671, an inhibitor of p70 S6 kinase 
(Selleck Chemicals) were dissolved in DMSO. All agents were stored in 15 ll aliquots and 
frozen at -4℃. Antibodies including LC3-I/II (Cell Signalling Technology, Netherlands), S6, 
phospho- S6, p70 S6 kinase, phospho-PKB, 4E-BP1 and β-actin (Santa Cruz Biotech, Santa 
Cruz, CA); anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (Stressgen, 
Glandford Ave, Victoria, BC, Canada) were used for Western blot. Lentiviral particles of GFP-
LC3-II (Millipore, Billerica, MA, USA), expressing GFPLC3 fusion protein, were used for 
visualisation of autophagy formation. Other reagents including EBSS medium (Lonza), E-64-d 
(Santa Cruz Biotech, Santa Cruz, CA), pepstatin A (Santa Cruz Biotech, Santa Cruz, CA) and 
chloroquine (Sigma–Aldrich) were also used. 
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HEV cell culture models 
HEV genomic RNA was generated from a plasmid construct containing the full-length 
HEV genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene (p6-
luc), using the Ambion mMESSAGE mMACHINE in vitro RNA transcription Kit (Life 
Technologies Corporation) 10,11. The human hepatoma Huh7 cells were collected and 
centrifuged for 5 min, 1500 rpm, -4 ℃. Supernatant was removed and washed with 4 ml 
Optimem by centrifuging for 5 min, 1500 rpm, -4 ℃. The cell pellet was re-suspended in 100 
μL Optimem and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. 
Electroporation was performed with the Bio-Rad’s electroporation systems using the 
protocol of a designed program (240 volt, pulse length 0.5, number 1 and cuvette 4 mm) 10. 
The supernatant of cultured p6 full-length HEV RNA electroporated cells was collected and 
used for secondary infection. 
Cell culture 
Naïve or vector transduced HuH7 cells (human hepatoma cell line) and HEK293T cells 
(human fetal kidney epithelial cell line) were cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Invitrogen-Gibco, Breda, The Netherlands) complemented with 10% (v/v) fetal calf 
serum (Hyclone, Lonan, Utah), 100 IU/ml penicillin, 100 lg/ml streptomycin and 2 mM L-
glutamine (Invitrogen-Gibco). Stable firefly luciferase expressing cells were generated by 
transducing naïve Huh7 cells with a lentiviral vector expressing the firefly luciferase gene 
under control of the human phosphoglycerate kinase (PGK) promoter (LV-PGK-Luc). For 
visualisation of autophagy formation, Huh7 cells were transduced with lentiviral vector 
expressing the GFP-LC3 fusion protein. 
Gene knockdown by lentiviral vector delivered short hairpin RNA (shRNA) 
Lentiviral vectors (Sigma–Aldrich), targeting mTOR, 4E-BP1 or GFP (shCon), were 
obtained from the Erasmus Center for Biomics and produced in HEK 293T cells as previously 
described 16. After a pilot study, the shRNA vectors exerting optimal gene knockdown were 
selected. These shRNA sequences were described in Supplementary Table 1. 
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To generate stable gene knockdown cells, Huh7 cells were transduced with lentiviral 
vectors. Since the vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 2.5 μg/ml puromycin (Sigma) to the cell culture medium. 
For the infectious model, HEV particles were incubated with knockdown and control Huh7 
cells. 
Measurement of luciferase activity 
For Gaussia luciferase, the activity of secreted luciferase in the cell culture medium 
was measured using BioLux Gaussia Luciferase Flex Assay Kit (New England Biolabs). For 
firefly luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and incubated 
for 30 min at 37 ℃. Both gaussia and firefly Luciferase activity was quantified with a 
LumiStar Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) 
was added to cells seeded in 96-well plates and the cells grow at 37 ℃ with 5% CO2 for 3 h. 
The medium was removed and 100 μL of DMSO was added to each well. The absorbance of 
each well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 
nm. All measurements were performed in triplicates. 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
prepared from total RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of HEV 
and GAPDH were amplified by 40 cycles and quantified with a SYBRGreen-based real-time 
PCR (MJ Research Opticon, Hercules, CA, USA) according to the manufacturer’s instructions. 
GAPDH was considered as reference gene to normalize gene expression. The HEV primer 
sequences were 5’-ATTGGCCA GAAGTTGGTTTTCAC-3’ (sense) and 5’-
CCGTGGCTATAATTGTGGTCT-3’ (antisense), and the primers of housekeeping gene GAPDH 
were 5’-TGTCCCCACCCCCAATGT ATC-3’ (sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
(antisense). 
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Western blot assay 
Proteins in cell lysates were heated 5 min at 95 ℃ followed by loading onto a 10–15% 
sodium dodecyl sulphate-polyacrylamide gel and separated by electrophoresis (SDS-PAGE). 
After 90 min running at 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 h with an electric current of 
250 mA. Subsequently, the membrane was blocked with 2.5 ml blocking buffer and 2.5 ml 
PBS containing 0.05% Tween 20 (PBS-T). It was followed by incubation with rabbit LC3-I/II, 
p-PKB, p-mTOR, mTOR 4E-BP1, p-4E-BP1 or p-S6 (1:1000) antibody overnight at 4 ℃. The 
membrane was washed 3 times followed by incubation for 1.5 h with anti-rabbit or anti-
mouse IRDye-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, USA) (1:5000) 
at room temperature. Blots were assayed for actin content as standardisation of sample 
loading, scanned, and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, 
NE, USA). Results were visualised with Odyssey 3.0 software. 
Confocal laser electroscope assay 
Lipidated LC3 (LC3-II) is a robust marker of autophagic membranes. Autophagosomes 
were visualised as bright green fluorescent protein GFP-LC3-II puncta by fluorescence 
microscopy. For nutrient starvation, cells were incubated in EBSS medium with 1 mM 
pepstatin A and E-64-d solution overnight prior to fix for confocal laser electroscope analysis. 
The cells were fixed with 70% ethanol and GFP-LC3-II puncta was detected using confocal 
electroscope. 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were 
performed with Mann-Whitney test. Differences were considered significant at a p value 
less than 0.05. 
Results 
mTOR inhibition by rapalogs facilitates HEV replication 
The 7.2-kb genome of HEV is a single strand positive-sense of RNA containing three 
overlapping reading frames (ORFs). We employed a model, in which human hepatoma cells 
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(Huh7) were transfected with a 3’ subgenomic construct of the HEV coding sequence, in 
which the 5’ portion of ORF2 was replaced with the in-frame secreted form of luciferase 
derived from the marine copepod Gaussia princeps (p6-luc) (Supplementary Figure 1). 
Accumulation of luciferase in Huh7 cells thus serves as reporter for HEV RNA synthesis, 
whereas the loss of the capsid protein in the model system precludes the formation of novel 
viral particles 10,11. In parallel, Huh7 cells constitutively expressing a nonsecreted firefly 
luciferase are used for normalisation of non-specific effects on luciferase signals. In addition, 
a Huh7 based full length infectious HEV model (p6) was also employed (Supplementary 
Figure 1) 10,11. 
Direct investigation of the phosphorylation status of phospho-Ser-240/224 S6 and 
phospho-Ser-473 PKB showed that Huh7 cells represent a PI3K-PKB-mTOR-proficient model 
system (Figure 1A and B). Importantly, inhibiting mTOR rendered this system sensitive to 
HEV infection, as evident from higher levels of G. princeps luciferase, which increased over 
time. Treatment with 100 and 1000 ng/ml of rapamycin for 48 h resulted in a 1.9 ± 0.4 
(mean ± SD, n = 3, p <0.05) and 2.7 ± 0.6 (mean ± SD, n = 3, p < 0.01) -fold increase of HEV 
luciferase activity (Figure 1C) and corresponds to a concomitant decrease in mTOR activity 
as assessed by phospho-Ser-240/224 S6 levels (Figure 1A). At 72 h, HEV luciferase activity 
was further increased up to 3.8 ± 0.5 (mean ± SD, n = 3, p < 0.01) and 4.9 ± 0.5 (mean ± SD, n 
= 3, p < 0.01) -fold, respectively (Figure 1C). A possible artefact here could be due to the 
direct growth-promoting effects of rapamycin, but the MTT assay showed that rapamycin 
did not promote cell growth (Figure 1D). 
Next to rapamycin, everolimus is often used for clinical mTOR inhibition following 
orthotropic organ transplantation. Like rapamycin, everolimus also remarkably permitted 
HEV replication. In the p6-Luc model, treatment with 1 ng/ml of everolimus has already 
significantly increased HEV luciferase activity. Treatment with 100 and 1000 ng/ml of 
everolimus resulted in 7.0 ± 2.2 (mean ± SD, n = 3, p < 0.01) and 6.7 ± 1.4 (mean ± SD, n = 3, 
p < 0.01) -fold increase at 48 h, 5.3 ± 0.8 (mean ± SD, n = 3, p < 0.01) and 5.6 ± 1.9 (mean ± 
SD, n = 3, P < 0.05) -fold increase of HEV luciferase activity at 72 h (Figure 1E). Everolimus 
also did not promote cell proliferation determined by MTT assay (Figure 1F). 
Dephosphorylation of S6 was also confirmed (Figure 1B). 
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Figure 1. mTOR inhibition by rapalogs facilitate HEV replication. (A) Western blot showing inhibition of S6 
phosphorylation by treatment with 500 nM rapamycin for 48 h. β-actin served as an internal reference. (B) 
Western blot showing inhibition of S6 phosphorylation by treatment with 500 nM everolimus for 48 h. β-actin 
served as an internal reference. (C) In the Huh7 cell-based subgenomic HEV replicon, treatment with 
rapamycin dose-dependently increased viral replication-related luciferase activity (mean ± SD, n = 3 
independent experiments with each 2–3 replicates). (D) Rapamycin did not increase cell proliferation 
determined by MTT assay (OD490 value) (mean ± SD, n = 5). (E) In the Huh7 cell-based subgenomic HEV 
replicon, treatment with everolimus dose-dependently increased viral replication-related luciferase activity 
(mean ± SD, n = 3 independent experiments with each 2–3 replicates). (F) Everolimus did not increase cell 
proliferation determined by MTT assay (OD490 value) (mean ± SD, n = 5). (G) In the HEV infectious model, (G) 
rapamycin (mean ± SD, n = 5) as well as (H) everolimus (mean ± SD, n = 3–6) significantly increased cellular viral 
RNA determined by qRTPCR. * p < 0.05; ** p < 0.01. 
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To exclude that this effect is a consequence of the loss of the capsid protein and ORF3 
protein in our luciferase model, we repeated the experiments with the full-length infectious 
HEV model. Again, HEV infection was facilitated under mTOR-deficient conditions. For 
instance, treatment with 100 or 1000 ng/ml rapamycin has increased viral RNA levels up to 
2.6 ± 0.6 (mean ± SD, n = 5, p < 0.01) or 2.1 ± 0.4 (mean ± SD, n = 5, p < 0.01) -fold, 
respectively (Figure 1G). Treatment with 1, 10, 100, and 1000 ng/ml of everolimus for 48 h 
resulted in an increase of cellular viral RNA up to 1.6 ± 0.1 (mean ± SD, n = 3, p < 0.01), 1.5 ± 
0.3 (mean ± SD, n = 6, p < 0.05), 2.0 ± 0.1 (mean ± SD, n = 3, p < 0.01) and 2.1 ± 0.2 (mean ± 
SD, n = 3, p < 0.01) (Figure 1G). Hence, both major drugs used for clinical mTOR inhibition 
provoke an altered cellular state in hepatocyte-like cells that allows efficient HEV replication 
to proceed. 
Gene silencing of mTOR by RNAi enhances HEV replication 
To evaluate the direct effects of mTOR on HEV, Huh7 cells were transduced with 
integrating lentiviral vectors expressing short hairpin RNA (shRNA) specifically targeting 
mTOR or a control shRNA (shCon). As shown in Figure 2A, three of the four tested shRNA 
vectors targeting mTOR exert potent gene silencing capacity, resulting in a profound 
downregulation of mTOR protein level but an elevation of PKB expression (probably due to a 
feedback activation). Correspondingly, mTOR silencing resulted in a significant increase of 
cellular HEV RNA, which was measured by qRTPCR after inoculation of cell culture produced 
infectious HEV particles for 72 h. For instance, knockdown of mTOR by the shmTOR clone 2 
led to 2.6 ± 0.8-fold (mean ± SD, n = 3, p < 0.05) increase of HEV RNA (Figure 2A). These data 
provide direct and strong evidence that mTOR plays an important role in restricting HEV 
infection. 
mTOR limits HEV replication via 4E-BP1 
mTOR is a key kinase controlling cellular behaviour. Its most important effector 
pathways include induction of protein transcription via the p70 S6 kinase pathway (Figure 
2B) 15. However, this pathway does not seem to be a major effector mechanism as inhibition 
of p70 S6 kinase by its inhibitor PF-478671 did not affect HEV infection (Supplementary 
Figure 2). Inhibition of another downstream target of mTOR, hypoxia-inducible factor-
1alpha (HIF-1a) by FG-4592 (Supplementary Figure 3) also did not affect HEV infection. 
Rapamycin and Everolimus Facilitate Hepatitis E Virus Replication 
 
- 63 - 
 
Notably, mTOR is also the main inhibitor of autophagy in cellular metabolism and it is 
possible that HEV replication requires autophagosome formation. However, inhibition of 
mTOR did not change the levels of microtubule-associated protein 1 light chain 3 b (LC3-II) 
in our model system (Figure 2C), a hallmark of autophagosome formation. Furthermore, 
Huh7 cells stably intergraded with a lentiviral vector expressing GFP-LC3-II were used to 
visualise autophagosome formation. In the positive control groups, cells were either treated 
with 30 μM chloroquine or under condition of starvation in EBSS medium. As expected, 
green puncta of LC3-II were clearly emerging, indicating the formation of autophagosomes 
(Figure 2D). In contrast, no changes of the autophagy machinery were observed with 
treatment of rapamycin or everolimus (Figure 2D), which was consistent with the results of 
Western blot (Figure 2C). Thus, these findings exclude the possibility that the proviral effect 
of rapamycin/everolimus is via the autophagy machinery. 
4E-BP1 is another important element induced by mTOR for cellular cap-dependent 
translation 17. Treatment with the mTOR inhibitor everolimus (500 nM) for 48 h resulted in 
clear dephosphorylation of 4E-BP1 as shown by Western blot (Figure 2E). To further confirm 
the regulation of HEV replication by 4E-BP1, Huh7 cells were transduced with integrating 
lentiviral vectors expressing shRNA specifically targeting 4E-BP1 or a control shRNA (shCon). 
Cells stably transduced with the vector were also selected and expanded by adding 
puromycin to the relevant cell cultures. Four out of five shRNA vectors targeting 4E-BP1 
exert gene silencing capacity, resulting in downregulation of total 4E-BP1 protein (Figure 2F). 
Correspondingly, we selected two 4E-BP1 silencing cell-lines with optimal gene silencing 
potency that resulted in a significant increase of cellular HEV RNA level, which was 
measured by qRT-PCR of HEV RNA. For instance, knockdown of 4E-BP1 led to a 1.7 ± 0.6-fold 
(mean ± SD, n = 5, p < 0.01) (by the sh4E-BP1 clone 53) and 2.4 ± 0.9-fold (mean ± SD, n = 4, 
p < 0.05) (by the clone 56) increase of HEV RNA, respectively (Figure 2G). Consistently, clone 
54, with minimal gene silencing efficacy, only exerted a minor effect (1.3 ± 0.3-fold, mean ± 
SD, n = 4, p > 0.05) on HEV replication (Figure 2G). These data indicated that the antiviral 
effect of mTOR is via its downstream target, 4E-BP1. 
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Figure 2. Gene silencing of mTOR and 4E-BP1 by lentiviral RNAi enhances HEV replication independent of 
autophagy machinery. (A) Knockdown of mTOR by lentiviral shRNA vectors. Compared with the control vector 
transduced cells, the shmTOR clones 1, 2, and 3 but not 4 exert potent silencing capability shown at protein 
levels of both total- (t-mTOR) and phospho-mTOR (p-mTOR), which also resulted in dramatic elevation of 
phospho-PKB (p-PKB). S6 phosphorylation (p-S6) was also determined by Western blot and β-actin served as 
an internal reference. Correspondingly, knockdown of mTOR resulted in significant increase of cellular HEV 
RNA level (mean ± SD, n = 3), which were measured by qRT-PCR after inoculation of cell culture produced 
infectious HEV particles for 72 h. * p < 0.05; ** p < 0.01. (B) Illustration of the effects on HEV infection by 
inhibiting different components of the PI3K-PKB-mTOR pathway. Rapamycin/everolimus, inhibitors of mTOR; 
LY294022, an inhibitor of PI3K-PKB; BEZ-235, a dual inhibitor of PI3K-PKB and mTOR; PF-4708671, an inhibitor 
of p70 S6 kinase and FG-4592, an inhibitor of HIF-1a were used. (C) Naïve Huh7, subgenomic HEV replicon and 
HEV infected Huh7 cells were treated with rapamycin and everolimus for 48 h. The accumulation of LC3-II, a 
hallmark of autophagy formation, was not observed by Western blot analysis. β-actin was served as an internal 
reference. (D) Consistently, green puncta formation, an indication of autophagosome formation, was not 
observed in Huh7 cells expressing GFP-LC3-II fusion protein, by treatment of rapamycin and everolimus for 24, 
48, and 72 h. In contrast, autophagosome formation was observed in the positive control groups treated with 
30 μM chloroquine for 48 h or at the circumstance of starvation in BESS media with 1 mM pepstatin A and E-
64-D for either 18 or 24 h. Oil-lenses (40 ×) was used (1024 × 1024 image). (E) Western blot showed inhibition 
of 4E-BP1 phosphorylation by treatment of 500 nM everolimus for 48 h. β-actin served as an internal reference. 
(F) Knockdown of 4E-BP1 by lentiviral shRNA vectors. Compared with the control vector transduced cells, the 
sh4E-BP1 clone 53, 55, 56, and 57 but not 54 expert potent silencing efficacy shown at protein levels of total 
4E-BP1 (t-4E-BP1), β-actin served as an internal reference. (G) Correspondingly, knockdown of 4E-BP1 resulted 
in significant increase of cellular HEV RNA level (mean ± SD, n = 5). * p < 0.05; ** p < 0.01. (This figure appears 
in colour on the web.) 
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Inhibition of PI3K-PKB promotes viral replication  
Although distinct molecules, rapamycin and everolimus share important structural 
characteristics. To exclude the possibility that the effects of these compounds on HEV 
replication represent a mTOR-independent off-target effect, independent confirmation of 
the role of PI3K/PKB/mTOR signaling cascade in preventing HEV replication was sought 
through experiments, in which more upstream elements of this signaling cascade were 
targeted (Figure 2B). When Huh7 p6-Luc cells were treated with different concentrations 
(0.1–10 μM) of the well-established PI3K inhibitor LY294002, enhancement of HEV 
replication became apparently similar to that observed with mTOR inhibitors (Figure 3A), 
which was also not related to enhanced cell proliferation (Figure 3B). Consistently, LY294002 
also significantly increased cellular HEV RNA in the infectious model up to 3.2 ± 1.1-fold 
(mean ± SD, n = 3, p < 0.05) at a dose of 10 μM (Figure 3C). These effects corresponded to 
the observed inhibition of the biological target (Figure 3D). 
 
Figure 3. Inhibition 
of PI3 K-PKB 
promotes viral 
replication. (A) In 
the Huh7 cell-
based subgenomic 
HEV replicon, 
treatment with 
LY294022, a PI3K 
inhibitor, dose 
dependently 
increased viral 
replication-related 
luciferase activity 
(mean ± SD, n = 3). 
(B) LY294022 did 
not affect cell 
proliferation 
determined by 
MTT assay (OD490 
value) (mean ± SD, 
n = 4). (C) In the HEV infectious model, LY294022 significantly increased cellular viral RNA determined by qRT-
PCR (mean ± SD, n = 3). (D) Western blot showed inhibition of PKB, S6 and p70 S6 kinase phosphorylation by 
treatment of 5 lm LY294022 for 48 h. β-actin served as an internal reference. Treatment time was indicated as 
24, 48 or 72 h. * p < 0.05; ** p < 0.01. 
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Simultaneous inhibition of PI3K and mTOR further enhanced viral replication 
Simultaneous treatment with rapamycin/everolimus and LY294002 apparently had 
stronger effects than rapamycin or LY294002 alone. The strongest effect on HEV replication 
was observed with the combination of 100 ng/ml rapamycin and 10 μM LY294002 at 48 h 
(up to 12.1 ± 3.1-fold, mean ± SD, n = 11, p < 0.01 vs. untreated; p < 0.01, vs. rapamycin; p < 
0.01, vs. LY294002) (Figure 4A), and at 72 h with the combination of 1000 ng/ml rapamycin 
and 10 μM LY294002 (up to 31.7 ± 9.9-fold, mean ± SD, n = 11, p < 0.01 vs. untreated; p < 
0.05, vs. rapamycin; p < 0.01, vs. LY294002) (Figure 4A). Similar effects were observed when 
everolimus was combined with LY294002 (Figure 4B). Furthermore, these results were 
found not to be related to enhancement of cell proliferation either with rapamycin 
(Supplementary Figure 4A) or everolimus (Supplementary Figure 4B). BEZ-235 is a dual 
inhibitor of mTOR and PI3K signalling, which is at the stage of clinical development for 
treating cancer patients (NCT00620594, ClinicalTrials.gov) (Figure 2B). We further 
investigated the effect of simultaneously inhibiting PI3K-PKB and mTOR by a single 
compound BEZ-235. As shown in Figure 4C and D, BEZ-235 significantly promoted HEV 
infection in both models. Furthermore, results corresponded to inhibition of biological 
targets of this pathway (Figure 4E). The most straightforward interpretation of these data is 
that HEV can efficiently replicate in the context of deficient signaling through the PI3K-PKB-
mTOR cascade. 
Discussion 
Large zoonotic reservoirs of hepatitis E exist in cattle and poultry and it is generally 
accepted that humans are frequently infected with the virus 7. Almost invariably, however, 
the disease remains subclinical 2. Here we present evidence that the inability of HEV to 
effectively replicate in humans is linked to constitutive mTOR activation. This novel action of 
mTOR in directly counteracting viral replication in liver cells themselves rather than acting 
through the adapted immune system, represents a highly novel non-canonical action of this 
kinase in a new adapted immune system-independent antiviral mechanism and thus our 
results are highly unexpected. 
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Figure 4. Simultaneous inhibition of PI3K and mTOR further increased viral replication. In the HEV 
subgenomic replicon, viral replication-related luciferase activity was present when 1, 5 or 10μMLY294022 was 
combined with 100/1000 nM of rapamycin (A) or everolimus (B). Treatment time was indicated as 24, 48 or 
72h. Data was presented as mean ± SD, n = 11 replicates in total. (C) BEZ-235 is a dual inhibitor of PI3K-PKB 
and mTOR. In the Huh7 cell-based subgenomic HEV replicon, treatment with BEZ-235 significantly increased 
viral replication-related luciferase activity (mean ± SD, n = 5). (D) In the HEV infectious model, BEZ-235 
significantly increased cellular viral RNA determined by qRT-PCR (mean ± SD, n = 3). (E) Western blot showed 
inhibition of PKB, S6 and p70 S6 kinase phosphorylation by treatment of 1 nM BEZ-235. β-actin served as an 
internal reference. Treatment time was indicated as 24, 48 or 72 h. * p < 0.05; ** p < 0.01. 
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Patients after orthotropic organ transplantation when receiving immunosuppressants, 
such as rapalogs, to prevent rejection are well known to be at extremely high risk of Patients 
after orthotropic organ transplantation when receiving immunosuppressants, such as 
rapalogs, to prevent rejection are well known to be at extremely high risk of developing 
chronic hepatitis with persistence of infection 3,6,18. It is known that the clinical symptoms of 
this hepatitis reacts very well to reducing dose of immunosuppression 6. Hitherto, this 
beneficial effect of decreasing immunosuppressive therapy was attributed to increased 
immunity 19. However, different types of immunosuppressants can also have direct effects 
on HEV replication in the target cells of the virus 20. In transplantation patients, the blood 
concentrations of rapalogs can reach approximately 15 ng/ml 21,22, whereas the levels in 
cancer patients can be up to approximately 100 ng/ml 23. We have demonstrated that 1 
ng/ml everolimus was sufficient to trigger significant stimulatory effects on HEV replication 
in vitro, which thus clearly bears important clinical relevance. 
In fact, more evidence supporting the potential proviral effects of rapalogs have come 
from hepatitis B virus (HBV) infected patients. In a randomised clinical trial comparing two 
everolimus dosing schedules in patients with advanced hepatocellular carcinoma, four 
patients were hepatitis B surface antigen (HBsAg)-seropositive. During treatment of 
everolimus, all these patients experienced episodes of HBV flare with >1-log increase in the 
serum HBV DNA level accompanied by alanine transaminase elevations 24. Similarly, a 
patient with renal cell carcinoma also experienced a HBV flare during everolimus treatment 
25. These observations could be explained by affecting the adaptive immune system but may 
also by direct effects on viral replication. The current experimental study has firmly 
demonstrated the proviral effects of both rapamycin and everolimus in two state-of the- art 
HEV cell culture models. Further detailed mechanistic investigation has revealed an antiviral 
function of the PI3K-PKBmTOR pathway, which appears to support the recent clinical 
observations in viral hepatitis patients 18,24,25. 
Another group of patients at high risk for HEV caused death constitute pregnant 
women 26. Although this effect is in literature generally linked to diminished immunity 26, 
immune suppression during pregnancy is relatively moderate 27. Interestingly, the increased 
nutritional demands of pregnancy 28 provoke a powerful activation of the ATP/ADP-sensitive 
kinase AMPK 29. In turn, this kinase is a potent inhibitor of mTOR 30 and indeed pregnancy is 
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associated with a significant downregulation of mTOR 31. It is tempting to speculate that 
pregnancy-specific downregulation of mTOR may help to understand why this group is 
specifically sensitive to HEV infection. In apparent agreement, malnutrition in general is also 
associated with susceptibility to HEV 8. We thus speculate that HEV may preferentially affect 
the human population when hepatic mTOR activity is below its constitutive level. 
Because of its favourable side-effect profile, rapalog therapy is quickly gaining 
popularity for treating a variety of clinical syndromes, especially in oncological disease, in 
congenital diseases like the Peutz-Jeghers syndrome and the Tuberous sclerosis complex, in 
transplantation medicine and autoimmunity. Therefore, recognition of the anti-HEV 
function of PI3K-PKB-mTOR pathway bears magnificent implications in clinical practice 
regarding the choice of particular immunosuppressant for HEV-infected organ transplant 
recipients. In particular, the use of mTOR inhibitors in these patients should be taken with 
caution. In addition, these results may also help to understand the underlying mechanism 
why pregnant women are more susceptible to HEV infection with devastating outcome. 
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Supplementary Materials  
Supplementary Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Genomic structure of the infectious HEV (p6) and subgenomic HEV replicon (p6-Luc) 
models. 
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Supplementary Figure 2. PF-478671, a p70 S6 kinase inhibitor has no effect on HEV replication. (A) In the 
Huh7 cell-based subgenomic HEV replicon, treatment with PF-478671 for 24, 48 and 72 hrs did not have clear 
effects on viral replication-related luciferase activity. (B) PF-478671 did not increase cell proliferation 
determined by MTT assay (relative OD490 value). (C) In the HEV infectious model, treatment with PF-478671 
also did not have clear effects on HEV cellular RNA. 
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Supplementary Figure 3. FG-4592, a HIF-1α inhibitor has no effect on HEV infection. (A) In the Huh7 cell-
based subgenomic HEV replicon, treatment with FG-4592 for 24, 48 and 72 hrs did not have clear effects on 
viral replication-related luciferase activity. (B) FG-4592 did not increase cell proliferation determined by MTT 
assay (relative OD490 value). (C) In the HEV infectious model, treatment FG-4592 also did not have clear effects 
on HEV cellular RNA.  
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Supplementary Figure 4. Simultaneous inhibition of PI3K and mTOR did not affect cell proliferation. In the 
HEV subgenomic replicon, viral replication-related luciferase activity was presented when 1, 5 or 10 µM 
LY294022 was combined with 100/1000 nM of rapamycin (A) or everolimus (B). Treatment time was indicated 
as 24, 48 or 72 hrs. Cell proliferation determined by MTT assay (relative OD490 value). 
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Supplementary Table 1. shRNA sequences 
shmTOR-1 CCGGGCCAGAATCTATTCATTCTTTCTCGAGAAAGAATGAATAGATTCTGGCTTTTTG 
shmTOR-2 CCGGGCCTTGTTTGTGGCTCTGAATCTCGAGATTCAGAGCCACAAACAAGGCTTTTTG 
shmTOR-3 CCGGGAACCAATTATACCCGTTCTTCTCGAGAAGAACGGGTATAATTGGTTCTTTTTG 
shmTOR-4 CCGGGCTGTGCTACACTACAAACATCTCGAGATGTTTGTAGTGTAGCACAGCTTTTTG 
sh4E-BP1-53 CCGGGCCAGGCCTTATGAAAGTGATCTCGAGATCACTTTCATAAGGCCTGGCTTTTTG 
sh4E-BP1-54 CCGGAGGATCATCTATGACCGGAAACTCGAGTTTCCGGTCATAGATGATCCTTTTTTG 
sh4E-BP1-55 CCGGACAGTTTGAGATGGACATTTACTCGAGTAAATGTCCATCTCAAACTGTTTTTTG 
sh4E-BP1-56 CCGGCGGTGAAGAGTCACAGTTTGACTCGAGTCAAACTGTGACTCTTCACCGTTTTTG 
sh4E-BP1-57 CCGGGCGCAATAGCCCAGAAGATAACTCGAGTTATCTTCTGGGCTATTGCGCTTTTTG 
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Purpose of review 
Solid-organ recipients infected with hepatitis E virus (HEV) bear an extremely high risk of 
developing chronic hepatitis, although this virus only causes acute infection in the general 
population. Immunosuppressive medication universally used after transplantation to 
prevent organ rejection appears to be a main risk factor for developing chronic infection. 
This review aims to overview and emphasize the current clinical and experimental evidence 
regarding the key implications of immunosuppressants in chronic hepatitis E. 
Recent findings 
Over 60% of organ recipients who are infected with HEV develop chronic hepatitis. 
Immunosuppressant treatment after transplantation was identified as a key risk factor. 
Therefore, dose reduction or even withdrawal of immunosuppressants is considered as the 
first intervention strategy to achieve viral clearance in these patients. Otherwise, ribavirin, 
as an off-label medication, is considered as an antiviral treatment, with compelling 
outcomes observed so far. Interestingly, in addition to a common immunosuppression 
property that can favour HEV infection in general, different types of immunosuppressants 
may exert differential impacts on the infection course in patients. Furthermore, potential 
interaction may exist between particular immunosuppressant and ribavirin. With the recent 
development of a cell culture system for HEV, experimental research has been initiated to 
investigate how immunosuppressive drugs interact with HEV infection. 
Summary 
On the basis of the current evidence, it remains impossible to define an optimal 
immunosuppressive protocol for these HEV-infected patients. However, the realization of 
this clinical issue and the initiation of translational research using cell culture models of HEV 
have been represented as milestones in this field. 
Keywords 
chronic HEV, clinical evidence, experimental evidence, immunosuppressive medication 
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Key points 
 Over 60% of organ recipients who are infected with HEV develop chronic hepatitis. 
 Thus, the universal use of immunosuppressants after transplantation bears the 
foremost importance in the development of chronic hepatitis E in organ recipients. 
 Dose reduction or even withdrawal (if possible) of immunosuppressants is now 
considered as the first intervention strategy to achieve viral clearance. 
 In addition to a common immunosuppressive property, strong evidence from both 
clinical and experimental research indicates that different types of 
immunosuppressants could differentially affect the course of HEV infection. 
 The recent development of genotype-3-based cell culture models has enabled 
mechanistic investigation of how immunosuppressants act on HEV infection. 
Introduction 
Hepatitis E virus (HEV) is one of the most common causes of acute hepatitis worldwide 
and is emerging as a global health issue. Initially, this infection was only thought to be a 
health issue in developing countries, caused mainly by the water-transmitted genotype 1 
and 2 viruses. Although it is self-limiting and cleaned spontaneously in general, fulminant 
hepatitis and high mortality are described, reaching 25% in the case of pregnant women 1. 
Epidemics affecting thousands of people have periodically occurred in Asia and Africa. In the 
recent (2012–2013) hepatitis E outbreak amongst refugees in South Sudan, a total of 5080 
acute jaundice syndrome cases had been reported and an acute jaundice syndrome case-
fatality rate of 10.4% was observed amongst pregnant women 2.  
In the Western world, the prevalence of HEV is mainly genotypes 3 and 4 with 
zoonotic nature, and eating undercooked pork or game products serves as the primary 
transmission route. HEV infection of healthy individuals almost exclusively remains 
subclinical, and otherwise causes an acute and self-limiting infection with low mortality rate 
3. However, it is occasionally recognized as a potential cause of decompensation in patients 
with pre-existing chronic liver disease and can result in a very high mortality 4,5. In fact, the 
emerging issues of HEV infection in developed countries are arising from 
immunocompromised individuals that include HIV patients 6, cancer patients receiving 
chemotherapy 7 and organ transplantation recipients 8. In contrast to the initial thought that 
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HEV only causes acute infection, those immunocompromised patients, with solid-organ 
transplantation recipients as the most representative population, appear to have extremely 
high risk of developing chronic hepatitis 9. 
Despite the under diagnosis and lack of indepth mechanistic investigation, the use of 
immunosuppressants after transplantation is conceivably a key determinant of developing 
chronic hepatitis in HEV-infected recipients. In addition to a general suppressive effect on 
the immune system that is crucial for controlling viral infection by the human body, 
different types of immunosuppressive drugs may also exert differential interactions with the 
virus, resulting in either favouring or restricting the infection 10. Therefore, we aim to 
provide a comprehensive overview and indepth emphasis regarding the role of 
immunosuppressive medication in the development of chronic hepatitis E in solid-organ 
transplantation. With substantial evidence from both clinical practice and experimental 
investigations, we hope that this article can serve as an important reference for the choice 
of an optimal immunosuppressive protocol for solid-organ recipients who are infected with 
HEV. 
Chronic hepatitis E in solid-organ transplantation 
Chronic hepatitis is an ongoing process that causes injury to the cells of the liver, with 
inflammation which lasts for longer than 6 months. The commonly used tests for diagnosing 
HEV infection include detection of IgM and IgG anti-HEV antibodies, and detection of HEV 
RNA in human serum and plasma 11. In general, IgM antibody is detectable only for 3–12 
months, whereas IgG antibody persists for many years. As the presence of HEV RNA 
indicates ongoing infection, the current definition of chronic hepatitis E is based on the 
positivity of HEV RNA for more than 6 months 3. 
Although persistent infection was reported in cases a decade ago 12,13, HEV was 
considered as an agent resembling hepatitis A that causes acute hepatitis only 14, until then 
an unexpected finding that 8 out of 14 HEV-infected organ transplant recipients developed 
chronic hepatitis. Subsequently, a series of studies have confirmed the existence of chronic 
hepatitis E in various organ transplantation settings, including liver 15–20, kidney 15,18,21,22, 
heart 18,23,24, lung 18,25 and multiorgan transplantation 18. Estimated from the series of 
published cohort studies (mainly from western countries), the prevalence of anti-HEV IgG is 
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approximately 11.6% and genomic viral RNA is 2% in solid-organ transplant patients. A total 
of 65% of patients who were positive for HEV RNA detection developed chronic infection 26. 
Chronic hepatitis E in organ recipients is often considered as a result of primary 
infection, whereas recent evidence suggested that HEV recurrence can also cause chronic 
hepatitis in transplantation recipients 27. The current assumption is that it is exclusively 
caused by genotype 3 HEV, which is prevalent in the industrialized countries. It is zoonotic 
(animals serve as a reservoir) and is spread mainly through eating undercooked pork or 
game products 1. An individual case study reporting a liver transplant recipient who received 
an organ from an occult HEV-infected donor, developing to chronic HEV infection, 
convincingly illustrated the transmission can also occur via the transplanted allograft 28. An 
intriguing question is whether other genotypes can also cause infection and develop chronic 
hepatitis in transplantation patients, as current diagnosis of HEV in these patients almost 
exclusively focus on genotype 3. 
Compared with patients with self-limiting infection, chronic HEV-infected patients 
have evidently a shorter interval time between organ transplantation and diagnosis of liver 
injury, resulting in a rapid progression to liver fibrosis and cirrhosis. This has been reported 
in kidney 29, liver 30 as well as heart 31 transplantation, although the exact risk rate is still 
unclear. In a large retrospective multicentre study, 8 out of 56 HEV-infected organ recipients 
developed cirrhosis, whereas two liver transplant patients required a second liver transplant 
and two died of decompensated cirrhosis. 
The crucial role of immunosuppressants in chronic hepatitis E 
Immunosuppressants are universally used after organ transplantation for life to 
prevent graft rejection. These medications can modulate viral infection not only by 
inhibiting host immunity but also by directly affecting the virus life cycle. Current clinical and 
experimental evidence has supported the crucial role of immunosuppressive drugs in 
developing chronic hepatitis after HEV infection in organ recipients. 
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Clinical evidence 
Clinically, chronic hepatitis E is almost exclusively associated with 
immunocompromised conditions caused either by the diseases itself (i.e. HIV infection 6) or 
by treatment (i.e. chemotherapy 7 or immunosuppressants 8). In addition, chronic hepatitis E 
was also described in a few cases with undefined disease conditions, but those patients 
conceivably are also immunocompromised 32. Although a very recent case report suggested 
the existence of chronic hepatitis E in immunocompetent patients 33, it remains a debate 
whether this patient with a history of an autoimmune disease can be considered as ‘truly’ 
immunocompetent 34. Thus, the universal use of immunosuppressants after transplantation 
bears the foremost importance in the development of chronic hepatitis E in organ recipients. 
Currently, different types of immunosuppressants with distinct mechanism of action 
are widely used after transplantation, including corticosteroids, calcineurin inhibitors, 
mammalian target of rapamycin (mTOR) inhibitors and select antiproliferative agents 35. 
These agents can effectively suppress the immune response via direct or indirect 
mechanism to prevent organ rejection. In addition to their primary task of inhibiting T-cell 
proliferation, immunosuppressants can also affect the function of other types of immune 
cells, including B cells, dendritic cells and natural killer cells 36. As the immune system plays a 
central role in controlling and even eliminating viral infection, suppression of immune 
response will thus favour the infection. Extensive clinical evidence has demonstrated the 
association of immunosuppressive medication with a more aggravated course of hepatitis C 
virus (HCV) re-infection after liver transplantation as well as more resistance to antiviral 
therapy 37,38. Potent immunosuppression is also associated with BK virus reactivation in 
kidney transplant recipients 39. Despite the limited study, the current available clinical data 
has already indicated a strong association between immunosuppressive medication and 
high risk of chronic hepatitis E in organ transplantation patients 26. Virtually all types of 
immunosuppressants can profoundly inhibit T-cell activation and impair HEV-specific T-cell 
responses in solid-organ transplant patients, which was involved in chronic HEV infection. T-
cell responses can appear again after HEV clearance 27. In addition, attenuation of 
lymphocytes and CD2, CD3 and CD4 T cells were also reported in organ recipients with 
persistent infection. 
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Interestingly, different immunosuppressive regimens may differentially affect the 
infection course in patients. Steroids have been used in the transplantation setting since the 
early years. The current knowledge of effect of steroids on HEV infection after 
transplantation is limited, although one case report has documented a good clinical and 
biochemical response to steroid therapy in an acute hepatitis E patient with autoimmune 
hepatitis, who maintained health with low doses of steroids 40. Tacrolimus is one type of 
calcineurin inhibitor. A relatively large retrospective study has reported that tacrolimus, but 
not another type of calcineurin inhibitor cyclosporine A (CsA), is significantly associated with 
high risk of chronic hepatitis E in organ recipients 26. Reducing the dosage of tacrolimus was 
proposed to result in clearance of HEV in cases of kidney transplantation with acute 
infection 41. Mycophenolatemofetil (MMF), a pro-drug of mycophenolic acid (MPA), is part 
of the antiproliferative agents. Recent evidence from heart transplant recipients supported 
the potential benefits of immunosuppressive treatments containing MMF, which may lead 
to more frequent HEV clearance 23. 
Given the strong association between immunosuppressants and chronic hepatitis E, it 
is not surprising that withdrawal or dose reduction of immunosuppression is often used as 
the first intervention strategy to achieve viral clearance in HEV infected organ recipients, 
despite this approach may bear a high risk of acute rejection 21,42,43. However, long-term 
follow-up is required to assess the eventual outcome. This strategy should be used with 
extra caution in patients at higher risk of rejection or in those who are more difficult to 
monitor for rejection (e.g. in heart and lung transplantation). Nevertheless, manipulation of 
immunosuppression does not always result in viral clearance. Although no licensed drug is 
available, pegylated interferon, ribavirin or a combination are currently used as off-label 
treatment 44,45. In particular, ribavirin monotherapy has achieved substantial success in a 
series of patients with viral clearance 25,46–49. A recent, retrospective, multicentre study 
based on 59 solid-organ transplant patients with prolonged HEV viraemia observed HEV 
clearance in 95% of the patients after ribavirin medication 50. This is very different from the 
setting of chronic hepatitis C that ribavirin is generally considered to have little or no 
detectable antiviral activity as monotherapy in HCV patients 51. Only when combining with 
interferon-alpha, ribavirin doubles the sustained virologic response rate, compared with 
interferon alone 52. When applying ribavirin, in addition to the side-effect of treatment-
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induced low haemoglobin level, potential drug–drug interaction should also be taken 
caution 48. In a case series of six heart recipients with chronic hepatitis E, one patient under 
combination treatment of tacrolimus and everolimus could not clear the virus even after 
ribavirin treatment, whereas others with tacrolimus combined with prednisolone and MMF 
cleared the virus spontaneously, after immunosuppression reduction or ribavirin treatment 
31. Thus, it is very important and urgent to properly evaluate the definitive efficacy of 
ribavirin as well as the potential interaction with immunosuppressants with well-designed 
clinical trials in chronic hepatitis E patients. 
Experimental evidence 
Translational and fundamental research of hepatitis E has long been hampered by the 
lack of efficient cell culture system. The identification of a genotype 3 clone (the exact 
genotype causing chronic hepatitis) that can propagate in cell culture paved the way 
towards the establishment of cell culture models 53. On the basis of this isolate, a 
subgenomic replicon that can mimic viral replication without viral production and a full-
length infectious model have been recently established 54. With this system that can 
efficiently model HEV infection in cell culture, the antiviral effects of ribavirin and 
interferon-alpha have been confirmed in vitro 55. Moreover, the effects and mechanism of 
action of immunosuppressants on HEV are also being investigated 56,57. 
In these cell culture models, HEV infection is not affected by treatment with steroids, 
but can be enhanced by both the calcineurin inhibitors, CsA and tacrolimus 57. This is very 
different from the setting of HCV cell culture system. Studies have reported on the 
enhancement of HCV entry by steroids 58, no effect of tacrolimus 59,60 and potent antiviral 
effect of CsA 59. The cellular targets of CsA, cyclophilin A and B, are the host factors 
supporting HCV 61,62 but suppress HEV infection 57. This may explain the dichotomal effects 
on these two viruses. The proviral effects were also reported with mTOR inhibitors, 
rapamycin and everolimus 56. mTOR is a central element within the phosphatidylinositol-3 
kinase (PI3K)–protein kinase B–mTOR signalling, and integrates nutritional information and 
receptor tyrosine kinase signalling to control cellular growth via a variety of cellular 
effectors, including activation of p70 S6 kinase and subsequent protein synthesis as well as 
inhibition of autophagy 63. Autophagy plays an important role in the regulation of viral 
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infections 64, whereas the stimulatory effects of mTOR inhibitors on HEV were thought to be 
independent of autophagy machinery 56. 
MPA has been extensively demonstrated to be antiviral against a broad spectrum of 
DNA and RNA viruses, including dengue virus 65, West Nile virus 60, yellow fever virus 66, 
Chikungunya virus 67 and HCV 60. Consistently, the antiviral effect of MPA was also observed 
in the cell culture models of HEV 55,57. In addition, the combination of MPA and ribavirin 
resulted in a moderately enhanced antiviral effect against HEV 57. The antiviral mechanism 
of MPA was thought to bind and inhibit inosine -5’-monophosphate dehydrogenase enzyme 
to deplete cellular nucleotide pools. Supplementation of exogenous guanosine in cell 
culture completely overcomes the anti-HEV activity of MPA, confirming this mechanism of 
action in the setting of HEV 55,57, whereas this is not in case of HCV infection 68. 
Conclusion 
Immunosuppressive medication after transplantation is one of the most important risk 
factors associated with chronic hepatitis in organ recipients who are infected with HEV. Thus, 
dose reduction or even withdrawal (if possible) of immunosuppression is now considered as 
the first intervention strategy to achieve viral clearance in these patients. Despite a common 
immunosuppressive property, strong evidence from both clinical and experimental research 
indicates that different types of immunosuppressants could differentially affect the course 
of HEV infection. Calcineurin and mTOR inhibitors may promote but MMF/MPA suppress 
the HEV infection independent of their general effects on immune system. 
Nevertheless, the current clinical studies are not able to conclusively address the 
impacts of different immunosuppressants, because of limited patient numbers and the lack 
of long-term follow-up to assess the eventual outcome. On the other hand, the mechanistic 
investigation has only been recently initiated. Therefore, it is still not sufficient to fully 
explain the clinical observations by experimental findings. However, the realization of this 
clinical issue in organ recipients and the development of cell culture models of this virus 
have paved the way for a flourishing future in this field. Hopefully, it will also promote the 
initiation of randomized, controlled clinical studies to unravel the differential actions of 
different immunosuppressants in HEV-infected patients in the near future. 
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Abstract 
Hepatitis E virus (HEV) is a common cause of acute hepatitis that results in high mortality in 
pregnant women and may establish chronic infections in immunocompromised patients. We 
demonstrate for the first time that alpha interferon (IFN-α) and ribavirin inhibit in vitro HEV 
replication in both a subgenomic replicon and an infectious culture system based on a 
genotype 3 strain. IFN-α showed a moderate but significant synergism with ribavirin. These 
findings corroborate the reported clinical effectiveness of both drugs. In addition, the 
antiviral activity of ribavirin against wild-type genotype 1, 2, and 3 strains was confirmed by 
immunofluorescence staining. Furthermore, the in vitro activity of ribavirin depends on 
depletion of intracellular GTP pools, which is evident from the facts that (i) other GTP-
depleting agents (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide [EICAR] and 
mycophenolic acid) inhibit viral replication, (ii) exogenously added guanosine reverses the 
antiviral effects, and (iii) a strong correlation (R2=0.9998) exists between the antiviral 
activity and GTP depletion of ribavirin and other GTP-depleting agents. 
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Introduction 
Hepatitis E virus (HEV) is a positive-sense, single-stranded RNA virus and is classified as 
the sole member of the Hepevirus genus in the Hepeviridae family 1,2. HEV is usually 
transmitted feco-orally and may cause self-limiting acute hepatitis. At least four genotypes 
are currently recognized: genotypes 1 and 2 seem to infect only humans and are endemic in 
developing regions, with an estimated 70,000 deaths annually 3, while genotypes 3 and 4 
are zoonotic agents, with domestic pigs as their main reservoir 1,2. The latter two genotypes 
cause sporadic autochthonous infections in both developing and industrialized parts of the 
world, e.g., through consumption of undercooked pig meat 1,2. In addition, related viruses 
have been found in several animal species, including chickens (avian HEV) 4, rats 5, rabbits 6, 
ferrets 7, bats 8, and trout (cutthroat trout virus [CTV]) 9.  
Infections with HEV are often severe in pregnant women infected with genotype 1, 
with up to 25% mortality 1,10. In addition, genotype 3 can cause chronic infections, 
particularly in immunocompromised individuals 11. The first consideration in treating chronic 
hepatitis E, especially in transplant patients, is lowering immunosuppressive therapy, which 
induces clearance in over 30% of cases 12. An additional course of pegylated alpha interferon 
(IFN-α) for 3 months or longer proved successful in most cases described 13, but ribavirin 
(RBV) monotherapy is probably the most frequently used option for chronic hepatitis E 11, 
and it also seems effective in severe acute infections 14,15. 
Research on HEV has long been hampered by a lack of efficient cell culture models; 
however, in vitro cultures have been established in recent years 16,17. By employing a 
replicon, an infectious virus yield assay, and immunofluorescence staining, we investigated 
the antiviral activities of both IFN-α and RBV against in vitro HEV replication. Depletion of 
intracellular GTP pools was found to be an important aspect of the mechanism of action of 
RBV. 
Materials and Methods 
In vitro transcription and capping. HEV Kernow-C1 p6 (GenBank accession number 
JQ679013) and p6/luc-encoding RNAs were transcribed in vitro from MluI-digested plasmid 
DNA 17 by use of the T7 RiboMAX Large Scale RNA production system (Promega, Madison, 
Chapter 5 
 
- 100 - 
 
WI) and were capped with the ScriptCap m7G capping system (Cellscript, Madison, WI). To 
generate a transfection control for luminescence-based antiviral assays, the T7-IRES-FFLuc-
YFsfRNA DNA fragment was PCR amplified from pT7-IRES-FFLuc-YFsfRNA with primers 5’-
CATATGTCGACTAATACGACTCACTATAGGGATCCGCCCCTCTCCC-3’ and 5’-AGTGG 
TTTTGTGTTTGTCATCC-3’ and with Kapa HiFi HotStart ReadyMix master mix (Kapa 
Biosystems, Woburn, MA). The resulting fragment was in vitro transcribed. The internal 
ribosome entry site (IRES) alleviates the need for capping, and the yellow fever virus-derived 
small flaviviral RNA (YFsfRNA) enhances the cellular stability of this firefly luciferase (FFLuc)- 
encodingRNA 18. The generation of pT7-IRES-FFLuc-YFsfRNA will be described elsewhere.  
Cells and viruses.  
Huh7 cells (a kind gift from Ralf Bartenschlager, University of Heidelberg, Heidelberg, 
Germany) and HepG2/C3A cells (a kind gift from Luc Verschaeve, Scientific Institute of Public 
Health, Brussels, Belgium) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Integro, Leuvenheim, 
Netherlands) in a humidified 5% CO2 incubator at 37°C. To obtain infectious HEV stocks, 
HepG2/C3A cells seeded in a 6-well plate (BD Falcon, Franklin Lakes, NJ) were transfected 
with capped Kernow-C1 p6RNAby use of DMRIE-C (Invitrogen, Carlsbad, CA) and were 
incubated at 35°C. Part of the culture medium was changed every 2 to 3 days to ensure 
long-term cell survival, and culture medium was harvested from the original plate after 34 
days of incubation. The obtained virus stock was propagated once more in HepG2/C3A cells, 
with weekly changing of half of the culture medium. Culture medium was harvested after 22 
days. Since the Kernow-C1 p6 strain has been adapted to growth in HepG2/C3A cells 19, 
culturing of HEV p6 virus stocks in these cells resulted in higher-titer stocks than those 
obtained by culture in Huh7 cells (results not shown). 
HEV strain Sar 55 (GenBank accession number M80581), Akluj (accession number 
AF107909), LBPR-0379 (accession number JN564006), and Kernow-C1 (accession number 
HQ389543) inocula were obtained from human stool samples, while the human Mex 14 
strain (accession number M74506) was passaged once in a rhesus macaque. The work with 
human isolates was carried out under approved protocols of the Carolinas Medical Center 
(IRB-10-0709B) and the Royal Cornwall Hospital Trust (IRB-06Q2101/61), with the informed 
Ribavirin Inhibits Hepatitis E Virus via Depletion of Cellular GTP Pools 
 
- 101 - 
 
consent of the patients. The housing, maintenance, and care of the rhesus macaque met or 
exceeded all requirements for primate husbandry as specified in the Guide for the Care and 
Use of Laboratory Animals 20. 
Compounds.  
IFN-α 2a (Roferon-A) was purchased from Roche Pharmaceuticals (Basel, Switzerland), 
diluted to 3 × 105 international units (IU)/ml in phosphate-buffered saline (PBS; Lonza, Basel, 
Switzerland) supplemented with 10% glycerol and 0.1% bovine serum albumin, stored at -
80°C, and kept at 4°C after thawing. RBV [1-(β-D-ribofuranosyl)-1H-1,2,4-triazole-3-
carboxamide (Virazole)] was purchased from ICN Pharmaceuticals (Costa Mesa, CA). 5-
Ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) was a gift from Akira Matsuda 
(Hokkaido University), and mycophenolic acid (MPA) was purchased from Santa Cruz 
Biotechnology (Dallas, TX). Guanosine was from Sigma-Aldrich (St. Louis, MO). Stock 
solutions of the compounds were made in dimethyl sulfoxide (DMSO) and stored at 4°C. 
Luminescence-based antiviral assay.  
Huh7 cells were seeded in 96-well plates (BD Falcon) at 7.5×103 cells per well in 100 μL 
of DMEM with 10% FBS and were incubated at 37°C. After 24 h, cell layers were washed 
once with DMEM and transfected with IRES-FFLuc-YFsfRNA and capped p6/luc RNA (100 ng 
per well [each]) by use of DMRIE-C reagent (0.2 μL per well) according to the manufacturer’s 
instructions. For cell control (CC) wells, viral RNA was omitted. Plates were incubated at 
37°C for 4 h. Afterwards, the transfection medium was removed, cell layers were washed 
twice with PBS (100 μL per well), and 100 μL of compound diluted in DMEM with 10% FBS 
was added to each well. For virus control (VC) and CC wells, the compound was omitted. 
After incubation at 35°C for 3 days, 20 μL of the culture medium was transferred to a white 
96-well CulturPlate (PerkinElmer, Waltham, MA), and luminescence produced by the 
secreted Gaussia luciferase (GLuc) was determined after addition of 50 μL of diluted Renilla 
luciferase assay substrate (Promega).Apilot study indicated that incubation for 3 days was 
sufficient to obtain a 100-fold increase in Gaussia-generated luminescence (data not shown), 
allowing for a fast and relatively sensitive readout. The remaining culture medium was 
removed, and 20 μL of passive lysis buffer (Promega) was added to each well. Next, the 
buffer with lysed cells was transferred to a white 96-well CulturPlate containing 100 μL of 
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diluted FFLuc assay substrate (Promega) per well, and luminescence counts were obtained. 
GLuc luminescence values were normalized with the following formula: LucNormcompound = 
(GLucreplicon+compound-GlucCC)/FFLucreplicon+compound. The percent antiviral activity was calculated 
as 100 - (LucNormcompound/LucNormVC × 100). The 50% effective concentration (EC50) was 
defined as the concentration of compound that caused a 50% reduction in the LucNorm 
signal compared to that of VC and was calculated through logarithmic interpolation. For 
toxicity evaluation, plates were prepared in parallel with antiviral assay mixtures, but the 
transfection step was omitted. After incubation for 3 days at 35°C, medium was removed 
and replaced with 100 μL of a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium/phenazinemethosulfate (MTS/PMS; Promega) solution, as 
described previously 21. After an incubation period of 2 h at 37°C, the optical density (OD) at 
498 nm was determined for each well. The percent cell viability was calculated as 
follows:%viability=ODcompound/ODCC × 100. 
For combination studies, a checkerboard with 3-fold dilutions of RBV and 4-fold 
dilutions of IFN-α was used. Data were analyzed with the MacSynergy II template at the 95% 
confidence level 22. Volumes of synergy or antagonism below 25 μM2 % are considered 
insignificant, while values between 25 and 50 μM2 % are minor but significant. Volumes 
between 50 and 100 μM2 % indicate moderate synergy or antagonism 22–24. 
Infectious virus yield assay 
Huh7 cells were seeded in 6-well plates at 5 ×105 cells per well in 2 ml of DMEM with 
10% FBS, penicillin (100 units/ml; Gibco), streptomycin (100 g/ml; Gibco), and amphotericin 
B (Fungizone) (2.5 g/ml; Gibco) and were incubated at 37°C. After 24 h, culture medium was 
removed and cell layers were inoculated with infectious p6 virus at 2.1 × 105 RNA copies/ml 
in 1ml of medium with DMSO (0.5%) or compound and then incubated at 35°C. After 5 h, 
the inoculum was removed, cell layers were washed 3 times with 2ml of PBS, and 3ml of 
medium with DMSO or compound was added to each well. After 1 h, a 150 μL sample was 
taken and stored at -80°C. Since HEV replication in vitro is rather poor, regular changing of 
the culture medium was required to allow cell survival over the full duration of the assay. 
Consequently, 750 μL was removed from each well every 2 to 3 days and stored at -80°C, 
and 1 ml of fresh medium with DMSO or compound was added. The viral loads in samples 
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from 1 h, 12 or 13 days, and 20 days post infection were determined by reverse 
transcription-quantitative PCR (RT-qPCR). Statistical significance was calculated with the 
Mann-Whitney U test. On day 20 postinfection, all medium was removed from the plate, 
cell layers were washed with 2 ml of PBS, and 1ml of MTS/PMS solution was added for 
evaluation of compound cytotoxicity. Cultures were incubated for 2 h at 37°C, and 
subsequently, the OD at 498 nm was determined for 100 μL from each well. Cell viability 
was expressed as a percentage of the DMSO control level. 
Immunofluorescence analysis and focus-forming assay 
HEV strains Sar 55, Akluj, Mex 14, LBPR-0379, Kernow-C1, and Kernow-C1 p6 were 
inoculated onto HepG2/C3A cells seeded in 8-well Lab-Tek II CC2 chamber slides (Nunc, 
Penfield, NY). Cells in triplicate wells were incubated with medium with or without RBV at 
200 μM. After 3 days, cells were fixed and stained for capsid protein as described before 19. 
Each well was manually scanned, and fluorescent cells or foci were counted. Cell viability of 
HepG2/C3Acells treated with RBV at 200 μM for 3 days was assessed with the MTS/PMS 
method. RBV was used at a higher concentration than that in Huh7 cells because HepG2 
cells appear to require higher concentrations to induce intracellular GTP depletion (e.g., see 
reference 25). 
Quantification of intracellular GTP concentrations 
RBV, MPA, or EICAR was added to 1-day-old cultures of Huh7 cells in DMEM with 10% 
FBS in 25-cm2 flasks. For RBV, concentrations of 2.5, 10, 25, and 100 μM were tested. For 
MPA and EICAR, concentrations of 0.1, 0.25, 1, and 2.5 μM were used. Untreated CC 
cultures were included as well. Flasks were incubated at 35°C for 3 days, and subsequently, 
cells were detached using trypsin-EDTA solution (Gibco) and collected by centrifugation. 
Nucleotides were extracted from the cell pellet, and GTP levels were quantified by high-
performance liquid chromatography as described previously 26. The 50% inhibitory 
concentration (IC50) was defined as the concentration of compound required to reduce the 
GTP levels to 50% of the levels in untreated control cultures. 
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RT-qPCR.  
Viral RNA was extracted from culture medium by use of a NucleoSpin RNA virus kit 
(Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions. Primer 
and probe sequences for TaqMan-based quantification of HEV RNA were published 
previously 27. The forward primer 5’-GGTGGTTTCTGGGGTGAC-3’ and the reverse primer 5’-
AGGGGTTGGTTGGATGAA-3’ were used. The probe was labeled with 6-carboxyfluorescein 
(FAM) at the 5’ end and with a minor groove binder (MGB) at the 3’ end (5’-FAM-
TGATTCTCAGCCCTTCGC-MGBNFQ-3’) 28. Reactions were performed with One-Step qRT-PCR 
mix (Eurogentec, Seraing, Belgium) in a final volume of 25 μL containing 250 nM of each 
primer, 100 nM of probe, and 5 μL of RNA sample. PCR was performed using an ABI 7500 
Fast real-time PCR system (Applied Biosystems, Foster City, CA) under the following 
conditions: 30 min at 48°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 
min at 60°C. Data were analyzed with ABI Prism 7500 SDS software (version 1.3.1; Applied 
Biosystems). For absolute quantification, standard curves were generated using 10-fold 
dilutions of the cloned target cDNA. 
Results 
We used a transient GLuc-expressing genotype 3 replicon (Kernow-C1 p6/luc) 17 in 
Huh7 hepatoma cells to assess the potential anti-HEV activity of RBV and IFN-α, two drugs 
whose clinical efficacy has been reported in several case studies of HEV-infected patients 
11,13. Both RBV and IFN-α efficiently inhibited HEV replication, with EC50s of 3 ± 2 μM (0.7 ± 
0.5 μM/ml) and 1.3 ± 0.5 IU/ml, respectively (Figure 1A and B). The combination of both 
inhibitors resulted in a moderately synergistic antiviral effect, with a synergy volume of 72 
μM2 % (Figure 1C). The combined antiviral activity was maximally 22% above the expected 
value (at about 4 IU/ml IFN-α and 0.4 M RBV). 
Next, the potential antiviral activity was assessed in Huh7 cells infected with the 
Kernow-C1 p6 virus 17. Viral replication was quantified by means of RT-qPCR detection of 
viral RNA in the culture medium. Both IFN-α and RBV resulted in significant reductions of 
viral titers at 12 and 20 days postinfection (Figure 1D), without decreasing cell viability (RBV 
concentrations of up to 100 μM for 20 days) (Figure 1F). A dose-dependent inhibition of viral 
replication was observed with RBV, with a 4.1-log10 reduction in viral titer after 20 days at a 
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concentration of 100 μM. Some differences in the antiviral potency of RBV observed 
between the replicon and virus yield assays, though limited, may be explained by the 
different setups (luminescence versus quantification of released viral RNA) and the 
respective time windows (3 versus 20 days) of the assays. 
Since RBV was reported to be effective in the treatment of acute genotype 1 
infections 14,15, the antiviral activity of RBV against genotypes 1 and 2 was assessed. To this 
end, HepG2/C3A cells were infected with wild-type isolate Sar 55, Akluj (both genotype 1), 
or Mex 14 (genotype 2) and stained for capsid protein. These strains do not spread in cell 
culture but are able to replicate intracellularly. RBV treatment (200 μM) reduced the 
number of fluorescent foci to almost zero (Figure 1E). Comparable results were obtained for 
the wild-type genotype 3 strains LBPR-0379 and Kernow-C1 and for the cell culture-adapted 
Kernow-C1 p6 strain. No cytotoxicity was observed for RBV at 200 μM for 3 days (Figure 1G). 
In addition, treatment of Sar 55 Gluc-containing replicon cells with RBV resulted in a 
pronounced reduction of viral replication, even when addition of RBV was delayed until 4 
days posttransfection and activity was assessed at 15 days posttransfection (data not 
shown).  
One of the proposed mechanisms of action for the broad-spectrum antiviral activity of 
RBV is that inhibition of IMP dehydrogenase (IMPDH) by RBV 5’-monophosphate results in 
depletion of the intracellular GTP pools, thus impeding RNA virus replication 29,30. To 
determine whether GTP depletion is involved in inhibition of in vitro HEV replication, we 
assessed the antiviral activities of two known IMPDH inhibitors: MPA (an 
immunosuppressive agent) and EICAR, a 5-ethynylimidazole analogue of RBV 31,32. Marked 
inhibition of HEV replication was observed in the replicon assay, with EC50s of 0.20 ± 0.04 
μM and 0.115 ± 0.007 μM for MPA and EICAR, respectively (Figure 2A and B). 
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Figure 1. Inhibitory activities of IFN-α and RBV against HEV replication. Huh7 cells were transfected with 
capped p6/luc RNA and treated with RBV (A) or IFN- α(B) for 3 days. (C) Antiviral activities below or above 
those expected for RBV–IFN-α combinations. (D) Antiviral activities were also assessed in an infectious virus 
yield assay with RT-qPCR detection of viral RNA. *, P ﹤ 0.05; **, P ﹤ 0.01. GE, genome equivalents. (E) RBV 
(200 μM) inhibited formation of foci in HepG2/C3A cells infected with strains Sar 55, Akluj, Mex 14, LBPR-0379, 
Kernow-C1, and Kernow-C1 p6. (F) Cell viability of Huh7 cells used in the infectious virus yield assay after 20 
days in the presence of IFN-α or ribavirin, as assessed by the MTS/PMS method. (G) Cell viability of HepG2/C3A 
cells treated with RBV at 200 μM for 3 days was assessed by the same method. Values represent means 
standard deviations (SD) for at least 3 independent experiments (A to D, F, and G) or 3 replicates (E). 
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Figure 2. Dependence of the 
antiviral activity of RBV on the 
depletion of intracellular GTP 
pools. MPA (A) and EICAR (B) 
are known inhibitors of IMPDH 
and are potent inhibitors of HEV 
replication in the replicon assay. 
Values represent means SD for 
at least 3 independent 
experiments. 
 
 
It has been shown for several viruses that are sensitive to RBV that replenishing of 
intracellular GTP pools through addition of exogenous guanosine restores virus replication 
29,33. Concordantly, the anti-HEV activities of RBV, MPA, and EICAR were reversed following 
addition of guanosine to the cell culture medium (Figure 3A to C). Next, we quantified the 
intracellular GTP pools of Huh7 cells and the effects of different concentrations of the three 
compounds. Normal GTP concentrations were calculated to be around 350M, and RBV, MPA, 
and EICAR effectively depleted GTP pools, with IC50s of 18 ± 9 μM, 0.5 ± 0.1 μM, and 0.3 ± 
0.2 μM, respectively. A strong correlation between both the IC50s for GTP depletion and the 
respective antiviral EC50s was calculated (R2 = 0.9998) (Figure 3D). 
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Figure 3. Replenishing GTP pools salvages HEV replication. Addition of exogenous guanosine to the culture 
medium (40 μM) salvages HEV replication and abolishes the antiviral effects of RBV (A), MPA (B), and EICAR (C) 
in the replicon assay. (D) Relationship between the IC50s for GTP depletion and EC50s for inhibition of viral 
replication. Values represent means SD for at least 3 independent experiments. 
Discussion 
Pegylated IFN-α and RBV are the only drugs that are currently available to treat acute 
and chronic hepatitis E 5,7,9. Treatment duration is at least 12 weeks for chronic infections 13 
and a minimum of 3 weeks for acute infections 14,15,34 (compare with the current standard of 
care for hepatitis C, i.e., pegylated IFN-α plus RBV for up to 48 weeks, combined with a 
protease inhibitor for genotype 1 infections 35). The scientific evidence for these hepatitis E 
treatments is limited to a number of case series and the in vitro activity against CTV, a HEV 
surrogate 36. None of these interventions or the superiority of one over the other has been 
validated in controlled trials yet. Here we demonstrate the antiviral activity of IFN-α and 
RBV against HEV in vitro, thus providing additional evidence for the clinical use of these 
drugs. In addition, a moderate but statistically significant synergy was calculated for the 
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combination of IFN-α and RBV (Figure 1C). The clinical relevance of this observation is 
unclear, however, since antiviral activity was maximally 22% above that expected. 
Nevertheless, since no antagonistic effects were observed, it might be an option to treat 
patients with a combination of IFN-α and RBV, as is the case in the management of 
infections with hepatitis C virus (HCV). Lower doses of both drugs may possibly be sufficient 
in a combination regimen, thus reducing the frequency and severity of adverse effects. In 
fact, successful combination therapy has already been reported for a chronically HEV-
infected HIV patient 37. 
When the in vitro inhibitory concentrations of IFN-α and RBV are compared to the 
serum concentrations typically obtained in (HCV-infected) patients, they seem to be in a 
roughly similar concentration range. For instance, mean pegylated IFN-α serum 
concentrations of around 80 IU/ml have been reported 38, which is considerably higher than 
the EC50 for inhibition of the HEV replicon, although this is lower than the 300 IU/ml that 
resulted in a 0.9-log10 reduction in the virus yield assay. For RBV, serum concentrations 
between 8 and 13 μM have been reported 38,39, and hepatic accumulation of ribavirin has 
been claimed, with a steady-state liver concentration of 250 μM 40. We calculated an EC50 
of 3 μM for RBV and observed strong antiviral effects in the virus yield assays for 
concentrations above 10 μM. Although the relevance of such comparisons may be 
questionable, the fact that both IFN-α and RBV are active in vitro is in agreement with the 
observed clinical efficacy of both in chronically HEV infected patients. 
In a recent study by Dong and colleagues, the HEV ORF3 protein was shown to inhibit 
IFN-α signaling 41. In line with this finding, high concentrations of IFN-α were required to 
reduce release of HEV RNA into the culture medium after infection (e.g., 50% reduction at 
concentrations as high as 1,000 units/ml). A similarly high concentration of 300 IU/ml was 
needed in our infectious HEV system to achieve reductions of viral RNA levels in the virus 
yield assay of 98% and 87% at 12 and 20 days postinfection, respectively (Figure 1D). In the 
replicon assay, on the other hand, we observed strong inhibition by IFN-α at concentrations 
as low as 10 IU/ml (Figure 1B). Slight differences obtained in the infectious HEV system may 
be explained by the use of different cell lines (A549 versus Huh7) and virus isolates and/or 
the fact that the HEV infection was already established before the start of IFN-α treatment 
in the study of Dong et al., while IFN-α was included in the inoculum during initial infection 
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in our virus yield system. However, the pronounced potency of IFN-α against the 
subgenomic HEV replicon system can readily be explained by the lack of an interferon-
antagonizing activity in p6/luc, where expression of ORF3 is ablated by replacement with a 
reporter cassette, making the replicon especially susceptible to inhibition by IFN-α. This is 
fully in line with the findings of Dong et al. 41. 
The data presented here indicate that depletion of cellular GTP pools is the 
predominant mechanism by which ribavirin inhibits in vitro HEV replication. It is unclear, 
however, to what extent hepatic GTP levels can be decreased by RBV in vivo 30. Other 
proposed mechanisms of action of RBV include immunomodulatory effects, modulation of 
IFN-α stimulated gene expression, lethal mutagenesis forcing the virus into an error 
catastrophe, interference with viral methyltransferase activity, direct inhibition of the viral 
polymerase, and inhibition of eukaryotic initiation factor 4E interfering with cap-dependent 
translation 30. Although one or several of these mechanisms could be involved in the 
antiviral activity of RBV against HEV, the results presented here suggest that GTP depletion 
is an important mechanism contributing to its antiviral activity.  
Interestingly, the use of mycophenolate mofetil, a prodrug of MPA, for 
immunosuppressive therapy in transplant patients with chronic hepatitis E was significantly 
associated with HEV clearance 42. This observation is in accordance with the strong antiviral 
activity observed in our replicon assay (Figure 2A). However, it is questionable whether the 
antiviral effect outweighs the immunosuppression that initially allowed HEV to establish a 
chronic infection. 
The replicon-based antiviral assay as described here is rather labor-intensive, but to 
our knowledge, it is the first reported system that allows testing of potential antiviral 
molecules targeting HEV replication. In addition, the results of the infectious virus yield 
indicate that it is feasible to study the impact of potential antiviral compounds on the 
replication of full-length replication competent HEV. Although the isolation of the Kernow-
C1 p6 strain was a major step forward, the replication kinetics are (still) rather slow, thus 
requiring long incubation times to obtain sufficiently high HEV titers for detection by RT-
qPCR. Further adaptation to cell culture may be a possible solution; this strategy proved 
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successful, for instance, for hepatitis A virus and allowed for the development of relatively 
fast virus yield assays 43. 
In conclusion, the observed in vitro antiviral activities provide additional support for 
the clinical use of both RBV and (pegylated) IFN-α for the treatment of severe cases of 
hepatitis E. However, both therapies require long treatment periods and can have severe 
adverse effects. RBV dose reductions because of anemia have resulted in treatment failure 
and death in some cases 15. Consequently, the assays presented here may serve as a starting 
point for developing convenient systems for high-throughput screening. This should allow 
the development of more potent anti-HEV drugs with a better safety profile. Ideally, these 
drugs should be safe during pregnancy. Since HEV appears to be emerging and its impact on 
public health has been underestimated, it would be wise to invest in research toward such 
antivirals. 
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Abstract 
Viruses are solely dependent on host cells to propagate, therefore understanding virus-host 
interaction is important for antiviral drug development. Since de novo nucleotide 
biosynthesis is essentially required for both host cell metabolism and viral replication, 
specific catalytic enzymes of these pathways have been explored as potential antiviral 
targets. In this study, we investigated the role of different enzymatic cascades of 
nucleotides biosynthesis in hepatitis E virus (HEV) replication. By profiling various 
pharmacological inhibitors of nucleotides biosynthesis, we found that targeting the early 
steps of the purine biosynthesis pathway led to enhancement of HEV replication; whereas 
targeting the later step resulted in potent antiviral activity via depletion of purine nucleotide. 
Furthermore, inhibition of pyrimidine pathway resulted in potent anti-HEV activity. 
Interestingly, all these inhibitors with anti-HEV activity concurrently triggered the induction 
of antiviral interferon-stimulated genes (ISGs). Although ISGs are commonly induced by 
interferons via the JAK-STAT pathway, their induction by nucleotides synthesis inhibitors is 
completely independent of this classical mechanism. In conclusion, this study revealed an 
unconventional novel mechanism as to a crosstalk between nucleotide biosynthesis 
pathways and cellular antiviral immunity in constraining HEV infection. Targeting particular 
enzymes in nucleotide biosynthesis represents a viable option for antiviral drug 
development against HEV. 
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Author Summary 
HEV is the most common cause of acute viral hepatitis worldwide and is also associated 
with chronic hepatitis, especially in immunocompromised patients. Although often an acute 
and self-limiting infection in the general population, HEV can cause severe morbidity and 
mortality in certain patients, a problem compounded by the lack of FDA-approved anti-HEV 
medication available. In this study, we have investigated the role of nucleotide synthesis 
pathway in HEV infection and its potential for antiviral drug development. We show that 
targeting the later but not the early steps of purine synthesis pathway exert strong anti-HEV 
activity. In particular, IMPDH is the most important anti-HEV target of this cascade. 
Importantly, the clinically used IMPDH inhibitors, including mycophenolic acid and ribavirin, 
have potent anti-HEV activity. Furthermore, targeting pyrimidine synthesis pathway also 
exerts potent antiviral activity against HEV. Interestingly, antiviral effects of nucleotide 
synthesis pathway inhibitors appear to depend on medication-induced transcription of 
antiviral interferon-stimulated genes. Thus, this study reveals an unconventional novel 
mechanism as to how nucleotide synthesis pathway inhibitors can counteract HEV 
replication.  
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Introduction 
Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus, which mainly 
infects the liver. It is the most common cause of acute viral hepatitis worldwide. In general, 
HEV infection is a self-limiting disease and associated with low mortality, but epidemics of 
hepatitis E occur periodically throughout the developing world, resulting in 70,000 death 
yearly 1. In western countries, HEV primarily affects immunocompromised patients, in 
particular organ transplant recipients, as well as hematopoietic stem cell transplant 2-5. 
More than 60% of organ recipients infected with HEV develop chronic hepatitis with rapid 
progression to cirrhosis 2. Despite an emerging global health issue, no FDA-approved anti-
HEV therapy is currently available, only interferon-α, ribavirin or a combination have been 
occasionally used as off-label treatment. Thus, further research aimed at understanding its 
infection biology and developing effective antiviral treatment is urgently required.  
Cellular nucleotides, including purines and pyrimidines, are the basic building blocks 
that form the nucleic acids RNA and DNA. Nucleotides are the fundamental components 
that are required for cell metabolism, such as genome replication. In vivo, nucleotides can 
be synthesized de novo through a series of enzymatic reactions or recycled through salvage 
pathways. Since viral replication heavily relies on the host cells to supply nucleosides, 
targeting nucleotide biosynthesis pathway thus represents an attractive strategy for 
antiviral drug development. The nucleotide biosynthesis pathways have been well-studied 
for decades 6-8. Numerous compounds have been developed and well-characterized to 
target particular enzymes of this pathway to inhibit viral infections by depletion or causing 
imbalance of nucleotide pools 9-18. Among them, inhibitors of inosine monophosphate 
dehydrogenase (IMPDH), a key enzyme of the purine synthesis pathway, have been 
successfully used in the clinic for decades. These drugs including ribavirin and mycophenolic 
acid (MPA), used as antiviral or immunosuppressive medication respectively, have been 
demonstrated to have broad antiviral activity against a spectrum of viruses, including 
dengue virus, yellow fever virus (YFV), hepatitis B, hepatitis C and hepatitis E virus 14,15,18-21. 
Likewise, Brequinar and Leflunomide, the inhibitors of dihydroorotate dehydrogenase 
(DHODH), an essential enzyme of pyrimidine nucleotide synthesis, have been shown to 
inhibit human polyomavirus type BK (BKV), YFV and dengue virus 12,22.  
Nucleotide Synthesis Pathways as Targets to Constrain Hepatitis E Virus 
 
- 121 - 
 
Besides their function as building blocks of genetic material, free nucleotides also play 
important roles in cell signalling. We and others have previously reported the potential 
interaction of nucleotide deprivation and cellular antiviral immune response, such as 
provoking the expression of interferon-stimulated genes (ISGs) 19,23. Given that the liver is a 
major site for nucleotide synthesis, we comprehensively profiled the role of purine and 
pyrimidine synthesis pathways in HEV cell culture models, aimed at identifying potential 
antiviral drug targets and understanding the crosstalk with cellular antiviral immunity 
against HEV infection. 
Materials and Methods  
Reagents  
Guanosine (CAS: 118-00-3), Adenosine (CAS: 58-61-7), Uridine (CAS: 58-96-8), 6-TG 
(CAS: 154-42-7), Lometrexol hydrate (CAS: 106400-81-1), MTX hydrate (CAS: 133073-73-1), 
FA phosphate (CAS: 75607-67-9), BQR sodium salt hydrate (MDL: MFCD21363375), LFM 
(CAS: 75706-12-6) and 6-AU (CAS: 461-89-2) were purchased from sigma. 23 IMPDH specific 
inhibitors were kindly provided by Center for Drug Design, University of Minnesota. All the 
reagents were dissolved in dimethylsulfoxide (DMSO). The effects of these de novo 
nucleotide biosynthesis inhibitors on host cell viability were determined by MTT assay 
(Supplementary Figure 7). Stocks of JAK inhibitor 1 (CAS 457081-03-7, Santa Cruz Biotech, 
CA) was dissolved in DMSO with a final concentration of 5 mg/mL. Stocks of CP-690550 
(Tofacitinib) (Santa Cruz Biotech, CA) were dissolved in DMSO with a final concentration of 
10 mg/mL. 
Cell culture 
Human hepatoma cell line Huh7 and human embryonic kidney epithelial cell line 293T 
cells were cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine serum, 100IU/mL penicillin and 100IU/mL 
streptomycin.  
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Cell culture models 
HEV replication model with subgenomic HEV sequence coupled with a Gaussia 
luciferase reporter gene and HEV infection model containing the full-length HEV genome 
were used in our study. The construction of two models has been described previously 18. 
Besides, Huh7 cells constitutively expressing the firefly luciferase reporter gene driven by 
the human PGK promoter were used as household luciferase activity for normalizing 
nonspecific effects on luciferase Activity 11. Huh7 cells transduced with lentiviral 
transcriptional reporter system expressing the firefly luciferase gene under control of a 
promoter containing multiple ISRE promoter elements (SBI Systems Biosciences, Mountain 
View, CA) was established and luciferase activity represents ISRE promoter activation. 
Quantification of HEV replication and infection 
The details for exanimating HEV replication and infection were described before 18. 
Briefly, For the HEV replication model (p6-Luc), the activity of secreted gaussia luciferase in 
the cell culture medium was measured using BioLux® Gaussia Luciferase Flex Assay Kit (New 
England Biolabs), as quantification of viral replication, which was normalized by firefly 
luciferase expression. For full- length HEV infectious model, SYBR Green based qRT-PCR was 
used to quantify the newly formed viral genomic RNA after cell lysis and the HEV primer 
sequences were shown in supplementary Table 2.  
Gene knockdown by lentiviral vector delivered short hairpin RNA (shRNA) 
Lentiviral vectors, targeting PPAT, GART, ATIC, DHODH, were produced in 293T cells as 
previously described 11. To generate stable gene knockdown cells, Huh7 cells were 
transduced with lentiviral vectors. Since the vectors also express a puromycin resistance 
gene, transduced cells were subsequently selected by adding 2.5 μg/ml puromycin (Sigma) 
in the cell culture medium. After pilot study, the shRNA vectors (Supplementary Figure 1 
and Supplementary Table 3) exerting optimal gene knockdown were selected by qPCR with 
the corresponding primers shown in supplementary Table 2. Meanwhile, shRNA vector 
expressing Green fluorescent protein (GFP) was used as control (shCTR). The amount of HEV 
were assessed after 3 days of infectious HEV medium post-infecting shGFP cells and 
knockdown cells. For the experiment comparing the activity of compounds between shGFP 
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and knockdown cells, infectious HEV cells were directly transduced with lentiviral shRNA 
vectors and selected by puromycin.  
Statistical analysis  
Statistical analysis was performed using the nonpaired, nonparametric test (Mann–
Whitney test; GraphPad Prism software). P values less than 0.05 were considered as 
statistically significant. 
Results 
Exogenous guanosine, but not uridine, stimulates HEV replication  
Purine and pyrimidine nucleotides are the major cellular energy carriers and 
constitute the defining subunits of nucleic acids. Two distinct pathways are responsible for 
the biosynthesis of these two types of nucleotides (Figure 1A and 2A). Their fundamental 
role in cellular biochemistry raises the possibility that modifying flux through nucleotide 
biosynthesis pathways would profoundly influence the course of viral infection. Thus we 
decided to assess the overall impact of either purine or pyrimidine synthesis on HEV 
infection. A first indication that such effects might exist came from experiments in which we 
arbitrarily increased the purine and pyrimidine content by supplementation of exogenous 
guanosine (Figure 1A) and uridine (Figure 2A) in human hepatoma cell line (Huh7)-based 
HEV cell culture models. Guanosine, a purine nucleoside containing guanine attached to a 
ribose, can be converted to guanosine monophosphate (GMP) through purine salvage 
synthesis pathway, subsequently replenishes purine nucleotide pool (Figure 1A). 
Mechanistically, the cleavage of exogenous guanosine was catalysed by purine nucleoside 
phosphorylase (PNP) to form guanine. In the presence of hypoxanthine/guanine 
phosphoribosyl transferase (HGPRT), guanine was converted to GMP by addition of ribose 5-
phosphate from phosphoribosyl pyrophosphate (PRPP). Supplementation of guanosine 
dose-dependently enhanced HEV replication-related luciferase activity in the subgenomic 
replicon (p6-Luc) model and increased cellular viral RNA in the full-length (p6) infectious 
model (Figure 1B). Likewise, uridine, which is a pyrimidine nucleoside consisting of uracil 
binding to ribose, commonly presents as uridine monophosphate (UMP) to rescue cells from 
pyrimidine nucleotide depletion (Figure 2A). In contrast, supplementation of exogenous 
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uridine had no effect on HEV replication (Figure 2B). Thus interaction between at least some 
of the pathways involved in nucleotide biosynthesis and the HEV infectious process might 
exist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Exogenous guanosine stimulated HEV replication. (A) Schematic overview of de novo biosynthesis of 
purine nucleotide. PRPP, 5-phosphoribosyl-1-pyrophosphate; PRA, 5-phosphoribosylamine; GAR, glycinamide 
ribonucleotide; FGAR, formyl-GAR; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide. (B) Huh7 cell-
based subgenomic HEV replicons containing the luciferase reporter gene were treated for 24 h, 48 h, and 72 h 
with a dose range of guanosine (n = 4). Data are presented as means standard errors of the means (SEM). 
Meanwhile, Huh7 cells with the infectious HEV containing the full-length p6 genome were treated for 48 h 
with a dose range of guanosine (n = 5). Data were normalized to two housekeeping genes (GAPDH and RP2) 
and are presented relative to the control (CTR) (set as 1). Data represent means ± SEM. *, P < 0.05; **, P < 0.01; 
***, P< 0.001. 
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Figure 2. Exogenous uridine does not affect HEV replication. (A) Schematic overview of de novo biosynthesis 
of pyrimidine nucleotide. (B) Huh7 cell based subgenomic HEV replicon containing the luciferase reporter gene 
was treated for 24 h, 48 h, and 72 h with a dose range of uridine (n = 5). Data are presented as means ± SEM. 
Targeting the catalytic steps leading to the primary purine nucleotide synthesis (inosine 
monophosphate ; IMP), stimulates HEV replication 
Given the clear pro-viral effect of exogenous guanosine, we were encouraged to 
explore potential anti-HEV strategies targeting the different enzymes that are involved in 
purine nucleotide synthesis. De novo purine is mainly synthesized in the liver, which begins 
with the starting material 5-phosphoribosyl-1-pyrophosphate, PRPP. The first fully-formed 
nucleotide IMP is catalyzed through ten reactions by six enzymes (Figure 1A). We first 
selectively targeted three key enzymes of this cascade, including amido 
phosphoribosyltransferase (APRTase), glycinamide ribonucleotide trasnformylase (GART) 
and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT) through 
6-thioguanine (6-TG), lometrexol and methotrexate (MTX), respectively. Somewhat 
counterintuitively, all three compounds increased HEV replication in both cell culture 
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models (Figure 3). To further clarify the role of their targets, lentiviral-mediated RNAi was 
used for knockdown of these three genes PPAT, GART and ATIC that encode the 
corresponding enzymes APRTase, GART and AICARTF, respectively (Figure 4A). Consistent 
with the pharmacological results, down-regulation of these enzymes enhanced HEV 
replication (Figure 4B). Furthermore, the pro-viral effects of the pharmacological inhibitors 
were largely absent in a context in which their targets were silenced, suggesting that 
pharmacological effects are not due to off-target effects (Figure 4C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Inhibitors of IMP synthesis cascade stimulate HEV replication. The Huh7 cells containing 
subgenomic HEV replicons with luciferase reporter genes were incubated with increasing doses of 6-TG (A), 
lometrexol (B), and MTX(C). The luciferase activity was determined at 24 h, 48 h, and 72h. Accordingly,Huh7 
cells infected with full-length HEV were treated with increasing doses of 6-TG (A), lometrexol (B), and MTX (C). 
The HEV RNA level was quantified by qRT-PCR after 48 h. Data were normalized to two housekeeping genes 
and are presented relative to the control (CTR) (set as 1). Data represent means  SEM from five to eight 
experiments. *, P ﹤0.05; **, P ﹤ 0.01; ***, P ﹤ 0.001. 
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Fig 4. Silencing of enzymes involved in IMP synthesis cascade facilitates HEV replication. (A) Huh7 cells 
were transduced with lentiviral shRNAs to stably silence the corresponding genes for PPAT, GART, and 
ATIC (a set of independent shRNA clones targeting each gene was used). Huh7 cells transduced with 
lentiviral shRNA targeting GFP (shCTR) were used as a control. The efficiency of gene knockdown was 
analyzed by qRT-PCR. (B) Silencing of PPAT, GART, and ATIC resulted in significant elevation of viral RNA 
upon inoculation of HEV. HEV RNA levels were determined 72 h after inoculation. (C) Silencing of PPAT, 
GART, and ATIC abrogated the pro-HEV effects of 6-TG, lometrexol, and MTX. Data were normalized to 
that for cells without treatment with the three compounds (green bar; set as 1). All data were normalized 
to two housekeeping genes and are presented relative to the control (CTR) (set as 1) (means ± SEM from 
four to eight experiments). *, P ﹤ 0.05; **, P ﹤ 0.01; ***, P ﹤ 0.001. 
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As a bifunctional enzyme, the N-terminal domain of ATIC has AICARFT activity, and the 
C-terminal domain has IMP cyclohydrolase (IMPCH) activity. FA, an IMPCH inhibitor, also 
promoted HEV replication but exerted cytotoxicity concurrently (Supplementary Figure 2). 
Thus these results highlight the interaction of nucleotide biosynthesis and the HEV infection 
process, but also show that rational design of therapy aimed at exploiting the nucleotide 
biosynthesis pathway for treatment of HEV is not straightforward. 
IMPDH inhibition counteracts HEV replication by depleting the purine nucleotide pool 
As a branching point in purine synthesis, IMP is converted to either AMP or XMP/GMP 
(Figure 1A). IMPDH, an enzyme consisting two isoforms (IMPDH1 and IMPDH2) in human, 
catalyses the reaction of IMP into XMP for further conversion to GMP. We have previously 
demonstrated that MPA, an clinically used immunosuppressant preferentially inhibiting 
IMPDH2, has anti-HEV activity 18. To further explore the potential of targeting this enzyme, a 
panel of 23 inhibitors were customized designed and synthesized with variable affinities in 
inhibiting IMPDH1 or IMPDH2 (Supplementary Table 1). As shown in Figure 5A, HEV 
replication was inhibited by all of the 23 IMPDH inhibitors at concentration of 10 μM 
measured by luciferase activity. Accordingly, 21 of the 23 inhibitors also supressed HEV 
infection as assessed by full-length HEV genome quantification by qRT-PCR (Figure 5B). The 
anti-HEV activity was also observed at 2 μM of 20 IMPDH inhibitors (Supplementary Figure 
3) . To further characterize, we selected three representative compounds with anti-HEV 
activity in both models. Similar to ribavirin and MPA, guanosine supplementation abrogated 
the anti-HEV activity of these compounds (Figure 5C), suggesting that depletion of the 
purine nucleotide pool is responsible for their antiviral action. Thus inhibitors with anti-HEV 
potential exert their action in this respect through targeting nucleotide synthesis. 
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Figure 5. IMPDH 
inhibitors potently 
inhibit HEV 
replication by 
depletion of the 
purine nucleotide 
pool. (A) Huh7 HEV 
replicon luciferase 
cells were treated 
with 23 specific 
IMPDH inhibitors (10 
M) with MPAas a 
positive control. 
Luciferase activity 
was quantified at 24 h after treatment (n = 3) (B) Huh7 cells harbouring full-length HEV were treated with 23 
specific IMPDH inhibitors with MPA as a positive control. HEV RNA levels were measured by qRT-PCR at 48 h 
after treatment (n = 5). (C) Supplementation of guanosine abrogated the anti-HEV effects of 3 representative 
IMPDH inhibitors (1346, 1347, and 1348) (n = 5). Ribavirin (RBV) and MPA served as positive controls. Data 
were normalized to two housekeeping genes and are presented relative to the control (CTR) (set as 1) (means 
± SEM). *, P ﹤ 0.05; **, P ﹤ 0.01; ***, P ﹤ 0.001. 
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Targeting pyrimidine biosynthesis inhibit HEV replication 
Even though supplementation of exogenous uridine has no effect on HEV, inhibitors of 
pyrimidine synthesis have been widely reported to inhibit infection of a broad spectrum of 
other viruses, prompting further exploration of the role of pyrimidine biosynthesis in HEV 
replication. We thus selected two catalytic enzymes involved in de novo pyrimidine 
synthesis for further study. Dihydroorotate dehydrogenase (DHODH), which localises to the 
mitochondria, is a critical enzyme that converts dihydroorotate to orotate. Brequinar (BQR) 
and leflunomide (LFM) are well-known clinically tested DHODH inhibitors. Treatment with 
BQR (10 - 500 nM) results in a significant reduction of HEV replication-related luciferase 
activity in the subgenomic replicon assay system (Figure 6A). Concordantly, BQR also dose-
dependently inhibits cellular viral RNA in our infectious HEV model. Treatment with 500 nM 
BQR for 48 hours resulted in 78 ± 17% (Mean ± SD, n = 7, P < 0.001) inhibition of HEV 
genomic RNA level (determined by qRT-PCR), compared with the control (Figure 6A). Similar 
results were observed with treatment of LMF (Figure 6B). The specificity of these effects 
was confirmed in experiments in which we examined by lentiviral RNAi-mediated silencing 
of the cognate target of these inhibitors, DHODH. Consistently, knockdown of DHODH 
inhibited HEV replication and abrogated the anti-HEV effect of BQR (Figure 7) and this 
enzyme does emerges as a relevant target in anti-HEV therapy. 
To further identify potential anti-HEV targets, we also examined Orotidine-5’-
monophosphate decarboxylase (ODCase), the downstream enzyme of DHODH that catalyses 
decarboxylation of OMP to UMP. To this end we employed 6-azauracil (6-AU), a potent 
inhibitor of ODCase. As shown in Figure 6C, HEV replication was dose-dependently inhibited 
by 6-AU. Conversely, supplementation with uridine fully restored the HEV infectious 
potential despite the presence of BQR, LMF or 6-AU (Figure.8). In conjunction, these results 
show that depletion of pyrimidine nucleotide pool is a powerful anti-HEV strategy. 
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Figure 6. Inhibition of pyrimidine nucleotide synthesis suppresses HEV replication. Huh7 cells containing 
subgenomic HEV replicons with luciferase report genes were treated with increasing doses of BQR (A), LFM (B), 
and 6-AU (C). The luciferase activity was determined after 24 h, 48 h, and 72 h. Accordingly, Huh7 cells 
harboring infectious HEV also were treated with increasing doses of BQR (A), LFM (B), and 6-AU (C). HEV RNA 
was quantified by qRT-PCR after 48 h of treatment. Data were normalized to two housekeeping genes and are 
presented relative to the control (CTR) (set as 1). Data represent means ± SEM from four to seven experiments. 
*, P ﹤0.05; **, P  0.01; ***, P ﹤ 0.001. 
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Figure 7. Anti-HEV activity by BQR can be attributed to the inhibition of its target DHODH. (A) Huh7 cells 
were transduced with lentiviral shRNA to stably silent DHODH (DHODH shRNA+). Huh7 cells transduced with 
lentiviral shRNA targeting GFP were used as control (DHODH shRNA-). DHODH knockdown was assessed by 
qRT-PCR (n = 3). DHODH knockdown resulted in significant inhibition of HEV replication. HEV viral RNA were 
determined 72h after HEV inoculation (n = 6). (B) DHODH knockdown abrogated the anti-HEV effect of BQR (n 
= 7). Data were normalized to cells without BQR treatment (green bar, set as 1 ). All data were normalized to 
two housekeeping genes and presented relative to the control (shCTR) (set as 1) (means ± SEM ). ∗∗, P < 0.01; 
∗∗∗, P < 0.001. 
Inhibitors of purine and pyrimidine synthesis provoke cellular antiviral immune responses  
through nucleotide depletion 
We previously has demonstrated that the IMPDH inhibitor, MPA, can induce the 
expression of interferon-stimulated genes (ISGs) to combat hepatitis C virus (HCV) infection, 
although the underlying mechanism remained unclear 19. ISGs are the ultimate antiviral 
effectors and are generally assumed to be induced solely through the action of antiviral 
cytokines, especially interferons. In HEV infection models, we observed that MPA as well as 
other (three selected) IMPDH inhibitors were able to induce the expression of a panel of 
antiviral ISGs (Figure 9A), challenging this dogma. The induction of ISGs by IMPDH inhibitors 
was associated with purine nucleotide depletion, since supplementation of guanosine at 
least partly abrogated the induction of ISGs (Figure 9B). 
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Figure 8. Uridine reverses the anti-HEV activity mediated by pyrimidine inhibition. The Huh7 subgenomic 
HEV replicon was incubated with BQR (A), LFM (B) and 6-AU (C), supplemented with increasing dose of uridine. 
After 72h, luciferase activity was determined. Accordingly, Huh7 cells harbouring full-length HEV RNA were 
treated with BQR (A), LFM (B) and 6-AU (C), and supplemented with 200 μM uridine. HEV viral RNA was 
assessed by qRT-PCR 48h after treatment. Data were normalized to two housekeeping genes and presented 
relative to the control (CTR) (set as 1). Data represent mean ± SEM of four to seven experiments. ∗, P < 0.05; ∗∗, 
P < 0.01; ∗∗∗, P < 0.001. 
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Figure 9. Inhibition of IMPDH stimulates ISG expression through purine nucleotide deprivation. (A) Huh7 
cells infected HEV were treated with MPA or 3 other IMPDH inhibitors (1346, 1347 and 1348). The expression 
of a panel of ISGs were determined by qRT-PCR after 48h treatment. Data were normalized to basal ISG 
expression without treatment (grey bar, set as 1). (B) Supplementation of guanosine abrogated the induction 
of ISGs by IMPDH inhibitors. The expression of ISGs were determined by qRT-PCR 48h after treatment. Data 
were normalized to basal ISG expression without treatment (purple bar, set as 1). All data were normalized to 
two housekeeping genes and represent means ± SEM of four experiments. 
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Figure 10. Inhibition of pyrimidine synthesis stimulates ISG expression through pyrimidine nucleotide 
depletion. (A) Huh7 cells infected with HEV were treated with BQR or 6-AU. After 48h, the expression of a 
panel of ISGs were determined by qRT-PCR. Data were normalized to basal ISG expression without treatment 
(grey bar, set as 1). (B) Supplementation of uridine completely abrogated the induction of ISGs by BQR (B) or 6-
AU (C).The expression of ISGs were determined by qRT-PCR at 48h after treatment. Data were normalized to 
basal ISG expression without treatment (purple bar, set as 1). All data were normalized to two housekeeping 
genes and represent mean ± SEM of five experiments. ∗, P < 0.05; ∗∗, P < 0.01. 
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In parallel, we also investigated the effects of pyrimidine synthesis inhibitors. We 
employed an interferon response reporter that Huh7 cells are stalely integrated with an 
interferon-stimulated response element (ISRE)-driven luciferase gene that measures ISG 
transcription upon interferon stimulation. BQR potently induces luciferase activity in this 
reporter assay, and triggers expression of a panel of ISGs (Supplementary Figure 4 and 
Figure 10A). Supplementation of uridine completely abrogated these effects on ISG 
transcription (Figure 10B and Supplementary Figure 4). Similar results were also observed 
with another pyrimidine synthesis inhibitor, 6-AU, targeting ODCase (Figure 10C). Thus, both 
purine and pyrimidine synthesis pathways can interact with cellular antiviral immune 
response, providing a rational explanation as to their antiviral effects.  
The induction of ISGs by nucleotide synthesis inhibitors is independent of the JAK-STAT 
machinery 
Classically, ISGs are thought only to be induced by interferons through activation of 
the JAK-STAT pathway. Briefly, the binding of interferons to their receptors leads to 
activation of Janus activated kinase 1 (JAK1), resulting in tyrosine phosphorylation of 
downstream substrates, including signal transducer and activator of transcription 1 (STAT1) 
and STAT2. The complex of STAT1–STAT2–IRF9 (IFN-regulatory factor 9) enters nucleus and 
binds to the IFN-stimulated response elements (ISRE) motifs in the target gene, 
subsequently regulating ISG transcription and thus mediating the innate anti-viral immune 
response. 
To assess whether the induction of ISGs by nucleotide synthesis inhibitors also occurs 
via this classical pathway, we blocked JAK-STAT cascade by employing the pharmacological 
JAK inhibitors, JAK inhibitor 1 or CP-690550, which were conceivably identified to impair the 
expression ISGs triggered by IFN-α (Supplementary Figure 5). Surprisingly, the induction of 
ISGs as well as the anti-HEV effects of these inhibitors were not affected (Figure 11). These 
results revealed that targeting nucleotide synthesis provokes ISG induction via a non-
canonical mechanism that is independent of the classical interferon signalling.  
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Figure 11. ISGs induction and the anti-HEV activity triggered by nucleotide synthesis inhibitors are 
independent of the JAK-STAT signalling pathway. The induction of ISGs (A, C) and the anti-HEV effects (B,D) 
by MPA were quantified in presence or absence of JAK inhibitor 1 (A, B)/CP-690550 (CP) (C, D); The induction 
of ISGs were normalized to basal ISG expression without MPA treatment (purple bar, set as 1). The relative 
HEV RNA levels were normalized to cells without treatment of MPA (set as 1). Similarly, the induction of ISGs 
(E, G) and the anti-HEV effects (F, H) mediated by BQR were quantified in presence or absence of JAK inhibitor 
1 (E, F)/CP (G, H). The induction of ISGs were normalized to basal ISG expression without BQR treatment 
(purple bar, set as 1). The relative HEV RNA levels were normalized to cells without BQR treatment (set as 1). 
Data were normalized to two housekeeping genes and represent means ± SEM of three to four experiments. 
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Discussion 
Nucleotides are key components involved in host cell metabolism and virus infection. 
Most of the inhibitors targeting de novo nucleotide biosynthesis have been well-
characterized by many studies and their efficacy in inhibiting nucleotide synthesis have been 
thoroughly demonstrated 16,17,24-31. Based on that, we profiled and established the effects 
and mechanism-of-action of inhibiting de novo nucleotides biosynthesis on HEV replication. 
Unexpectedly, targeting the early steps of the purine nucleotide synthesis pathway (before 
the primary purine IMP formed) leads to enhancement of HEV replication, whereas 
targeting later steps (IMPDH enzyme) results in potent antiviral activity against HEV, an 
effect apparently relating to purine nucleotide depletion. Inhibition of pyrimidine nucleotide 
synthesis pathway also inhibits HEV replication. Mechanistically, these effects are related to 
an unconventional interaction with cell-autonomous antiviral immunity dependent  on very 
strong induction of antiviral ISGs.  
It is counterintuitive that targeting the upstream enzymes of the purine pathway 
(before IMP formed) by pharmacological inhibitors facilitates HEV replication, but the 
specificity became evident from silencing genes encoding the enzymes involved. 
Supplementation with exogenous purine nucleotides (adenosine or guanosine) in culture 
medium in presence of these purine synthesis inhibitors were not capable of abrogating the 
stimulation of HEV replication, suggesting these pro-viral effects may only partly relate to 
the nucleotide synthesis pathway (Supplementary Figure 6A-C). It is worth noting that 
targeting the early stage of purine synthesis result in depletion of ATP and/or GTP pool. 
Cellular energy metabolism mediated by ATP might be important for the host cells to defend 
virus infection 32,33. Therefore, insufficient ATP level might facilitate HEV infection by 
escaping from host cellular immunity. However, how the ATP levels regulate virus infection 
deserves further investigation. Similarly, a previous study reported pro-viral activity by 
nucleotides biosynthesis inhibitors, LFM and FK778, in hepatitis B virus model, although 
these two compounds are generally antiviral against other viruses 17. Thus, the question 
whether the pro-HEV effects of targeting the early steps of the purine pathway are specific 
to this virus or a general phenomenon in virus biology remains unanswered.  
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IMPDH, as a target for antiviral drug development for a broad spectrum of viruses, has 
been widely investigated. We previously have demonstrated that the IMPDH inhibitors 
ribavirin and MPA inhibit HEV replication in vitro 18,20. This study further validated this 
notion by showing the anti-HEV potential of 23 specifically designed IMPDH inhibitors. The 
efficacy of 23 IMPDH inhibitors on HEV infection were consistent but with variable degree, 
which might be due to the different ability and variable affinities in inhibiting IMPDH1 and 
IMPDH2. As a competitive IMPDH inhibitor, ribavirin has been used in the clinic to treat 
chronic hepatitis C for decades. However, ribavirin monotherapy hardly has detectable 
effect on HCV viral load reduction 34, but only when combined with IFN-α, it doubles the 
response rate, compared with IFN-α alone 35. In contrast, ribavirin monotherapy as off-label 
treatment appears very effective for treating chronic HEV infection in that viral clearance 
was observed in the majority of the patients as reported by a recent large retrospective 
multicentre study 36, although prospective randomized trials are still required to confirm the 
findings. Of note that in addition to IMPDH inhibition, ribavirin also possesses pleiotropic 
biological properties, including immunomodulation, inhibition of gene translation, and 
interaction with viral RNA-dependent RNA polymerase (RdRp) and mutation of virus 37-39. 
Thus, the exact anti-HEV mechanism by ribavirin remains to be further elucidated, but the 
present study provides evidence that answer may lie in its relation to nucleotide 
biosynthesis.  
As a non-competitive IMPDH inhibitor, MPA has been used as an immunosuppressant 
to prevent allograft rejection following organ transplantation 40. Despite of the opposing 
effects of inhibitors targeting early or later steps of purine synthesis cascade on HEV, we 
demonstrated that the anti-HEV action of MPA was independent of those early step 
enzymes (Supplementary Figure 6D) Interestingly, clinical evidence appears to support our 
experimental observation that the use of immunosuppressive treatments containing 
mycophenolate mofetil (the pro-drug of MPA) may lead to more frequent HEV clearance in 
heart transplant recipients 41. Nevertheless, because of limited patient number, it is still not 
sufficient to draw solid conclusion regarding the in vivo effect of MPA. A recent cohort study 
reported the anti-HEV activity by ribavirin was not affected by MPA in patients, but they 
didn’t analyse the direct effect of MPA on HEV infection 42.  
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The three inhibitors used in our study interfering pyrimidine synthesis have been 
described in many previous studies 16,29-31. Adding to the previous knowledge that 
pyrimidine synthesis inhibitors, such as BQR and LFM, have broad antiviral activity against a 
spectrum of viruses 16,23,43, we now report their potent anti-HEV activity. Both BQR and LFM 
are immunosuppressive agents, although whether the mechanism of action is solely via 
pyrimidine inhibition remains controversially unclear 44-46. The efficacy of BQR against graft 
rejection has been extensively investigated in preclinical models 47-49; whereas LFM has been 
proposed as off-label immunosuppressive therapy in bone marrow 11 and renal 50 
transplantation. In addition, DHODH inhibitors have been explored to treat various other 
diseases, including malaria, autoimmune and inflammatory diseases, cancer, rheumatoid 
arthritis and psoriasis 51-55. Given the bifunctional effects of antiviral and 
immunosuppressive of BQR and LFM, these regimens may hold the potential to treat HEV-
infected organ recipients.  
Interestingly, nucleotide synthesis interacts with cellular antiviral immune responses. 
Here we demonstrated a direct effect of depletion of nucleotide pools on the transcription 
of antiviral ISGs. ISGs are ultimate antiviral effectors that are thought to be induced by 
interferons only. Although hundreds of ISGS have been identified, recent functional studies 
of individual ISG have surprisingly found out that only a small subset of ISGs actually have 
potent or broad antiviral activities, which include IRF1, DDX58 and IRF7 56,57. It is these 
antiviral ISGs that are induced in our HEV models upon treatment with nucleotide synthesis 
inhibitors. Consistently, previous studies in HCV models reported that induction of IRF1 or 
IRF7 was associated with the antiviral activity of MPA 19 or ribavirin 58, respectively. 
Furthermore, the antiviral activity of inhibitors of pyrimidine biosynthesis against measles 
virus, chikungunya virus and West Nile virus was also associated with the induction of ISGs 23.  
For now the mechanistic details as to inhibitors of nucleotide biosynthesis can induce 
ISGs remain obscure. Classically, transcription of ISGs is initiated from the binding of 
interferons to their receptors, which subsequently drives the activation of JAK-STAT cascade 
56. Inhibition of JAK1 to phosphorylate STAT1, the key event of interferon signalling 
transduction, often results in complete blockage of antiviral interferon responses 59. 
However, exceptions also exist in that ISGs can be induced in the absence of JAK1 or STAT1 
activation 60,61. Here, we found that induction of ISGs and the anti-HEV effects by nucleotide 
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synthesis inhibitors are independent of the classical JAK-STAT cascade, suggesting the 
involvement of a non-canonical mechanism that is independent of interferons and 
identification of these mechanisms should have substantial value for our understanding of 
antiviral immunity.  
In conclusion, selectively targeting host enzymes involved in de novo nucleotide 
biosynthesis potently inhibits HEV replication. Furthermore, nucleotide biosynthesis 
pathways interact with cellular immune response that all the pharmacological inhibitors 
exerting anti-HEV activity are capable of triggering antiviral ISG transcription. Thus, targeting 
nucleotide biosynthesis represents a viable option for antiviral drug development against 
HEV.  
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Supplementary Materials  
Supplementary Table 1. Information of 23 specific IMPDH inhibitors 
Inhibitory constant (Ki) on IMPDH1 and IMPDH2 of 23 specific IMPDH inhibitors. First 3 compounds in the table 
are insoluble in DMSO. Other compounds are soluble in DMSO. Compounds 1406 and 1407 do not inhibit 
IMPDH but if converted in the cell into their corresponding NAD analogues should show some inhibition of the 
enzymes. Ki of 1410-L-ABC, 1406 and 1407 was not determined (ND). Chemical structures of the IMPDH 
inhibitors will be published somewhere else. 
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Supplementary Table 2. Primer sequences 
Gene Sequences 5’ to 3’ 
HEV-F ATTGGCCAGAAGTTGGTTTTCAC 
HEV-R CCGTGGCTATAATTGTGGTCT 
DDX58-F CACCTCAGTTGCTGATGAAGGC 
DDX58-R GTCAGAAGGAAGCACTTGCTACC 
ISG15-F CTCTGAGCATCCTGGTGAGGAA 
ISG15-R AAGGTCAGCCAGAACAGGTCGT 
STAT1-F ATGGCAGTCTGGCGGCTGAATT 
STAT1-R CCAAACCAGGCTGGCACAATTG 
IFI27-F CGTCCTCCATAGCAGCCAAGAT 
IFI27-R ACCCAATGGAGCCCAGGATGAA 
IRF1-F GAGGAGGTGAAAGACCAGAGCA 
IRF1-R TAGCATCTCGGCTGGACTTCGA 
IRF9-F CCACCGAAGTTCCAGGTAACAC 
IRF9-R AGTCTGCTCCAGCAAGTATCGG 
IFIT1-F GCCTTGCTGAAGTGTGGAGGAA 
IFIT1-R ATCCAGGCGATAGGCAGAGATC 
IFIT2-F GGAGCAGATTCTGAGGCTTTGC 
IFIT2-R GGATGAGGCTTCCAGACTCCAA 
IFI6-F TGATGAGCTGGTCTGCGATCCT 
IFI6-R GTAGCCCATCAGGGCACCAATA 
IRF7-F CCACGCTATACCATCTACCTGG 
IRF7-R GCTGCTATCCAGGGAAGACACA 
CXCL10-F GGTGAGAAGAGATGTCTGAATCC 
CXCL10-R GTCCATCCTTGGAAGCACTGCA 
MX1-F GGCTGTTTACCAGACTCCGACA 
MX1-R CACAAAGCCTGGCAGCTCTCTA 
APRT-F GCGATTGAAGCACCTGTGGATG 
APRT-R CGGTTTTTACACAGCACCTCCAC 
GART-F GCACATCTCTGCCTGTTTGGCT 
GART-R CATGGAACACCTCCAGTCCTAG 
ATIC-F CCGAGAGTAAGGACACCTCCTT 
ATIC-R GGCATCTGAGATACGCCTTTGC 
DHODH-F GAGGACATTGCCAGTGTGGTCA 
DHOSH-R TTCCCACTCAGCCCTCCTGTTT 
 
 
 
 
 
 
Chapter 6 
 
- 150 - 
 
Supplementary Table 3. shRNA sequences 
No. Gene ACCESSIO
N 
Sequences Target 
Sequence 
APRT PPAT (3) NM_0027
03.3 
 
CCGGCCCTTCGTTGTTGAAACACTTCTC
GAGAAGTGTTTCAACAACGAAGGGTTT
TTG 
CCCTTCGTTG
TTGAAACACT
T 
 
 
GART
sh1 
 
GART (1) 
 
NM_0008
19.3 
 
 
CCGGGCCCAGGAGTTTGACTTACAACTC
GAGTTGTAAGTCAAACTCCTGGGCTTTT
TG 
 
 
GCCCAGGAG
TTTGACTTAC
AA 
 
GART
sh2 
GART (2) NM_0008
19.3 
 
CCGGGCACAGTCTCATCATGTCAAACTC
GAGTTTGACATGATGAGACTGTGCTTTT
TG 
 
GCACAGTCTC
ATCATGTCAA
A 
 
GART
sh3 
GART (3) NM_0008
19.3 
 
CCGGCCCTAACTGTTGTCATGGCAACTC
GAGTTGCCATGACAACAGTTAGGGTTTT
TG 
 
CCCTAACTGT
TGTCATGGCA
A 
 
ATICs
h1 
ATIC (1) NM_0040
44.4 
 
CCGGGCCTTGACAATACTTTCCAAACTC
GAGTTTGGAAAGTATTGTCAAGGCTTTT
TG 
 
GCCTTGACA
ATACTTTCCA
AA 
 
ATIC 
sh2 
ATIC (2) NM_0040
44.4 
 
CCGGGCAATCTCTATCCCTTTGTAACTCG
AGTTACAAAGGGATAGAGATTGCTTTTT
G 
 
GCAATCTCTA
TCCCTTTGTA
A 
 
ATIC 
sh3 
ATIC (3) NM_0040
44.4 
 
CCGGGCTGGAATCCTAGCTCGTAATCTC
GAGATTACGAGCTAGGATTCCAGCTTTT
TG 
 
GCTGGAATC
CTAGCTCGTA
AT 
 
DHO 
DH 
DHODH (5) NM_0013
61.3,NM_
00102519
3.1 
 
CCGGGTGAGAGTTCTGGGCCATAAACTC
GAGTTTATGGCCCAGAACTCTCACTTTTT 
 
GTGAGAGTT
CTGGGCCATA
AA 
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Supplementary Figure 1 
 
Figure S1. Gene knockdown of PPAT and DHODH with different shRNA lentiviral vectors. Huh7 cells were 
transduced with lentiviral shRNAs targeting at PPAT (A) and DHODH (B) using a set of 5 different independent 
shRNA preparations for each gene knockdown. Huh7 cells transduced with lentiviral shRNA targeting GFP 
(shCTR) were used as control. The efficiency of knockdown of the 2 genes were analysed by qRT-PCR using 
specific primers. Data were normalized to GAPDH and presented relative to control (set as 1).  
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Supplementary Figure 2 
 
Figure S2. Fludarabine enhances HEV replication. (A) Huh7 cell-based subgenomic HEV replicon containing the 
luciferase reporter gene were treated for 24h, 48h and 72h with a dose-range of FA. Data presented as means ± 
SEM. Meanwhile, Huh7 cells with the infectious HEV containing the full-length p6 genome were treated for 48h 
with a dose-range of FA. Data were normalized to GAPDH and presented relative to results from untreated cells 
(set as 1). (B) Huh7 cells were incubated with dose-range of FA. After 72h, MTT assay was performed to 
determine cytotoxicity of FA.  
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Supplementary Figure 3 
 
Figure S3. 2 μM IMPDH inhibitors moderately inhibit HEV replication. Huh7 HEV replicon luciferase cells were 
treated with 23 specific IMPDH inhibitors (2μM) with MPA as a positive control. Luciferase activity was 
quantified at 24h after treatment (n = 3). 
 
 
Supplementary Figure 4 
 
 
Figure S4. BQR stimulates ISRE transcription through pyrimidine depletion. Huh7-ISRE-Luc cells were 
incubated with BQR (B) in presence or absence of Uridine (U). ISRE promoter-related firefly luciferase activity 
was quantified 72h after culture. 
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Supplementary Figure 5 
 
Figure S5. JAK inhibitors diminish IFNα stimulated ISG expression. (A) Huh7 cells infected with HEV were 
incubated with IFNα in presence or absence of Jak inhibitor 1. After 48h, the expression of ISGs were assessed 
by qRT-PCR. (B) Same experiment was performed with another JAK inhibitor, CP-690550 (CP). Data were 
normalized to basal ISG expression without IFNα treatment (purple bar, set as 1). All data were normalized to 
two housekeeping genes and experiments were performed two to five times. 
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Supplementary Figure 6 
 
 
Figure S6. Inhibition of IMP synthesis enhanced HEV replication independent of purine depletion and does 
not affect the anti-HEV activity of MPA. Huh7 cells infected HEV were treated with 6-TG (A), lometrexol (B) and 
MTX (C), respectively, in the presence or absence of guanosine (G)/adenosine (A). The HEV RNA was assessed 
by qRT-PCR 48h after treatment. (D) Huh7 cells infected HEV were treated with 6-TG, lometrexol and MTX, 
respectively, in the presence or absence of MPA. The HEV RNA was assessed by qRT-PCR 48h after treatment. 
Data were normalized to two housekeeping genes and presented relative to the control (CTR) (set as 1). 
Experiments were performed two to five times. 
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Supplementary Figure 7 
 
Figure S7. The effects of nucleotide synthesis inhibitors on Huh7 cells viability. Huh7 cells were incubated 
with a dose-range of 6-TG, lometrexol, MTX, BQR, LFM or 6-AU for 72h treatment. Huh-7 cells were incubated 
with 23 IMPDH inhibitors at 10 μM for 48h. MTT assay was performed to determine cytotoxicity of these 
compounds.  
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Abstract 
Although hepatitis E has emerged as a global health issue, there is no approved medication 
and limited knowledge of its infection biology. Aiming to investigate the role of protein 
kinases in hepatitis E virus (HEV) infection and to identify potential antiviral targets, we 
screened a library of pharmacological kinase inhibitors on a state-of-art cell culture model: a 
subgenomic HEV replicon containing luciferase reporter. After screening, we identified 
protein kinase C alpha (PKCα) as an essential cell host element for defense against HEV 
replication. Both specific conventional PKC inhibitor and functional knockdown enhanced 
HEV replication. Whereas the functional over-expression or pharmacologic activator 
strongly inhibited HEV replication. Importantly, upon the stimulation of its activator, PKCα 
can efficiently activate its downstream NF-κB or AP-1 pathways. However, PKCα induced 
HEV inhibition is totally independent of these two downstream pathways. The discovery 
that activated PKCα restricts HEV replication provides a novel target for managing HEV 
infection. 
 
Keywords: PKCα, hepatitis E virus, PMA, NF-κB, AP-1 
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Introduction  
Hepatitis E virus (HEV) is one of the most common causes of acute viral hepatitis in the 
world. Although the mortality rate is < 1% among the general population, pregnant women 
can have a fatality rate of up to 30%. Additionally, chronic hepatitis E has increasingly 
become a significant clinical problem in immunocompromised patients. Up to date, there is 
still no proven medication available and its infection biology is poorly understood. 
Protein kinases are principal components of the machineries that orchestrate immune 
response against diverse pathogenic entities, including viruses, by subsequent stimulation of 
specific signal transduction cascades 1. However, kinase controlled pathways employed by 
the host cell to stimulate antiviral immunity remain largely obscure. Knowledge of such 
pathways could prove exceedingly useful for the rational design of therapeutic avenues 
against HEV infection. 
Encouragingly, numerous pharmacological kinase inhibitors or activators have been 
developed to target particular kinases. Among those, several are approved drugs in 
particular for treating cancer 2, and many are currently at various stages of preclinical and 
clinical development. These compounds have broad implications for treating various 
diseases, including cancer, inflammation, diabetes and viral infections 3,4.  
Thus, this study aims to comprehensively profile kinase-mediated cascades in cell–
autonomous antiviral immunity starting from screening a library of pharmacological kinase 
inhibitors on Huh7 based HEV replication cell model. We identified protein kinase C alpha 
(PKCα) as an important anti-HEV mediator. Hence, our results defined PKCα as a novel 
antiviral element in the machinery combatting HEV infection.  
Materials and Methods 
Pharmacological kinase inhibitors  
The kinase inhibitor library used for the screening was made available by the KU 
Leuven Centre for Drug Design & Development (www.cd3.eu). 
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Reagents and Antibodies 
Stocks of PMA (Sigma-Aldrich, St Louis, MO) and JAK inhibitor I (Santa Cruz Biotech, 
Santa Cruz, CA) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) 
to concentrations of 100 µg/ml and 20 mM, respectively. Antibodies including phospho-
PKCα/ (#9375), c-Fos (9F6, #2250), RelA (C22B4, #4764), Anti-rabbit IgG(H+L),F(ab') 2 
Fragment (Alexa Fluor 488 conjugate) and Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa 
Fluor® 488 Conjugate) were purchased from Cell Signaling Technology, the Netherlands. 
Anti-rabbit or anti-mouse IRDye-conjugated antibodies  were used as secondary antibodies 
for western blotting (Stressgen, Victoria, BC, Canada). 
Viruses and cell culture models 
Hepatocellular carcinoma cells Huh7 were kindly provided by Professor Bart 
Haagmans from Department of Viroscience, Erasmus Medical Center. Human Embryonic 
Kidney 293 cells were originally obtained from ATCC (www.atcc.org). The HEV infectious 
model was based on Huh7 cells containing the full-length HEV genome (Kernow-C1 p6 clone, 
GenBank Accession Number JQ679013). Infectious HEV particles are generated and secreted 
into cell culture medium, which can be collected and used for secondary infection 5-8. The 
HEV subgenomic model was based on Huh7 cells containing the subgenomic HEV sequence 
(Kernow-C1 p6/luc) coupled to a Gaussia luciferase reporter gene. Luciferase normalization 
cells (Huh7-norm) were generated by transducing Huh7 cells with a lentiviral vector 
expressing the firefly luciferase gene under control of the human phosphoglycerate kinase 
(PGK) promoter. NF-κB, AP-1 luciferase reporter cells were generated by transducing Huh7 
cells with lentiviral vectors expressing the firefly luciferase gene under the control of NF-κB, 
AP-1 promoters, respectively (System Biosciences).  
Screen of pharmacological kinase inhibitors 
After optimizing the screening protocol, a concentration of 0.8 µM was used to treat 
Huh7 cells transfected with HEV p6/luc replicon RNA for 72 hrs, followed by measurement 
of luciferase activity, as described previously 9  
Gene knockdown or over-expression by lentiviral vectors  
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Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting PKCα, PKC, RelA, c-Fos 
or control were obtained from the Erasmus Biomics Center and produced in HEK293T cells 
as previously described 10. After a pilot study, the shRNA vectors exerting optimal gene 
knockdown were selected. These shRNA sequences are listed in Supplementary Table 2. 
Stable gene knockdown cells were generated after lentiviral vector transduction and 
puromycin (2.5μg/ml; Sigma) selection. 
wtPKCα and caPKCα overexpression lentivral vectors were a kind gift from Dr. Lin from 
the University of Minnesota. To create a stable overexpression cell lines, following lentiviral 
vectors transduction, cell cytometry and FACS were used to detect and selectively pick up 
the positive cells by the GFP tag gene expression on the vector. 
Measurement of luciferase activity 
For Gaussia luciferase, the secreted luciferase activity in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and incubated for 30 
min at 37 °C. Both Gaussia and firefly luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany).  
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
synthesized from total RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of all 
detected genes was amplified for 50 cycles and quantified with a SYBRGreen-based real-
time PCR (Applied Biosystems) according to the manufacturer’s instructions. GAPDH was 
considered as reference genes to normalize gene expression. Relative gene expressions 
were normalized to GAPDH using the formula 2−ΔΔCT (ΔΔCT = ΔCTsample − ΔCTcontrol). All the 
primer sequences are included in Supplementary Table 3. 
Western Blot Assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated 5 
mins at 95 °C, followed by loading onto a 10% sodium dodecyl sulfate polyacrylamide gel 
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and separation by electrophoresis. After 90 mins running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride membrane (Invitrogen) for 
1.5 hrs with an electric current of 250 mA. Subsequently, the membrane was blocked with a 
mixture of 2.5 ml blocking buffer (Odyssey) and 2.5 ml phosphate-buffered saline containing 
0.05% Tween 20. It was followed by overnight incubation with primary antibodies (1:1000) 
at 4 °C. The membrane was washed 3 times followed by incubation for 1h with IRDye-
conjugated secondary antibody (1:5000). After washing 3 times, protein bands were 
detected with the Odyssey 3.0 Infrared Imaging System. 
Confocal laser electroscope assay 
Huh7 cells were seeded on glass coverslips. After 12 hrs, cells were washed with PBS, 
fixed in 4% formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% 
tween, 5g/L skim milk and 1.5g/L glycine). Samples were incubated with primary antibodies 
overnight at 4 °C. Subsequently, samples were incubated with 1:1000 dilutions of the anti-
mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) or anti-rabbit IgG(H+L), 
F(ab') 2 Fragment (Alexa Fluor 488 conjugate) secondary antibodies. Nuclei were stained 
with DAPI (4,6-diamidino-2-phenylindole; Invitrogen). Images were detected using confocal 
electroscope. 
MTT assay 
Cells were seeded in 96-well plates and cultured at 37 °C with 5% CO2 for 24, 48, 72 
hrs, respectively. Then 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) (Sigma) was added to cells and incubated for 4 hrs. Subsequently, medium was 
removed and 100 μl of DMSO was added to each well. The absorbance of each well was 
read on a microplate absorbance readers (BIO-RAD) at a wavelength of 490 nm. All 
measurements were performed in triplicate. 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were 
performed with Mann-Whitney test. Differences were considered significant at a P value 
less than 0.05.  
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Results 
A screening for kinases involved in antiviral immunity identifies conventional PKCs as 
novel cell-autonomous antiviral elements 
Protein kinases are pivotal mediators of signal transduction and identifying kinases 
involved in biological responses can shed important light on kinase associated virus-host 
interactions. The lack of understanding as to which signal pathways mediate cell-
autonomous antiviral immunity against HEV thus prompted us to execute a screening of 
kinase inhibitors with respect to their effects in antiviral responses. To this end, we 
employed a hepatocyte cell line, i.e. Huh7, transfected with a HEV replicon luciferase 
reporter as a platform for the screening of 132 pharmacological kinase inhibitors with 
known specificity profile 9 (Figure 1A and Table S1). We arbitrarily set the control luciferase 
value to 1 and identified 24 inhibitors that increase and 64 compounds that inhibit luciferase 
activity in this assay system (Figure 1B and Table S1). Inhibition of luciferase activity might 
be due to non-specific effects not related to the scientific question at hand (e.g. effects on 
translation or cell survival). Strikingly, stimulation of luciferase activity likely relates to the 
inhibition of signaling elements involved in constraining viral replication and hence we 
concentrated on luciferase enhancing compounds in our search for elements involved in 
antiviral immunity. The most clear and interesting of these enhancing compounds is Go6976, 
a fairly specific inhibitor of the conventional PKCs (PKC, PKC, PKC,and PKC) 
11. 
Subsequent western blot analysis for the phosphorylation state of PKC isoforms confirmed 
the inhibition of PKCα and PKCβ by Go6976 in our experimental system (Figure 1C). HEV 
promoting activity of Go6976 was further confirmed in two independent state-of-the-art 
cell culture models: a subgenomic HEV containing luciferase reporter and a full-length HEV 
infectious cell culture system (Figure 1D and E). 
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Figure 1. 
Conventional PKCs 
function as cell-
autonomous 
antiviral elements 
against HEV. (A) 
Diagram of 
screening a library 
of pharmacological 
kinase inhibitors in 
HEV subgenomic 
replicon. (B) 
Heatmap summary 
of the screening 
results. The Huh7 
cell line transfected 
with a subgenomic 
HEV luciferase 
reporter replicon 
was used. 
Compared to 
control, relative HEV 
luciferase activity 
depicted in red to 
green for each 
inhibitor. Red means 
that the signal is 
higher than control, 
whereas green 
means lower than 
control. See also 
Table S1. (C) 
Go6976 (10 µM) 
treatment inhibited 
phosphorylation of PKC and PKC protein levels in Huh7 cells as determined by western blot. (D) In the Huh7 
cell-based subgenomic HEV replicon model, treatment with different doses of Go6976 increased HEV 
replication-related luciferase activity (n = 3 independent experiments with 2 - 3 replicates each). (E) qRT-PCR 
analysis of HEV RNA in Huh7 cells harboring full-length HEV infectious genome. Treatment with Go6976 dose-
dependently increased cellular HEV RNA (n = 3). (F) The Huh7 cell-based subgenomic HEV replicon, treated 
with GO6976, IFN- or a combination of both. Luciferase values were measured at 24, 48 and 72 hours. IFN- 
induced anti-HEV effect was totally abrogated with the present of Go6976 (n = 3 independent experiments 
with 2 – 3 replicates each). (G) Same as (F) for GO6976, pan-JAK inhibitor I or a combination of both. The co-
treatment of Go6976 and pan-JAK inhibitor I exerted combined enhancement on HEV replication. (n = 3 
independent experiments with 2 – 3 replicates each). Data presented as means ± SEM (*, P < 0.05; **, P < 0.01; 
***, P < 0.001; ns, not significant). 
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IFN-α is a well-known HEV off-label drug used in clinic. Its antiviral effect against HEV 
was totally abrogated with the present of Go6976 (Figure 1F). Whereas the co-treatment of 
Go6976 with pan-JAK inhibitor I, a well-established inhibitor used to block IFN signaling, 
exerted combined enhancement on HEV replication (Figure 1G). Go6976 showed a slight 
inhibitory effect on host cell growth (Figure S1A), which is expected because of the crucial 
roles of PKCs in cell physiology. Collectively, these data demonstrated that conventional 
PKCs are important antiviral elements, at least with respect to HEV infection. 
PKCα is the key antiviral isoform against HEV 
The observation that conventional PKCs constrain HEV replication raises questions as 
to the role of different PKC isoforms. To dissect the effects of individual PKC isoforms, we 
silenced the expression of PRKCA (the gene coding for PKC) and PRKCB (that gives rise to 
PKC and PKC) in Huh7 cells using lentiviral-mediated RNAi. Since PKC has been shown 
to be specifically expressed in neuronal tissue 12, we ruled it out for further research. qRT-
PCR and Western blot confirmed successful down-regulation of PKC isoforms (Figure 2A and 
B) at protein and RNA levels. Subsequently, cells were inoculated with infectious HEV 
particles and cellular HEV RNA was quantified by qRT-PCR after 48 hrs. Knockdown of PKC 
led to a 2.25 ± 0.3 fold (n = 4, p < 0.05) increase of HEV RNA; whereas PKC knockdown 
resulted in no significant effect (Figure 2C), suggesting that PKC is the relevant isoform 
here.  
PKCα maintains its inactive state via an inhibitory region within the effector binding 
domain of the kinase. Its pseudosubstrate site mediates this inhibition by binding to the 
active site and preventing substrate interaction 13. A constitutively active PKCα (caPKCα) is 
available in which a glutamic acid present in this region is substituted for alanine. (Figure 
2D). This form dramatically increases effector-independent kinase activity, compared to the 
wild-type PKCα (wtPKCα) 14. Huh7 cells were transduced with integrating lentiviral vectors 
co-expressing GFP and caPKCα or wtPKCα (Figure S1B). Cell cytometry confirmed transgene 
expression by measuring GFP and positive cells were sorted and expanded for further 
experimentation (Figure S1C). Huh7 cells expressing caPKCα or wtPKCα were inoculated 
with infectious HEV particles and relative viral RNA level was quantified 48 hours post-
inoculation. Consistent with PKCα knockdown (Figure 2C), expression of caPKCα significantly 
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decreased HEV RNA by 49% (n = 4, p < 0.05), while wtPKCα over-expression showed no 
effect on HEV compared to control sample (Figure 1E). Thus, activated PKCα plays an 
important role in cell-autonomous anti-HEV immunity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PKC is the key antiviral isoform against HEV. (A) Western blot analysis of PKC and PKC 
knockdown by lentiviral shRNA vectors. Compared with the control vector transduced cells, the shPKC clone 
53 and shPKCβ clone 48 exerts potent silencing capability shown at protein levels. Blots depict phosphorylated 
PKC, PKC and -actin. (B) qRT-PCR analysis of PKC and PKC knockdown by lentiviral shRNA vectors. 
Compared to the control vector transduced cells, the no.53 and 48 clones of shPKC and PKC, respectively, 
exert a potent silencing capability shown at RNA levels ( n = 3). (C) Cellular HEV RNA level in PKC or 
PKCknockdown cells was determined by qRT-PCR 48 hrs post inoculation with HEV particles. Knockdown of 
PKC led to a 2.25 ± 0.3 fold increase of HEV RNA, whereas PKC knockdown resulted in no significant 
increase ( n = 4). (D) The change in amino acid sequence between wtPKC and caPKC is shown in the 
rectangular frame. (E) qRT-PCR analysis of cellular HEV RNA level in CTR, wtPKC or caPKC over-expressing 
cells after inoculation of infectious HEV particles for 72 hrs. caPKC over-expression inhibited HEV RNA by 49%. 
Data presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant).  
This promising result prompts us to investigate the potential role of canonical PKC 
pharmacologic activator, phorbol 12-myristate 13-acetate (PMA), also commonly known as 
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12-O-Tetradecanoylphorbol-13-acetate (TPA). PMA, structurally analogous to diacylglycerol, 
is commonly used to activate PKC. It is also a promising drug candidate, currently under a 
Phase II clinical trial in the treatment of patients with relapsed/refractory acute 
myelogenous leukemia (NCT01009931). As expected, PMA exerted strong anti-HEV effects 
in both HEV subgenomic and full-length infectious models (Figure 3A and B), while no clear 
effect on cell growth and viability was observed (Figure S1D). This exciting result prompted 
us to assess the combined antiviral effect of PMA with the off-label anti-HEV drugs IFN-α or 
ribavirin. Although PMA and IFN-α showed comparable anti-HEV capacity, they failed to 
exert further combined effect (Figure 3C and E). Whereas the combination of PMA with 
ribavirin showed strong additive anti-HEV effect (Figure 3D and F). These data collectively 
indicate PMA as a potential anti-HEV drug candidates. 
PKCα mediated anti-HEV effect is independent of NF-κB pathways 
NF-κB signaling is a central pathway involved in cellular innate immune response. PMA 
can activate NF-κB signaling via the phosphorylation of NF-κB/p65 by PKCα (Figure 4A) 15-17. 
Thus, we investigated the potential involvement of NF-κB pathway in PKCα mediated anti-
HEV effect. To this end, we used a lentiviral transcriptional reporter system expressing the 
firefly luciferase gene under the control of NF-κB responsive promoter. Huh7 cells were 
transduced with the vector to create a stable NF-κB reporter cell line. As expected, 
stimulation with PMA led to the strong activation of NF-κB luciferase activity and thus a role 
of NF-κB signaling cannot be ruled out. Thus, the Huh7 cell line was transduced with 
integrating lentiviral shRNA vectors to silence RelA (P65), an essential subunit of the NF-κB 
transcription complex, resulting in profound down-regulation of RelA expression (Figure 5C 
and D). However, PMA induced anti-HEV effect was not abrogated in RelA knockdown cells 
(Figure 5E). Thus, NF-κB signaling appears not to be involved in the PKC-induced anti-HEV 
effect. 
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Figure 3. PKC 
specific 
activator PMA 
exerts strong 
antiviral activity 
against HEV. (A) 
In the Huh7 cell-
based 
subgenomic HEV 
replicon model, 
treatment with 
different doses 
of PMA 
inhibited HEV 
replication-
related 
luciferase 
activity (n = 3 
independent 
experiments 
with2 - 3 
replicates each). 
(B) qRT-PCR 
analysis of HEV 
RNA derived 
from Huh7 cells 
harboring the 
full-length HEV 
infectious 
genome. 
Treatment with 
PMA (100 ng/ml) 
for 48 hrs 
significantly inhibited cellular HEV RNA by 68% (n = 9). (C) Huh7 cells harboring the full-length HEV infectious 
genome were treated with different doses of IFN-, PMA or a combination of both for 48 hrs. Cellular HEV 
RNA level was determined by qRT-PCR. PMA and IFN-α showed comparable anti-HEV capacity, but they failed 
to exert further combined effect (n = 4). (D) Same as (C) for ribavirin, PMA or a combination of both. The 
combination of PMA with ribavirin showed strong additive anti-HEV effect (n = 4). (E) The Huh7 cell-based 
subgenomic HEV replicon was treated with PMA, IFN- or a combination of both. Their combination showed 
no additive effect. Luciferase values were measured at 24, 48 and 72 hrs. (n = 3 independent experiments with 
2 – 3 replicates each). (F) Same as (E) for PMA, ribavirin or a combination of both. Their combination showed 
additive anti-HEV activity. (n = 3 independent experiments with 2 – 3 replicates each). Data presented as 
means ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant). 
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Fig 4. PKC mediated anti-HEV activity is independent of NF-κB signaling. (A) Illustration of key regulatory 
molecules in PMA induced NF-κB signaling. (B) In Huh7 based NF- κB luciferase reporter cells, treatment with 
PMA resulted in a dose-dependent induction of NF-κB related luciferase activity (n = 3 independent 
experiments with 2 – 3 replicates each). (C) Western blot analysis of RelA knockdown by lentiviral shRNA 
vectors in Huh7 cells. Blots depict RelA and β-actin. (D) qRT-PCR analysis of RelA knockdown by lentiviral 
shRNA vectors at RNA level (n = 3). (E) Knockdown of RelA did not block PMA induced anti-HEV activity as 
determined by qRT-PCR 48 hrs post inoculation with HEV particles (n = 4). Data presented as mean ± SEM (*, P 
< 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant). 
PKCα mediated anti-HEV effect is independent of AP-1 pathways 
AP-1 signaling is another important pathway involved in cellular innate immune 
response. PMA can also activate AP1 signaling via the activation of PKCα (Figure 5A) 18,19. 
Indeed, PMA stimulation provokes a strong induction of c-Fos, an essential subunit of the 
AP1 transcription complex (Figure 5B). Accordingly, unstimulated cells displayed hardly 
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detectable c-Fos protein, but c-Fos was substantially induced and translocated to nucleus 
following PMA stimulation (Figure 6C). Convincingly, we also used a lentiviral transcriptional 
reporter system expressing the firefly luciferase gene under control of an AP-1 responsive 
promoter. Huh7 cells were transduced with the vector to create a stable AP-1 reporter cell 
line. As shown in Figure 5D, stimulation with PMA led to the strong activation of AP-1 
luciferase activity. Thus, to determine the role of AP-1 activation, Huh7 cells were 
transduced with integrating lentiviral RNAi vectors to silence c-Fos (Figure 5E and F). 
Surprisingly, PMA mediated anti-HEV activity was not changed in c-Fos knockdown cells 
when compared with control cells (Figure 5G). Thus, AP-1 appears not essential for PKCα-
mediated anti-HEV activity. 
Discussion 
Protein kinases play pivotal roles in regulating immune responses either positively or 
negatively via regulating protein functions, signal transduction or other cellular processes.20-
22. This study comprehensively profiled kinase-mediated cascades in cell-autonomous 
antiviral immunity via screening a library of pharmacological kinase inhibitors on Huh7 
based HEV replication cell model. We identified PKC as an important antiviral host factor 
and a targetable host factor for antiviral drug development. PKC has been reported to be 
involved in several cellular innate immune responses, such as enhancing NF-κB translocation, 
participating in Toll like receptor signaling and modulating IFN- synthesis in particular cell 
types. In this study, we identified PKC as a powerful antiviral effector against HEV infection. 
Both functional over-expression and pharmacologic activation showed strong and 
comparable anti-HEV activity compared to HEV off-label drug IFN-α.  
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Figure 5. PKC mediated anti-HEV activity is independent of AP-1 signaling (A) Diagram of key regulatory 
molecules in the PKC/AP-1 signaling pathway. (B) Western blot analysis of c-Fos and c-Jun protein levels in 
Huh7 cells treated with PMA (100 ng/ml) for 4, 6 and 8 hrs. PMA stimulation provokes strong induction of c-
Fos but not c-Jun. (C) Confocal microscopy analysis of c-Fos localization in Huh7 cells treated with PMA for 4 
hrs. c-Fos was induced and translocated to nucleus upon PMA stimulation. c-Fos antibody (green). Nuclei were 
visualized by DAPI (blue). (D) In Huh7 based AP-1 luciferase reporter cells, treatment with PMA resulted in 
dose-dependent induction of AP-1-related luciferase activity (n = 3 independent experiments with 2 – 3 
replicates each). (E) Western blot analysis of c-Fos knockdown by lentiviral shRNA vectors. Compared to the 
control vector transduced cells, the NO.42 clone of shc-Fos exerts potent silencing capability shown at protein 
levels. Blots depict c-Fos and β-actin. (F) qRT-PCR analysis of c-Fos knockdown by lentiviral shRNA vectors at 
RNA level ( n = 3). (G) Knockdown of c-Fos in Huh7 cells did not abrogate PMA induced anti-HEV activity as 
determined by qRT-PCR 48 hrs post inoculation with HEV particles (n = 4). Data presented as means ± SEM (*, 
P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant). 
PMA, as a phorbol ester, binds to the C1 domain in the regulatory region of PKCs to 
promote their activation 23. Although PMA was reported to may have a tumor-promoting 
Chapter 7 
 
- 174 - 
 
role in experimental skin cancer mouse models 24, its anti-cancer potential in fact has been 
extensively investigated in the clinic, including in patients with hematological malignancy, 
squamous cell carcinoma, renal cell carcinoma, ovarian teratocarcinoma, subcutaneous 
adenocarcinoma and prostate cancer 25. Cancer patients often suffer from depressed white 
blood cell and neutrophil counts because of chemotherapeutic drugs. PMA treatment has 
been shown to increase white blood cell and neutrophil counts towards a normal range with 
only mild and reversible side effects observed 26. A Phase I trial of treating hematologic 
cancer or bone marrow disorder with PMA has been successfully conducted at The State 
University of New Jersey (NCT00004058). The same institute is currently pursuing a Phase II 
trial plus dexamethasone & choline magnesium trisalicylate in the treatment of patients 
with relapsed/refractory acute myelogenous leukemia (NCT01009931). An interesting link is 
that patients with leukemia or other cancers are prone to virus infections, including HEV 27-29 
The potential clinical prospects of PMA or its derivatives may be of achieving “one stone two 
birds” effects: simultaneously combating cancer and virus. 
In conclusion, we identified PKC as an important cell-autonomous antiviral factor 
against HEV in host defense. The anti-HEV activity is totally independent of its downstream 
NF-κB or AP-1 pathways These results provide valuable antiviral target and shed new 
insights of virus-host interactions. 
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Supplementary Materials  
 
Figure S1. PKC exerts strong anti-HEV activity. (A) MTT assay to determine GO6976 effects on the Huh7 cell 
line. Go6976 showed a slight inhibitory effect. (B) Illustration of lentivector map of wtPKC and caPKC. (C) 
Cell cytometry sorting result of wtPKC and caPKC positive cells based on the GFP tag. (D) MTT assay to 
determine PMA effects on the Huh7 cell line. PMA exerts no clear cell toxicity 
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Table S1. the library information of pharmacological kinase inhibitors   
Name Formula MolWeight Catalog Number 
Alsterpaullone, 2-
Cyanoethyl 
C19H14N4O3 346,33946 12687
1 
Cdc2-Like Kinase 
Inhibitor, TG003 
C13H15NO2S 249,3287 219479 
Cdk1 Inhibitor C17H11ClN2O 294,73504 217695 
Aurora Kinase/Cdk 
Inhibitor 
C17H15F2N7O3S 435,4079064 189406 
Cdk4 Inhibitor II, 
625987 
C15H13NO2S 271,33422 219477 
GSK-3 Inhibitor IX C16H10BrN3O2 356,1735 361550 
MK2a Inhibitor C22H20FNO2 349,3981032 475863 
GSK-3 Inhibitor X C18H12BrN3O3 398,21018 361551 
DNA-PK Inhibitor III C12H15NO3 221,2524 260962 
ERK Inhibitor II, 
Negative Control 
C18H12N6O 328,32748 328008 
Gö 6983 C26H26N4O3 442,50964 365251 
Gö 6976  C24H18N4O 378,42592 365250 
GSK-3b Inhibitor VIII C12H12N4O4S 308,31308 361549 
AG 1024 C14H13BrN2O 305,16982 121767 
Indirubin-3'-
monoxime 
C16H11N3O2 277,27744 402085 
Aloisine, RP106 C17H19N3O 281,35226 128135 
EGFR/ErbB-2/ErbB-4 
Inhibitor 
C17H11ClFN5O 355,7535432 324840 
PKR Inhibitor C13H8N4OS 268,29382 527450 
BAY 11-7082 C10H9NO2S 207,24896 196870 
GTP-14564 C15H10N2O 234,2527 371806 
PKCb Inhibitor C24H21N5O2 411,45584 539654 
VEGF Receptor C19H16ClN3O 337,80284 676481 
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Tyrosine Kinase 
Inhibitor II 
Bohemine C18H24N6O 340,42276 203600 
Cdk1/2 Inhibitor III C15H13F2N7O2S2 425,4362264 217714 
VEGF Receptor 2 
Kinase Inhibitor IV 
C17H13N3OS 307,36962 676489 
JAK3 Inhibitor II C16H14BrN3O3 376,20466 420104 
2826-26-8 C17H14N2O3 294,30466 658401 
PD 158780 C14H12BrN5 330,18258 513035 
PD 174265 C17H15BrN4O 371,2312 513040 
Casein Kinase II 
Inhibitor III, TBCA 
C9H4Br4O2 463,74286 218710 
VEGF Receptor 2 
Kinase Inhibitor III 
C15H14N2O 238,28446 676487 
Cdk2 Inhibitor IV, 
NU6140 
C23H30N6O2 422,5233 238804 
IRAK-1/4 Inhibitor C20H21N5O4 395,41184 407601 
Indirubin Derivative 
E804 
C20H19N3O4 365,38256 402081 
Flt-3 Inhibitor II C17H12N2O3 292,28878 343021 
Aurora Kinase 
Inhibitor III 
C21H18F3N5O 413,3957296 189405 
LY 294002 C19H17NO3 307,34318 440202 
Cdk4 Inhibitor III C15H12N2O2S 284,33298 219478 
ERK Inhibitor II, 
FR180204 
C18H13N7 327,34272 328007 
AGL 2043 C15H12N4S 280,34758 121790 
PKCbII/EGFR Inhibitor C20H13F2N3O2 365,3329264 539652 
Diacylglycerol Kinase 
Inhibitor II 
C28H25F2N3OS 489,5794064 266788 
Chelerythrine C21H18ClNO4 383,82492 220285 
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Chloride 
DNA-PK Inhibitor V C17H17NO3 283,32178 260964 
Chk2 Inhibitor II C20H14ClN3O2 363,79706 220486 
JAK Inhibitor I C18H16FN3O 309,3375432 420099 
PP1 Analog II, 1NM-
PP1 
C20H21N5 331,41424 529581 
VEGF Receptor 
Tyrosine Kinase 
Inhibitor III, KRN63 
C20H21ClN4O4 416,85814 676482 
Rho Kinase Inhibitor 
III, Rockout 
C13H10N2 194,2319 555553 
GSK-3b Inhibitor II C14H10IN3OS 395,21817 361541 
AG 1295 C16H14N2 234,29576 658550 
GSK-3 Inhibitor XIII C18H15N5 301,3452 361555 
ROCK Inhibitor, Y-
27632ROCK Inhibitor, 
Y-27632 
C14H25Cl2N3O2 338,2732 688000 
Isogranulatimide C15H8N4O2 276,24962 371957 
Cdk2 Inhibitor III C20H28N6O3 400,47472 238803 
LY 303511 C19H18N2O2 306,35842 440203 
AG 9 C11H8N2O 184,19402 658390 
PI 3-KbInhibitor II C11H5F2NO4S 285,2235064 528108 
Compound 
56Compound 56 
C18H18BrN3O2 388,25842 234505 
PKR Inhibitor, 
Negative Control 
C15H8Cl3NO2 340,58852 527455 
VEGF Receptor 2 
Kinase Inhibitor II 
C17H15BrN2O 343,2178 676485 
AG 112 C13H8N4O 236,22882 658440 
Flt-3 Inhibitor III C21H23N3OS 365,49182 343022 
Syk Inhibitor II C14H21Cl2F3N6O3 449,2561496 574712 
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PI-103 C19H16N4O3 348,35534 528100 
Syk Inhibitor C18H15N3O3S 353,395 574711 
Alsterpaullone C16H11N3O3 293,27684 126870 
IC261 C18H17NO4 311,33188 400090 
ATM Kinase Inhibitor C21H17NO3S2 395,49458 118500 
AG 1478 C16H14ClN3O2 315,75426 658552 
JNK Inhibitor V C20H16N6S 372,44624 420129 
EGFR/ErbB-2 
Inhibitor 
C23H21N3O3 387,43114 324673 
Flt-3 Inhibitor C18H20N2O4S 360,4274 343020 
JAK3 Inhibitor IV C23H26ClNO 367,91164 420121 
SU6656 C19H21N3O3S 371,45334 572635 
DNA-PK Inhibitor II C17H15NO3 281,3059 260961 
cFMS Receptor 
Tyrosine Kinase 
Inhibitor 
C20H22N4O3 366,41368 344036 
VEGF Receptor 2 
Kinase Inhibitor I 
C18H18N2O3 310,34712 676480 
Aminopurvalanol A C19H26ClN7O 403,90904 164640 
Compound 52 C16H19ClN6O 346,81466 234503 
TGF-b RI Kinase 
Inhibitor 
C17H12N4 272,30398 616451 
AMPK Inhibitor, 
Compound C 
C24H25N5O 399,4882 171260 
Cdk1/5 Inhibitor C9H7N5 185,18538 217720 
Casein Kinase I 
Inhibitor, D4476 
C23H18N4O3 398,41402 218696 
TGF-b RI Inhibitor III C20H22ClN3O2 371,86058 616453 
Syk Inhibitor III C9H7NO4 193,15618 574713 
Cdk4 Inhibitor C20H10BrN3O2 404,2163 219476 
PDGF Receptor C27H27N5O4 485,53438 521232 
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Tyrosine Kinase 
Inhibitor III 
Bcr-abl Inhibitor C18H13F3N4O2 374,3166296 197221 
Rho Kinase Inhibitor 
IV 
C18H28Cl2N4O4S 467,41032 555554 
Akt Inhibitor V, 
Triciribine 
C13H16N6O4 320,30394 124012 
BPIQ-I C16H12BrN5 354,20398 203696 
ERK Inhibitor III C12H10N6O5 318,245 328009 
PI 3-Kg Inhibitor C12H7N3O2S 257,26788 528106 
GSK-3b Inhibitor XI C18H15N5O3 349,3434 361553 
JNK Inhibitor II C14H8N2O 220,22612 420119 
Aurora Kinase 
Inhibitor II 
C23H20N4O3 400,4299 189404 
JNK Inhibitor IX C20H18N2O2S 350,43412 420136 
GSK-3b Inhibitor I C10H10N2O2S 222,2636 361540 
IKK-2 Inhibitor IV C12H10FN3O2S 279,2901032 401481 
PP3 C11H9N5 211,22266 529574 
Lck Inhibitor C23H22N4O 370,44698 428205 
Src Kinase Inhibitor I C22H19N3O3 373,40456 567805 
Aloisine A, RP107 C16H17N3O 267,32568 128125 
AG 1296 C16H14N2O2 266,29456 658551 
IGF-1R Inhibitor II C18H16ClN3O2 341,79154 407248 
ATM/ATR Kinase 
Inhibitor 
C23H18Cl3FN4O3S 555,8364232 118501 
Bisindolylmaleimide 
IV 
C20H13N3O2 327,33612 203297 
JAK3 Inhibitor VI C19H17N3O4S 383,42098 420126 
Staurosporine, N-
benzoyl- 
C35H30N4O4 570,6371 539648 
Akt Inhibitor X C20H26Cl2N2O 381,33924 124020 
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JNK Inhibitor VIII C18H20N4O4 356,3758 420135 
PDGF Receptor 
Tyrosine Kinase 
Inhibitor II 
C21H18N2O3 346,37922 521231 
PDGF Receptor 
Tyrosine Kinase 
Inhibitor IV 
C18H16FN3O2 325,3369432 521233 
PDGF RTK Inhibitor C26H29N3O7S 527,58936 521234 
JNK Inhibitor, 
Negative Control 
C15H10N2O 234,2527 420123 
Aurora Kinase 
Inhibitor III 
C21H18F3N5O 413,3957296 189405 
Met Kinase Inhibitor C28H30ClN5O4S 568,0869 448101 
Bisindolylmaleimide I C25H24N4O2 412,48366 203290 
Cdk/Crk Inhibitor C23H22Cl2N4O3 473,35178 219491 
DMBI C17H16N2O 264,32174 317200 
EGFR Inhibitor C21H18F3N5O 413,3957296 324674 
KN-62 C38H35N5O6S2 721,8444 422706 
Cdk1 Inhibitor, 
CGP74514A 
C19H24ClN7 385,89376 217696 
SU11652 C22H27ClN4O2 414,92838 572660 
Rapamycin C51H79NO13 914,17186 553210 
Akt Inhibitor VIII, 
Isozyme-Selective, 
Akti-1/2 
C34H29N7O 551,64036 124018 
PDK1/Akt/Flt Dual 
Pathway Inhibitor 
C10H4N6O 224,17836 521275 
Fascaplysin, synthetic C18H11ClN2O 306,74574 341251 
Herbimycin A, 
Streptomyces sp. 
C30H42N2O9 574,66248 375670 
Staurosporine, C28H26N4O3 466,53104 569397 
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Streptomyces sp. 
Akt Inhibitor IV C31H27IN4S 614,54235 124011 
   
Table S2. shRNA sequences  
Name Oligo Sequences(5’ - 3’) 
shPKC-51 CCGGCTTTGGAGTTTCGGAGCTGATCTCGAGATCAGCTCCGAAACTCCAAAGTTTTT 
shPKC-52 CCGGCGAGCTATTTCAGTCTATCATCTCGAGATGATAGACTGAAATAGCTCGTTTTT 
shPKC-53 CCGGCATGGAACTCAGGCAGAAATTCTCGAGAATTTCTGCCTGAGTTCCATGTTTTT 
shPKC-47 CCGGCGTCCTTCATTTCTGTCATTCCTCGAGGAATGACAGAAATGAAGGACGTTTTTT
G 
shPKC-48 CCGGGCCATGAATTTGTCACATTCTCTCGAGAGAATGTGACAAATTCATGGCTTTTTTG 
shPKC-49 CCGGGAAACAAAGATGGTTGTATTCCTCGAGGAATACAACCATCTTTGTTTCTTTTTTG 
shPKC-50 CCGGGACGACCTGCTTTGATTTAACCTCGAGGTTAAATCAAAGCAGGTCGTCTTTTTT
G 
shRelA-06 CCGGGCCTTAATAGTAGGGTAAGTTCTCGAGAACTTACCCTACTATTAAGGCTTTTT 
shRelA-07 CCGGCGGATTGAGGAGAAACGTAAACTCGAGTTTACGTTTCTCCTCAATCCGTTTTT 
shRelA-08 CCGGGCAGGCTATCAGTCAGCGCATCTCGAGATGCGCTGACTGATAGCCTGCTTTTT 
shRelA-09 CCGGCACCATCAACTATGATGAGTTCTCGAGAACTCATCATAGTTGATGGTGTTTTT 
shRelA-10 CCGGCCTGAGGCTATAACTCGCCTACTCGAGTAGGCGAGTTATAGCCTCAGGTTTTT 
shc-Fos-37 CCGGGCTGGTAGTTAGTAGCATGTTCTCGAGAACATGCTACTAACTACCAGCTTTTT 
shc-Fos-38 CCGGGCGGAGACAGACCAACTAGAACTCGAGTTCTAGTTGGTCTGTCTCCGCTTTTT 
shc-Fos-39 CCGGCACTGCTTACACGTCTTCCTTCTCGAGAAGGAAGACGTGTAAGCAGTGTTTTT 
shc-Fos-40 CCGGGTGGAACAGTTATCTCCAGAACTCGAGTTCTGGAGATAACTGTTCCACTTTTT 
shc-Fos-42 CCGGGCGGAGACAGACCAACTAGAACTCGAGTTCTAGTTGGTCTGTCTCCGCTTTTTG 
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Table S3. Primer sequences 
Gene Sequences 5’ to 3’ 
HEV-F 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ 
HEV-R 5’-CCGTGGCTATAATTGTGGTCT-3’ 
PKC-F 5'-GCCTATGGCGTCCTGTTGTATG-3' 
PKC-R 5'-GAAACAGCCTCCTTGGACAAGG-3' 
PKC-F 5'-GAGGGACACATCAAGATTGCCG-3' 
PKC-R 5'-CACCAATCCACGGACTTCCCAT-3' 
GAPDH-F 5’-TGTCCCCACCCCCAATGTATC-3’ 
GAPDH-R 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
RelA-F 5’-TGAACCGAAACTCTGGCAGCTG-3’ 
RelA-R 5’-CATCAGCTTGCGAAAAGGAGCC-3’ 
c-Fos-F 5’-GCCTCTCTTACTACCACTCACC-3’ 
c-Fos-R 5’-AGATGGCAGTGACCGTGGGAAT-3’ 
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Abstract 
The liver is rich in mitochondria, an organelle which plays important roles in physiology and 
pathogenic processes. Viruses have been reported to manipulate mitochondrial dynamics, 
especially their fusion and fission to facilitate their infection. This study aims to investigate 
whether hepatitis E virus (HEV) alters mitochondrial dynamics and how these effects relate 
to the infectious process. We observe that HEV promotes mitochondrial fusion, as evident 
from a dramatic increase in mitochondrion length following infection. Mechanistically, these 
effects relate to HEV-dependent increased expression of OPA1 and Mfn1, which are both 
established mediators of mitochondrial fusion. Consistently, in OPA1 and Mfn1 knock-down 
cells, HEV no longer provoked mitochondrial fusion and this effect coincided with a 
significant reduction in HEV RNA levels, suggesting that HEV-induced mitochondrial fusion 
facilitates viral infection. Since mitochondrial dynamics have been reported to be strongly 
associated with innate immunity, we therefore explored the effect of inhibiting 
mitochondrial fusion on the cell-autonomous anti-viral immune response. Interestingly, 
production of the antiviral interferon-stimulated genes (ISGs) was substantially enhanced in 
OPA1- or Mfn1-knock-down cells. In conjunction our data suggest that HEV-induced 
mitochondrial fusion facilitates hepatocyte HEV infection by interfering with cell-
autonomous antiviral immunity. 
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Introduction 
Hepatitis E virus (HEV) infection is the most common cause of acute viral hepatitis 
world-wide. HEV is a single-stranded positive-sense RNA virus, which mainly infects liver 
hepatocytes. In general, HEV infection is a self-limiting disease and associated with low 
mortality, however, more than 60% of organ recipients infected with HEV will develop 
chronic hepatitis with rapid progression to cirrhosis 1. Despite HEV infection being an 
emerging global health issue, no effective anti-HEV therapy is currently available. Only type I 
interferons (IFN-α/β), ribavirin or a combination as off-labelled compounds for clinically 
treatment are available, thus there is an urgent for novel approaches to combat infection 2. 
The lack of knowledge as to the interaction of HEV with the hepatocellular host cell 
machinery represents a major gap in our understanding of the biology of this virus and 
hampers design of rational treatment.  
Viral life cycles intimately interact with all aspect of cellular metabolism and 
accordingly also interact with host cell organelles. For survival and replication, viruses 
corrupt normal cell organelle function to interfere with anti-viral immunity. In this respect 
especially mitochondria appear interesting as there is substantial evidence that various 
viruses modulate mitochondrial behavior to facilitate infection 3. The exact mechanisms 
employed by viruses to affect mitochondria are still very much subject to an intense 
research effort but especially mitochondrial dynamics have been proposed to constitute a 
principal target in this respect 4. Mitochondrial dynamics involve continuous fusion of these 
organelles (leading to more elongated mitochondria) and their fission (division of 
mitochondria, leading to smaller organelles). These processes are subject to tight regulation 
and can be adapted as to provide adequate responses to alterations in the cellular 
environment, such as stress, infection, or inhibition of ATP production 5. The balance 
between mitochondrial fusion and fission is constantly adapted as to allow optimal 
maintenance of mitochondrial integrity and energy supply, but also plays roles in metabolite 
maintenance, apoptosis, autophagy and viral elimination 6, 7. For many viruses, however, the 
interaction with mitochondrial dynamics remains unclear and the importance of such events 
for infection uncharacterized. Also as to how hepatocyte HEV infection influences 
mitochondrial dynamics has not yet been investigated. 
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Earlier dysfunctional mitochondrial dynamics have been strongly linked to 
neurodegenerative disease. Knowledge on the role of mitochondrial dynamics in viral 
infection is still immature and scanty, but might provide a novel avenue in explaining virus-
host interaction. Indeed, several viruses have been reported to manipulate the 
mitochondrial dynamics of host cells, influencing the balance between fusion and fission to 
facilitate their infections 8-11. Nevertheless, the role of altered mitochondrial dynamics 
remains underexplored. 
Therefore, in this study we investigated the role of mitochondrial dynamics and its 
regulatory factors in HEV replication, as well as the potential involvement of altered 
dynamics in the anti-viral immune response. We found that HEV infection provokes 
profound modulation of mitochondrial dynamics through regulation of OPA1 and Mfn1 and 
that this effect is important in the HEV life cycle by impairing cell- autonomous immunity 
against HEV. 
Materials and Methods 
Compounds 
Ethidium bromide (EB) (CAS 1239-45-8 ) was bought from Sigma, 2',3'-Dideoxycytidine 
(ddC) was bought from ITK Diagnostics B.V. (CAS 7481-89-2). goat anti-HSP60 (N-20) was 
bought from Bio-connect. Alexa Fluor® 488 AffiniPure Donkey Anti-Goat IgG (H+L) secondary 
Antibody was from Jackson ImmunoResearch. Goat anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor® 555 conjugate was from Invitrogen. OPA1 antibody was brought 
from BD pharmingen. 
Cell Cultures 
Human hepatoma cell line huh7 and human embryonic kidney epithelial cell line 293T 
were cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented 
with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 IU/ml streptomycin. 
Cell culture models 
An HEV replication model with subgenomic HEV sequence coupled with a Gaussia 
luciferase reporter gene and an HEV infection model containing the full-length HEV genome 
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were used in our study. HEV genomic RNA was generated from a plasmid construct 
containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank Accession Number 
JQ679013) or a construct containing subgenomic HEV sequence coupled with a Gaussia 
luciferase reporter gene (p6-luc), using the Ambion MESSAGE MACHINE in vitro RNA 
transcription Kit (Life Technologies Corporation). All cells were grown at 37 °C, 5% CO2, and 
100% humidity. Huh7 cells constitutively expressing the firefly luciferase reporter gene 
driven by the human PGK promoter were used to represent household luciferase activity for 
normalizing nonspecific effects on luciferase activity.  
Quantification of Hepatitis E Virus Infection 
RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
prepared from total RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA was 
quantified with a SYBR Green-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) 
according to the manufacturer's instructions. GAPDH or β-actin was considered as reference 
gene to normalize gene expression.  
Immunofluorescence and Confocal microscope 
For immunofluorescence staining, cells grown on glass cover slips were fixed with 4% 
formaldehyde in phosphate-buffered saline solution (PBS) for 15 min at room temperature. 
Slips were permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 10 
min and then blocked by % H2O2 in PBS for 5min. The slips were incubated with primary 
antibody anti-HSP60 overnight at 4°C, washed with PBS for 3 times, and incubated with 
secondary antibodies for 1 h at room temperature. After 3 times washing using PBS, DAPI 
staining was applied (nuclei). Images were observed under a Zeiss LSM 510 confocal 
microscope with a Plano Apochromat 63×/1.4-numerical-aperture oil immersion objective. 
Confocal images were acquired using Zeiss ZEN 2010LSM software. 
Electroporation of HEV RNA 
Huh-7 cells were collected and centrifuged for 5 min, 1500 rpm, 4°C. The supernatant 
was removed and the cells were washed with 4 ml Opti-DMEM (Thermo Scientific, the 
Neterlands) by centrifuging for 5 min, 1500 rpm, 4°C. The cell pellet was re-suspended in 
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100 μl Opti-DMEM and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. 
Electroporation was performed with the Bio-Rad’s electroporation systems using the 
protocol of a designed program (400 volt, pulse length 0.5, number 1 and cuvette 4 mm).  
Mitochondrial length quantification 
Mitochondrial length was assessed by staining with HSP60 antibody and measured by 
tracing the mitochondria using ImageJ software. Mitochondrial length was binned into 
different categories (<0.5 mm, 0.5–1 mm, 1–2 mm, and >2 mm). 
Gene knockdown by lentiviral vector delivered short-hairpin RNA 
Lentiviral vectors, targeting OPA1 and Mfn1 and control, were produced in 293T cells 
as previously described. To generate stable gene knockdown cells, Huh7 cells were 
transduced with lentiviral vectors obtained from the Erasmus Center for Biomics. Control 
vector (shCTR) is a short hairpin sequence containing 5 bp mismatches and scrambled 
sequences not aligning to any known human or mouse gene. Since the vectors also express 
a puromycin resistance gene, transduced cells were subsequently selected by adding 2.5 
μg/ml puromycin (Sigma) in the cell culture medium. After pilot study, the shRNA vectors 
(supplement table 1) exerting optimal gene knockdown were selected by qPCR with the 
corresponding primers shown in supplement table 2. The amount of HEV was assessed after 
3 days of infectious HEV medium post-infecting shCTR cells and knockdown cells.  
Western blot assay 
Proteins in cell lysates were heated 5 min at 95 °C followed by loading onto a 10-15% 
sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. 
After 90 min running at 100 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 h with an electric current of 
250 mA. Subsequently, the membrane was blocked with blocking buffer. It was followed by 
incubation with OPA1 (1:1000) antibodies overnight at 4 °C. The membrane was washed 3 
times followed by incubation for 1 h with anti-rabbit IRDye-conjugated secondary antibodies 
(LI-COR Biosciences, Lincoln, USA) (1:5000) at room temperature. Blots were assayed for β-
actin content as standardization of sample loading, scanned, and quantified by Odyssey 
Hepatitis E virus Induces Mitochondrial Fusion to Facilitate Viral Replication 
 
- 195 - 
 
infrared imaging (Li-COR Biosciences, Lincoln, NE, USA). Results were visualized and 
quantitated with Odyssey 3.0 software. 
Statistical Analysis 
Statistical analysis was performed using a nonpaired, nonparametric test (Mann-
Whitney test; GraphPad Prism Software). P values of less than 0.05 were considered 
statistically significant. 
Results 
HEV infection induces mitochondrial fusion  
Up to date, the impact of HEV infection on mitochondrial dynamics is unknown, 
prompting investigation in this respect. To this end a high concentration stock of HEV 
particle was prepared by ultracentrifugation of lysed (freeze thawing) HEV infected Huh7 
cells, whereas a similar preparation of non-infected Huh-7 cells was used as control.  
Subsequently were inoculated with resulting preparations for 3 days after which cells were 
fixed and analyzed by immunofluorescence and confocal microscopy for mitochondrial 
characteristics.  As evident from Figure 1A, these experiments revealed obvious elongated 
mitochondria in HEV infected cultures, apparently indicating mitochondrial fusion, whereas 
uninfected cells displayed the canonical rod-shaped mitochondria. This notion was 
confirmed by morphometric analysis in which the length of induvial mitochondria was 
directly quantified (Figure 1B) and the changes in mitochondrial shape correlated with 
production of HEV RNA as analyzed by qRT-PCR (Figure 1C) showing that these effects 
related to the infectious process. Subsequently, we investigated whether HEV can induce 
mitochondrial fusion in other types of cells as well and results as obtained with Huh7 cells 
were observed in the liver cell line HeprG, the canonical HEV infection model A549, and in 
intestinal CaCo2 cells (Figure 2). We concluded that HEV infection is associated with clear 
alterations of mitochondrial dynamics and experiments were initiated to dissect the 
molecular basis of these events.  
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Figure 1. HEV secondary infection induces mitochondrial fusion. Immunofluorescence analysis showing 
mitochondrial fusion in HEV infected Huh7 cells. Huh7 cells infected with HEV particles obtained from freeze-
thawing infected cell pellets (viral copy number, 5,96 × 107 ) or with a preparation obtained from freeze-
thawing uninfected Huh7 cell pellets. At 3 days post infection, cells were immunostained with anti-HSP60 
(mitochondrial marker) and DAPI (nuclei). Shown confocal images are representative for three independent 
experiments. (63x oil immersion objective). (B) Quantification of mitochondrial length was performed by 
imageJ software and is shown in (B). (C) qRT-PCR analysis showed the Ct value of targeting HEV sequence in 
mock Huh7 cells and HEV infected Huh7 cells. (D) Transcription of 4 mitochondrial dynamics regulatory 
proteins was assessed by qRT-PCR and the OPA1 expression was measured by Western blot. 
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Figure 2. HEV secondary infection induces mitochondrial fusion in a variety of cell types. Hepatocyte HeprG 
cells, lung cancer cell A549, and intestinal cell CaCo2 were infected with HEV particles obtained from freeze-
thawing the cell pellets of infected Huh7 cells. At 3 days post infection, cells were immunostained with anti-
HSP60 (mito) and DAPI (nuclei). Shown confocal images are representative for three independent experiments. 
(63x oil immersion objective). 
We next examined whether electroporation of full length of HEV genome in Huh-7 
cells also alter mitochondrial dynamics. HEV ORF2 protein (red) and mitochondria (green) 
were detected three days electroporation of HEV. As shown in Figure 3, HEV infected cells 
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displayed distinct elongated mitochondria. This confirms that mitochondrial fusion is a 
consequence of HEV infection. 
Figure 3. Electroporation of HEV induces mitochondrial fusion. Immunofluorescence staining of viral protein 
ORF2 (red) and mitochondria (green) in Huh-7 cells upon electroporation of the full-length genomic HEV RNA. 
DAPI (blue) was applied to visualize nuclei. Shown confocal images are representative for three independent 
experiments. (63x oil immersion objective). 
HEV infection provokes expression of mitochondrial fusion -stimulating proteins 
Mitochondrial morphology is subject to dynamic regulation, these organelles 
constantly fusing and fission, also to meet alterations in metabolic demand or in response to 
mitochondrial damage. This regulation is exerted by key regulatory proteins that either 
facilitate mitochondrial fusion or induce their fission 12,13. Mitochondrial fusion is mediated 
by the inner membrane fusion protein dynamin-related GTPase (OPA1) and the outer 
membrane fusion protein Mitofusin1 (Mfn1), whereas fission is brought about by 
mitochondrial fission factors (Mff) and dynamin-related protein 1 (Drp1). Altered expression 
of these gene products is thus an obvious explanation for the effects of HEV infection on 
mitochondrial morphology. Hence, after qRT-PCR analysis was performed to determine 
alterations in the transcription of these four genes in response to hepatocyte HEV infection 
(Figure 1D). In line with the evident mitochondrial fusion following HEV infection, we 
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observed increased levels of OPA1 and Mfn1 transcripts HEV infected cells. No clear effect, 
however, on the levels of Drp1 and Mff transcripts was observed. The relevance of these 
observations was supported by experiments in which we analyzed OPA1 expression on the 
protein level. The Western blot in Figure 1D reveals increased OPA1 protein levels in HEV 
infected cells. Hence our results show that increased HEV-provoked expression of 
mitochondrial fusion proteins underlies the effects of HEV infection on mitochondrial 
morphology 14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Silencing OPA1 and Mfn1 abrogates HEV-induced mitochondrial fusion. Huh7 cells were transduced 
with lentiviral vectors targeting OPA1, Mfn1 and control. Upon selection of clones displaying substantial gene 
silencing, cells were infected with HEV particles. Confocal images showing the inhibition of HEV induced 
mitochondrial fusion by silencing OPA1 or Mfn1 (A). (B) Quantitative analysis of mitochondrial length in these 
cultures. 
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HEV induced mitochondrial fusion facilitates HEV replication 
Subsequently we decided to investigate the functional importance of HEV-induced 
mitochondrial fusion. To this end Huh7 cells were transduced with shRNA-expressing 
lentivirus either containing a scrambled control sequence or sequences expecting to silence 
expression of OPA1 and Mfn1. After puromycin selection and expansion of the resulting 
clones, we found that silencing either OPA1 or Mfn1 induced mitochondrial fragmentation, 
as revealed by a significant increase in the number of mitochondria per cell and a decrease 
in mean size per mitochondrion compared to control vector-transduced cells (Figure 4A). 
The apparent functionality of OPA1 and Mfn1 in our experimental system with respect to 
the regulation of mitochondrial elongation supports the notion that HEV effects on 
mitochondrial morphology are mediated by altered expression of these fusion proteins. 
Definitive proof of this line of thought came from experiments in which the transduced cells 
were infected with HEV for 3 days. Silencing OPA1 or Mfn1 abolished HEV effects on 
mitochondrial fusion, whereas the control vector did not have such effects (Figure 4A) and 
morphometric analysis of mitochondrial length confirmed this interpretation (Figure 4B). 
Importantly when subsequently the effects of inhibiting of mitochondrial fusion on the HEV 
infectious process were determined by qRT-PCR, we observed that knockdown of OPA1 and 
Mfn1 significantly suppressed HEV infection (Figure 5). Thus induction of mitochondrial 
fusion by HEV facilitates infection. 
 
 
 
 
Figure 5. Inhibition of mitochondrial 
fusion affects HEV infection. Huh-7 
cells were transduced with lentiviral 
vectors targeting OPA1, Mfn1 and 
control. Upon selection of clones 
displaying satisfactory knock down, 
cells were infected with HEV virus. 
At 3 days post infection, qRT-PCR 
was performed to establish the 
resulting HEV mRNA levels.  
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Disruption of mitochondrial fusion provokes cellular antiviral immune responses 
ISGs are the ultimate cell-autonomous antiviral effectors. The mechanisms leading to 
production of ISGs following viral infection are now partially understood and appear to 
involve signaling steps at the mitochondrial level, especially relating to MAVS (mitochondrial 
anti-viral signaling protein). Thus reduced ISG induction following HEV-provoked 
mitochondrial fusion may constitute explanation of the observed effects of mitochondrial 
fusion on HEV replication. Interestingly, knockdown of OPA1 or Mfn1 stimulated the 
expression of a panel of antiviral ISGs during HEV infection and thus diminished IGS 
transcription may be the relevant cellular target for HEV-provoked mitochondrial fusion 
(Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inhibition of mitochondrial fusion increases antiviral innate immunity. Huh7 cells with OPA1 and 
Mfn1 silence were infected with HEV particles. The expression of a panel of ISGs was determined by qRT-PCR 
at 3 days post infection. Data were normalized to basal ISG expression in cells transduced with a scrambled 
shRNA (white bar, set as 1). 
Disruption of mitochondrial fission promotes HEV infection 
Mitochondrial fission is initiated by recruitment of cytosolic Drp1 to the 
mitochondrion and is thus a principal regulator of the mitochondrial fission process 15. The 
apparent importance of Drp1 in mitochondrial dynamics raises obvious questions as to the 
importance of this protein in restraining HEV infection through stimulating cell-autonomous 
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immunity. As phosphorylation on residue S616 residue of Drp1 by CDK1 seems the main 
biochemical event provoking translocation of Drp1 to the mitochondria. Thus treatment of 
cells with CDK1 inhibitors in the context of HEV infection should provide insight into the role 
of Drp1 in particular and the mitochondrial fission machinery in general with respect to their 
role in HEV infection. As shown in Figure 7, treatment with CDK1 inhibitor in HEV infected 
Huh7 cells provoked the appearance of grossly-enlarged mitochondria (Figure 7A), which 
was accompanied by stimulation of HEV replication and infection (Figure 7B). Thus these 
results further emphasize the relation between mitochondrial morphology and the HEV 
infectious process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CDK1 inhibition increases concomitantly mitochondrial fusion and HEV infection. (A) Huh7 cells 
were treated with the CDL1 inhibitor for 2 days and confocal images showing the morphology of mitochondria. 
(B) Stable infectious HEV cells were directly treated with CDK1 inhibitor for 2 days, HEV mRNA were assessed 
by qRT-PCR. 
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The inhibitory effects of impaired mitochondrial fusion on HEV infection are 
independent of mitochondrial DNA dysfunction 
In cells mitochondria constantly fuse and fission to ensure integrity of mitochondrial 
genome and to ascertain proper functionality of this organelle compartment. Accordingly, 
OPA1 has important roles in maintaining mitochondrial DNA (mtDNA) stability and integrity 
16 and induction of excessive mitochondrial fission in response to interfering with the 
mitochondrial fusion machinery has been associated with mtDNA instability as evident by 
reduced mtDNA copy numbers and an increase in the amount of mutant mtDNA 16-19. It is 
thus possible that the effects seen with respect to the effects of modulating mitochondrial 
fusion on HEV replication result from mitochondrial dysfunction per se rather as constituting 
specific effects on the HEV infectious process. Thus we evaluated the effects of OPA1 knock-
down on the quality of the mtDNA. mtDNA polymerases γ (POLG) encoding protein is an 
essential enzyme for mtDNA replication. We found silence of OPA1 significantly decreased 
POLG transcription (Figure 8A). In addition, we evaluated transcription of Cytochrome c 
oxidase I (COX1) proteins, which are encoded by mitochondrial DNA, serving as relatively 
quantification of mtDNA. The expression of COX1 were evidently reduced in OPA1 silenced 
cells, in contrast with scramble knockdown cells (Figure 8A). These data suggested that 
modulating mitochondrial dynamics indeed affected mitochondrial functionality in our 
model system, with possible effects on the capacity of cells to sustain HEV infection. Hence, 
we decided to investigate the effect of full mtDNA depletion on HEV infection. To this end 
Huh7 cells were exposed to a low concentration of ethidium bromide (EB), with is well 
known to affect mtDNA replication by intercalation of EB into mtDNA genome without 
affecting nucleus genome. Indeed, when cellular mtDNA levels were measured by 
transcription of COX1 and ND1 protein of complex I (MTND1) relative to the nuclear-
encoded GAPDH by real-time PCR, expression of both mtDNA encoding genes MTND1 and 
COX1 were evidently diminished following EB treatment (Figure 8C). Intriguingly, upon a 
subsequent inoculation of significant promotion of HEV infection was observed in mtDNA-
depleted cells as compared to control cells (Figure 8B). Similar results were obtained when 
deoxyribonucleoside analogue dideoxycytidine (ddC) was employed, a compound that 
destroys mtDNA replication through inhibiting mtDNA polymerase γ (POLG). The ddC pre-
treated Huh7 cells were evidently more permissive to HEV infection when compared to 
Chapter 8 
 
- 204 - 
 
vehicle control-treated cells (Figure 8B). In apparent agreement, when the POLG gene itself 
was silenced using lentiviral-delivered shRNA and selection for transduced clones using 
puromycin and experimentation with those clones which displayed most efficient POLG 
knockdown, it appeared that such knockdown made Huh7 three times more permissive to 
HEV infection; at least when compared to clones transduced with a scrambled shRNA 
(Figure 8D). Similarly, when lentiviral-mediated RNAi delivery was used for knockdown the 
gene PPARGC1A, a gene that encodes peroxisome proliferator-activated receptor c 
coactivator 1α (PGC-1α), a transcriptional coactivator that positively regulates mitochondrial 
biogenesis), HEV infection was enhanced (Figure 8E). Thus whereas this experimentation 
further highlights the link between mitochondrial function and cellular capacity to combat 
HEV infection, it also demonstrates that overall loss of mitochondrial function upon 
increasing mitochondrial fission is unlikely to explain to the reduced capacity of HEV to 
propagate in such cells.  
 
 
Figure 8. Inhibition of mitochondrial fusion leads to a decline of mtDNA 
content and promotes HEV infection. (A) Expression of POLG and COX1 was 
detected in OPA1 or Mfn1 knockdown cells, results are normalized to cells 
transduced with a scrambled sequence. (B) HEV infection was assessed in 
Huh7 cells in presence or absence of 4 days EB, or 6 days ddC treatment. (C) 
Two mtDNA encoded genes COX1 and MTND1 were determined after EB or 
ddC treatment in Huh7 cells. HEV infection was determined in Huh7 cells with 
knockdown of mtDNA polymerases γ (C) and PGC-1α (E) 
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Discussion  
The HEV infectious process remains relatively poorly characterized; especially there is 
a lack of understanding as to the cell biology of the infection and how the host cell 
machinery is corrupted to perform translation of viral gene products. Generally speaking, 
however, mitochondrial dynamics have become linked to viral infection in recent years 5. 
Here we reveal a novel role for HEV-induced mitochondrial fusion for furthering the HEV life 
cycle, apparently interfering with cell-autonomous viral immunity. Thus our study has 
uncovered a previously unrecognized aspect of viral infection, in which the regulation of 
mitochondrial dynamics is high-jacked to allow the pathogen to escape its constraint by 
cellular antiviral signaling. It should prove highly interesting to determine whether also 
other viruses employ likewise strategies. If so, mitochondrial dynamics may become a focus 
point for the rational design of novel antiviral therapy.  
Mitochondrial dynamics were already implicated in immunity. Mitochondria are the 
location of MAVS, a protein that links intracellular viral detection to the activation of 
antiviral effectors by stimulating IFN synthesis and NF-κB activation, and the action of MAVS 
seems to be influenced by mitochondrial fusion and fission 20, 21. Intriguingly, HBV and HCV 
also influence mitochondrial dynamics, but these viruses promote mitochondrial fission and 
mitophagy to attenuate apoptosis and allow persistent infection, whereas HEV-associated 
mitochondrial fusion appears to serve to suppress cell-autonomous anti-viral immunity 9, 22, 
23. This may relate to chronic properties of HBV and HCV – apparently these viruses are able 
to co-exist with human immunity and reduction of the infected compartment may be the 
major evolutionary pressure working on HBV and HCV. In contrast, HEV usually manifests 
itself as a self-limiting infection, under obvious attack of host immunity and thus more likely 
to develop cellular immunity subverting strategies. It should thus prove interesting to 
investigate whether viruses with non-chronic infectious behavior have developed similar 
strategies to corrupt cellular immunity. In this context it is interesting to note that severe 
acute respiratory syndrome-coronavirus (SARS) virus, impairs MAVS signaling by 
mitochondrial fusion via reduction of Drp1 10. In conjunction with the findings presented in 
this study, these data call for further characterization of the interaction of different viruses 
with mitochondrion-dependent antiviral immunity. 
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Generally speaking, in cell biology mitochondrial fusion is seen as a pivotal element of 
the processes that mtDNA stability and copy numbers 17, 19. A dramatic example of this 
functionality is found in autosomal dominant optic atrophy (ADOA) patients, who harbor 
OPA1 and Mfn1 mutations 24. Furthermore, heterozygous Mfn2 mutations have been 
associated with mtDNA depletion 16. Indeed, as recently described in yeast mitochondria by 
Hori et al., the fusion event facilitates recombination-mediated mtDNA replication and 
prevents the generation of cells with reduced mtDNA copy number 25. Accordingly, we 
observed a decline of mtDNA in the OPA1 or Mfn1 silenced cells. However, a reduction in 
mtDNA does not relate to the effects seen in this study on HEV replication, as mtDNA per se 
was associated with increased HEV replication. Thus modulation of intracellular antiviral 
signaling appears the main effector of the effects of altering mitochondrial dynamics on HEV 
infection.  
Fission of mitochondria is often accompanied by mitophagy and plays an important 
role in elimination of damaged mitochondrial material 26-28. Several morphological analyses 
on the mitochondrial size and its association with mitophagy showed an inverse correlation 
between mitochondrial elongation and mitophagy 29. Indeed the process of mitochondrial 
fission is a key event in the sorting of impaired mitochondria with mutant mtDNA copies 
from the healthy mitochondrial population 30. We thus feel it unlikely that HEV-induced 
mitochondrial fusion is a prelude to mitophagy, but will likely result in an impairment of the 
disposal of dysfunctional mitochondrial material. The resulting metabolic misbalance and 
mitochondrial stress may well disrupt antiviral immunity and thus be a factor explaining the 
effects observed on HEV infection, but obviously further work is essential to substantiate 
this notion.  
Mitochondrial fission and mitophagy are usually accompanied by apoptosis due to 
accumulated unhealthy pool of mitochondria 31-33,. Numerous of studies have established 
the positive correlation between fragmented mitochondria and cell apoptosis, evidenced by 
enhanced cytochrome C release or Bax/Bak activation 12, 13, 31, 32, 34. Accordingly, 
mitochondrial fusion has been associated with protection of cells from mitochondrial-
dependent apoptosis 13. HEV mediated mitochondrial fusion might probably dampen cell 
apoptosis to maintain viral infected cells homeostasis and facilitate HEV persistent infection, 
this precise role of mitochondrial fusion in adaption to cellar physiological stability 
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associated with infection deserves further investigation. Interestingly, stimulation of 
apoptosis was also observed in mitochondrial fission defective cells. Interference of 
mitochondrial fission induced by HCV infection results in an evident activation of apoptosis 
signaling, suggesting specific virus can also protect viral infected cells from apoptotic cell 
death via mitochondrial fission, contrasting to the common notion that apoptosis is 
accompanied by fission 9. 
Viral infection modulates host cell signaling via mitochondrial dynamics to facilitate 
infection, which might be a primary determinant in the pathogenesis of disease. 
Mitochondrial fusion induced by HEV appears to play an essential role to help virus evade 
cell-autonomous immune attack. This finding provides unique insight in to the viral-host 
interaction respective to HEV infection, and offer novel targets for design of antiviral 
strategies. 
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Supplementary Materials  
Supplementary Table 1. shRNA sequences 
No. Gene ACCESSION Sequences Target 
Sequence 
OPA1s
h28 
OPA1  "NM_130832.1,NM_
130831.1,NM_1308
33.1,NM_130834.1,
NM_130835.1,NM_
130836.1,NM_1308
37.1,NM_015560.1" 
CCGGCGGGAGTTTGATCTTACCAAACTC
GAGTTTGGTAAGATCAAACTCCCGTTTT
TG 
CGGGAGTTT
GATCTTACCA
AA 
OPA1s
h30 
OPA1  "NM_130832.1,NM_
130831.1,NM_1308
33.1,NM_130834.1,
NM_130835.1,NM_
130836.1,NM_1308
37.1,NM_015560.1" 
CCGGCCGGACCTTAGTGAATATAAACTC
GAGTTTATATTCACTAAGGTCCGGTTTTT
G 
CCGGACCTTA
GTGAATATAA
A 
Mfn1 
sh34 
MFN1 NM_033540.2 CCGGGCGGCTTTCCAAGCCTAATATCTC
GAGATATTAGGCTTGGAAAGCCGCTTTT
TG 
GCGGCTTTC
CAAGCCTAAT
AT 
Mfn1 
sh36 
MFN1 NM_033540.2 CCGGGCTCAAAGTTGTAAATGCTTTCTC
GAGAAAGCATTTACAACTTTGAGCTTTT
TG 
GCTCAAAGT
TGTAAATGCT
TT 
POLGs
h86 
POLG NM_002693.1 CCGGGCAGAGGTGCACAGACTTTATCTC
GAGATAAAGTCTGTGCACCTCTGCTTTTT
G 
GCAGAGGTG
CACAGACTTT
AT 
PGC-
1α 
sh39 
PPAR
GC1A 
NM_013261.2 CCGGCCTCCTCATAAAGCCAACCAACTC
GAGTTGGTTGGCTTTATGAGGAGGTTTT
T 
CCTCCTCATA
AAGCCAACC
AA 
 
 
Supplementary Table 2. Primer sequences 
Gene Sequences 5’ to 3’ 
HEV-F ATTGGCCAGAAGTTGGTTTTCAC 
HEV-R CCGTGGCTATAATTGTGGTCT 
DDX58-F CACCTCAGTTGCTGATGAAGGC 
DDX58-R GTCAGAAGGAAGCACTTGCTACC 
ISG15-F CTCTGAGCATCCTGGTGAGGAA 
ISG15-R AAGGTCAGCCAGAACAGGTCGT 
STAT1-F ATGGCAGTCTGGCGGCTGAATT 
STAT1-R CCAAACCAGGCTGGCACAATTG 
IFI27-F CGTCCTCCATAGCAGCCAAGAT 
IFI27-R ACCCAATGGAGCCCAGGATGAA 
IRF1-F GAGGAGGTGAAAGACCAGAGCA 
IRF1-R TAGCATCTCGGCTGGACTTCGA 
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IRF9-F CCACCGAAGTTCCAGGTAACAC 
IRF9-R AGTCTGCTCCAGCAAGTATCGG 
IFIT1-F GCCTTGCTGAAGTGTGGAGGAA 
IFIT1-R ATCCAGGCGATAGGCAGAGATC 
IFIT2-F GGAGCAGATTCTGAGGCTTTGC 
IFIT2-R GGATGAGGCTTCCAGACTCCAA 
IFI6-F TGATGAGCTGGTCTGCGATCCT 
IFI6-R GTAGCCCATCAGGGCACCAATA 
IRF7-F CCACGCTATACCATCTACCTGG 
IRF7-R GCTGCTATCCAGGGAAGACACA 
CXCL10-F GGTGAGAAGAGATGTCTGAATCC 
CXCL10-R GTCCATCCTTGGAAGCACTGCA 
MX1-F GGCTGTTTACCAGACTCCGACA 
MX1-R CACAAAGCCTGGCAGCTCTCTA 
OPA1-F GTGGTTGGAGATCAGAGTGCTG 
OPA1-R GAGGACCTTCACTCAGAGTCAC 
Mfn1-F GGTGAATGAGCGGCTTTCCAAG 
Mfn1-R TCCTCCACCAAGAAATGCAGGC 
Drp1-F GATGCCATAGTTGAAGTGGTGAC 
Drp1-R CCACAAGCATCAGCAAAGTCTGG 
Mff-F CAAGGTTCCAGGCACCGATTTC 
Mff-R GCGACAAAATGCCACGAGCAGA 
POLG-F AGATGGAGAACTTGCGAGCTGC 
POLG-R CACGTCGTTGTAAGGTCCATTGC 
PGC-1α-F CCAAAGGATGCGCTCTCGTTCA 
PGC-1α-R CGGTGTCTGTAGTGGCTTGACT 
COX1-F GATGAGCAGCTTTTCCAGACGAC 
COX1-R AACTGGACACCGAACAGCAGCT 
MTND1-F GGCTATATACAACTACGCAAAGGC 
MTND1-R GGTAGATGTGGCGGGTTTTAGG 
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Background 
HEV was originally identified as an acute and self-limiting infectious disease with in 
general spontaneous clearance. However, in the last decades, chronic hepatitis and high 
mortality have been described in various settings, such as in transplant patients and in the 
immunocompromised. More than 60% of organ transplant recipients infected with HEV 
develop chronic hepatitis with rapid progression to cirrhosis, and HEV infection is now 
considered to be an emerging and significant clinical problem. Reduction of 
immunosupprants is the first-line therapeutic approach for immunocompromised patients 
with HEV infection, which achieves HEV clearance in approximately 30% of patients, but also 
leads to side-effect with organ rejection looming large in this respect 1, 2. Of note, there is no 
FDA-approved anti-HEV therapy currently available, only interferon-α, ribavirin or a 
combination have been occasionally used as off-label treatment. Ribavirin is the first line 
option for anti-viral treatment because of its efficacy with it being well tolerated, safe, and 
capable of inducing a sustained virological response, as several larger studies have shown. 
However, the optimal dosage and duration of the treatment still need to be determined and 
standardized. In addition, both of these medications induce some severe adverse effects. In 
transplant recipients, elevated risk of organ rejection has been documented with interferon-
alpha treatment, and severe hemolytic anemia was observed in patients undergoing 
ribavirin treatment 3-6. Taken together, for the management of HEV infection, systematic 
profiling of immunosuppressive manipulation and its association with HEV infection is of 
prime importance. In addition, further research aimed at developing effective antiviral 
treatment by understanding its infection biology and interaction with host cells is urgently 
required. In this thesis I aimed to address these points. 
Immunosuppressive medication in HEV infection 
The main clinical challenge is posed by HEV genotype 3 infection in patients receiving 
orthotopic organ transplantation. Immunosuppressive medication universally used after 
transplantation to prevent organ rejection appears to be a main risk factor for developing 
chronic infection. Therefore, dose reduction or even withdrawal of immunosuppressants is 
considered as the first intervention strategy to achieve viral clearance in these patients. 
However, clinical evidence has showed different types of immunosuppressants may exert 
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differential impact on the infection course in patients. Generally speaking, such medication 
not only inhibits host immunity but also modulates other signaling pathways potentially 
involved in anti-viral immunity or may even directly affect the viral life cycle. This clinical 
observation inspired us to explore use of the immunosuppressants on HEV infection in cell 
culture models (chapter 2 and chapter 3). We found that steroids have no clear influence on 
HEV replication in vitro, while calcineurin and mTOR inhibitors both stimulate HEV 
replication. The proviral effect of the calcineurin inhibitor, cyclosporine A, is mediated by 
promotion of HEV replication through inhibition of cyclophilins A and B; another calcineurin 
inhibitor tacrolimus, only significantly enhances HEV replication at high does. mTOR 
inhibitors such as rapamycin and everolimus was found to be mediated by blocking an 
antiviral signaling pathway downstream of mTOR dependent on eIF4E-binding protein 1. A 
recent study provided in vivo evidence of significantly higher HEV RNA levels in patients with 
chronic HEV receiving an mTOR inhibitor as compared to those receiving calcineurin 
inhibitors as immunosuppressive regimen 7. MPA, the active component of mycophenolate 
mofetil, was found to exert potent in vitro anti-HEV activity, mediated by depletion of 
intracellular GTP pools. Analysis of a limited number of cases suggests that the use of the 
immunosuppressant mycophenolate mofetil is associated with HEV clearance. Although 
these findings provide interesting indications on what therapies may be beneficial or 
detrimental in preventing and treating chronic hepatitis E in transplant patients, they 
require verification in vivo. The current clinical and experimental evidence regarding the key 
implications of the use of different immunosuppressants in chronic hepatitis E was carefully 
reviewed in this thesis (chapter 4). 
Nucleotide synthesis pathways in HEV infection 
The proposed mechanism of action for the anti-HEV activity of ribavirin and MPA is 
the depletion of GTP pools caused by inhibition of IMP dehydrogenase (IMPDH), thus 
impeding RNA virus replication (chapter 2 and chapter 5). These data suggested viral 
replication heavily relies on the host cells to supply nucleosides for their propagation. 
Targeting nucleotide biosynthesis pathways thus represents an attractive strategy for 
antiviral drug development. Based on that, in chapter 4, I comprehensively profiled the role 
of purine and pyrimidine synthesis pathways in HEV cell culture models. Unexpectedly, 
targeting the early steps of the purine nucleotide synthesis pathway (before the primary 
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purine IMP formed) leads to enhancement of HEV replication, indicating these effects may 
only partly relate to the nucleotide synthesis pathway. It is worth noting that targeting the 
early stage of purine synthesis results in depletion of ATP and/or GTP pool. Cellular energy 
metabolism mediated by ATP might be important for the host cells to defend virus infection 
8, 9. Therefore, insufficient ATP level might facilitate HEV infection by escaping from host 
cellular immunity. However, how the ATP levels regulate virus infection deserves further 
investigation. Targeting later steps (IMPDH enzyme) results in potent antiviral activity 
against HEV, an effect apparently relating to purine nucleotide depletion. Inhibition of 
pyrimidine nucleotide synthesis pathway also powerfully inhibits HEV replication and 
represents a viable option for antiviral drug development against HEV. Mechanistically, 
these effects are related to an unconventional interaction with cell-autonomous antiviral 
immunity dependent on very strong induction of antiviral ISGs. For now the mechanistic 
details as to inhibitors of nucleotide biosynthesis can induce ISGs remain obscure and need 
further study. In addition, the concern that the nucleotides depletion restricts viral infection 
completely relies on activation of antiviral immunity or somehow have direct anti-viral 
effects remains unknown. 
Protein kinase in management of HEV 
Protein kinases are principal components of the machineries that orchestrate immune 
responses against diverse pathogenic entities, including viruses, by subsequent stimulation 
of specific signal transduction cascades. Numerous pharmacological kinase inhibitors or 
activators have been broadly implicated kinases as potential avenues for treating various 
diseases, including cancer, inflammation, diabetes and viral infections 10, 11. Thus, in chapter 
7, we comprehensively profile kinase-mediated cascades in cell–autonomous antiviral 
immunity starting from screening a library of pharmacological kinase inhibitors on the Huh7-
based HEV replication cell model. We identified protein kinase C alpha (PKCα) as an 
important anti-HEV mediator. Thus, our results defined PKCα as a novel antiviral element 
and machinery against HEV infection. The anti-HEV activity of such inhibitors is fully 
independent of its downstream NF-κB or AP-1 pathways. These results thus provide a 
valuable novel target for antiviral therapy, although it remains to be established what 
mechanisms mediate antiviral activity in this respect, and I call for such investigations to be 
pursued. 
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Outlook of HEV-mitochondria interaction 
The understanding of HEV biology is still limited despite that decades of research have 
uncovered several of its characteristics and achieved huge progress with respect to 
controlling HEV pathogenesis. Virus specific treatment for HEV is not available yet. Further 
efforts on exploring viral-host interaction, such as in the novel and interesting field of 
mitochondrial dynamics and its relation to viral infections and disease pathogenesis will 
possibly extend our knowledge here and aid finding new targets potentially useful to control 
HEV activity. My primary study, presented in this thesis, shows that HEV-mediated 
alteration of mitochondrial dynamics is a major determinant of viral infection and sheds 
light on this novel aspect of HEV infection. I show that HEV exploits mitochondrial dynamics 
to stimulate viral propagation (Chapter 8). However, the precise molecular mechanisms 
underlying the role of mitochondrial dynamics in HEV infection still remain to be 
comprehensively described. Although still relatively preliminary, my novel finding describing 
the association between HEV and host cell organelles opens a great possibility to 
understand to finally obtain intricate insight into HEV biology and demonstrates that 
mitochondrial quality control might be a promising therapeutic target in the quest to 
combat HEV infection and associated liver disease pathogenesis.  
I envision that in the future, two dimensions of the relation between mitochondrial 
function and HEV infection are promising areas for further investigation. One is based on 
mitochondrial features, including mitochondrial DNA, mitochondrial proteins, mitochondrial 
membrane potential, as well as mitochondrial dynamics and should establish whether and 
how these elements interact with HEV infection. The other dimension is cellular signaling 
regulated by mitochondria, including ATP production, mitophagy, apoptosis, and innate 
immunity. The role of such mitochondrially-mediated signaling pathways in HEV infection 
remains to be understood. The complicating point in exploring the mechanisms of HEV 
effects on mitochondrially-mediated signaling is that these two dimensions may function in 
conjunction, cross-effecting one dimension with the other. For example, HCV has been 
demonstrated to induce cell apoptosis; however, the activation of mitochondrial fission 
protein Drp1 by HCV infection has an important role in preventing apoptosis, suggesting 
that evolutionary pressure on the virus to prevent cellular apoptosis phenomena but that 
the resulting effect is not perfect. Thus we should take notion when draw conclusion on the 
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association between HCV induced mitochondrial fission and HCV induced cell apoptosis.  
Also taking HCV as a model, HCV infection was previously found to increase ATP production, 
later, novel findings revealed that inhibition of HCV induced mitochondrial fission led to a 
decline in ATP level, suggesting that the ATP production promotion might be attributed to 
the mitochondrial fission process, instead of direct HCV-dependent modulation. In our HEV-
based cell culture model altered mitochondrial dynamics not only influenced innate immune 
response, but also affected mtDNA copy number. The exact contributors to the ultimate 
effects of HEV on mitochondrial dynamics and vice versa remain to be clarified. Therefore, 
in future research, the challenge is not only understanding the mitochondrial 
multifunctionality during viral infection, but also to establish the cascade, and potentially 
matrix-like or reticular network-like links between individual signaling mediated by virus 
induced mitochondrial alterations. In addition, virus infection also seems influence 
mitochondrial responses to changes in environmental stimuli. The main effect of HCV 
infection on the mitochondrial compartment may be the induction of mitophagy by 
stimulation of mitochondrial fission, which may serve as a strategy to eliminate damaged 
and apoptosis-promoting mitochondria and thus facilitates maintaining the compartment 
harboring persistent viral infection 12. Intriguingly, however, Hara et.al. found that HCV is 
able to suppress mitophagy induced by CCCP, a widely used reagent for inducing mitophagy 
13. The authors believe this process is a strategy of HCV to sustain the presence of affected 
mitochondria and that the resulting increased production of reactive oxygen species is 
involved in the development of HCV progression. Thus questions remain as to the exact link 
between viral infection and mitochondrial quality control and associated effects on cellular 
metabolism. Addressing these questions is a challenge that urgently prompts future 
research. 
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Final remarks 
 Both cell culture based research and clinical evidences suggest that different 
immunosuppressive regimens can differentially affect the infection course of HEV. 
These observations indicates that immunosupprants can have direct effects on viral 
replication, apart from influencing antiviral immunity. Experimential evidences 
deminstrated the immmunosupprants can target their specific host factors to exert 
pro- or anti- viral effects, This knowledge gained from this study is certainly a 
valuable reference for the management of immunosuppression in organ transplant 
recipients infected with HEV. Hopefully, it will also promote the initiation of 
randomized controlled clinical studies to address these issues in the near future.  
 
 Targeting nucleotide biosynthesis pathways represents an promising strategy for 
treatment of HEV infection. As host factors, a number of catalytic enzymes involved 
in de vovo nucleotide synthesis are attractive targets for future drug development. 
 
 Discovery of regulation of mitochondria properties on HEV indeed sparks a novol 
avenue of combating HEV infection. Despite many issues remain unclear, the 
alteration of mitochondrial dynamics exploited by HEV infection to their own benefit 
can be implicated as a potential therapeutic target against HEV infection. Moreover, 
The relvence of mitochondrial dynamics and viral infection may help in 
understanding the pathogenic process. Undoubtelly, it remains important to study 
multiple mitochondrial functions that associated with mitochondrial dynamics to 
elucidate the physiological significance of enhanced mitochondrial fusion in the HEV 
infectious process and disease pathogenesis. 
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Eén van de verwekkers van virale hepatitis is het hepatitis E virus (HEV). Dit HEV komt 
via het maag-darm kanaal het bloed binnen en vermenigvuldigd zich dan in de lever. Het 
verloop van een acute HEV-infectie kent een aantal stadia: van subklinisch, naar acuut en 
uiteindelijk fulminant. Hepatitis E, dat in toenemende mate wordt gezien als een “public 
health concern”, heeft een mortaliteit van 0.2 – 1.0 %, maar kan bij zwangere vrouwen in 
het laatste trimester van hun zwangerschap oplopen tot een mortaliteit van 20-25%. 
Daarnaast is er zorg over het gevaar van het virus voor andere groepen, met name voor 
transplantatiepatiënten. Zulke patiënten krijgen immuunsysteem onderdrukkende 
medicatie voorgeschreven die potentieel de weerstand tegen HEV zouden kunnen 
verminderen. Orgaan transplantatie gaat gepaard met het gebruik van immunosuppressiva. 
Immers, anders wordt het getransplanteerde orgaan afgestoten. Verschillende 
immunosuppressiva werken mechanistisch op andere wijze; het is dus goed voorstelbaar 
dat sommige immunosuppressiva een directe interactie met de levenscyclus van het HEV en 
het virus direct remmen, terwijl andere immunosuppressiva niet zo’n interactie zouden 
hebben. Uiteraard zou het gebruik van een immunosuppressief regime dat tegelijkertijd ook 
virusreplicatie remt de voorkeur moeten hebben voor patiënten  met een verhoogd risico 
op het ontwikkelen van hepatitis E.  In hoofdstuk 3 en hoofdstuk 4 ga ik op zoek naar zulke 
immunosuppresiva. Ik vond dat verschillende immunosuppressiva inderdaad ander 
interactie met de HEV levens cyclus hadden. Sommige, in het bijzonder remmers van mTOR 
(een moleculair element dat informatie van de voedingsstaat van de cel integreert met de 
informatie gegeven door immunostimulatoire hormonen) leken HEV infectie te bevorderen 
(mTOR lijkt dan ook een element van de verdediging van de cel tegen HEV). Andere 
immunosuppresiva, zoals steroiden, hadden geen effect, maar mycofenolzuur (een potent 
middel om orgaanafstoting te voorkomen) remde juist HEV infectie. Dit laatste middel lijkt 
dan ook aangewezen bij patiënten met een verhoogd risico op hepatitis E 
In lijn met deze resultaten vond ik inderdaad bleek uit een systematisch door mij 
uitgevoerd literatuuronderzoek (hoofdstuk 4) met betrekking tot de vatbaarheid van 
transplantatiepatiënten voor HEV infectie dat zo’n twaalf procent van deze patiënten 
antistoffen voor HEV in haar bloed had. Bovendien was in zo’n twee procent der patiënten 
ook viraal RNA aanwezig. In deze laatste groep  ontwikkelde 65 % van de patiënten een 
chronische infectie. Ik concludeerde dat hepatitis E een groot probleem bij orgaan 
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transplantatie. Naast modulatie van immuunsuppressie is ook direct ook direct antivirale 
therapie een mogelijke therapeutische optie. Inderdaad beschrijf ik in hoofdstuk 5 dat het 
antivirale middel ribavirine een sterke werking tegen het HEV heeft, dat dit antivirale effect 
nog verder versterkt kan worden door co-therapie met interferon en dat het therapeutisch 
effects van ribavirine met betrekking tot HEV infectie ligt in haar modulatie van de de novo 
synthese van nucleinezuren. In hoofdstuk 6 karakteriseer ik de relatie tussen het cellulaire 
nucleinezuurmetabolisme en HEV infectie in detail en genereer ik dus nog meer inzich hoe 
ribavirine HEV kan bestrijden. Ribavirine heeft echter veel bijwerkingen en andere medicatie 
zou betere eigenschappen kunnen hebben. In praktijk zijn zogenaamde kinaseremmers vaak 
erg nuttig om ziekte te bestijden. In hoofdstuk 7 voer ik een zoektocht uit naar 
kinaseremmers die HEV infectie kunnen bestrijden. Heel onverwacht vond ik dat 
zogenaamde PKC remmers juist virusinfectie bevorderden. Niet alleen tonen deze data aan 
dat zulke PKC remmers niet nuttig zijnbij het behandelen van HEV infectie, ze laten ook zien 
dat PKC een niet eerder onderkende rol heeft in onze virale afweer. Het moduleren van PKC 
activiteit zou dus een mogelijkheid bieden om mensen te beschermen tegen bekende en 
nieuwe virussen. In het laatste experimentele hoofdstuk, hoofdstuk 8 karakteriseer ik 
tenslotte de interactie tussen de mitochondria (de energiefabriekjes van de cel) en het HEV. 
Ik laat zien dat het HEV virus fusie tussen mitochondrien teweeg brengt en dat deze fusie 
noodzakelijk is voor virale infectie, door het saboteren van antivirale responsen in 
levercellen. Op termijn kan deze observatie ook leiden tot nieuwe  medicatie om virale 
infectie te bestrijden. 
In het laatste hoofdstuk (hoofdstuk 9) van dit proefschrift tenslotte, probeer ik alle 
informatie die ik heb vergaard gedurende mijn promotieonderzoek te integreren en te 
duiden aan hand van de reeds bestaande biomedische literatuur. Ik concludeer dat de 
biologie van HEV nog vele onbegrepen aspect heeft en dat kennis van deze aspecten 
belangrijke mogelijkheden biedt voor het ontwikkelen van nieuwe medicatie.  . Samen hoop 
ik dat mijn studies een nieuwe bijdrage hebben in de strijd der mensheid tegen hepatitis E 
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